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TUMOR-INITIATING CELLS AND METHODS 
OF USE 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application claims the benefit of U.S. Provisional 
Application No. 61/133,497, filed on Jun. 30, 2008, the entire 
contents of which are incorporated herein by reference. 
STATEMENT OF RIGHTS TO INVENTIONS 
MADE UNDER FEDERALLY SPONSORED 
RESEARCH 
2 
Many cancers will eventually recur, and these recurrences can 
be fatal. This observation has given rise to the hypothesis that 
cancer may originate in a small population of cancer stem 
cells that are responsible for the growth of tumors and that are 
5 resistant to conventional cancer therapies. Cancer stem cells 
are believed to be quite rare, and have been difficult to isolate. 
Methods for generating cells that are capable of initiating 
tumors and isolated populations of such cells are required for 
the identification of novel anti-neoplastic agents that are use- 
10 ful not only as chemotherapeutic s, but that can prevent cancer 
relapse by targeting tumor-initiating cells that are capable of 
regenerating a tumor when anti-cancer therapy is completed. 
SUMMARY OF THE INVENTION 
The work was supported by in part, by NASA grant 15 
NNJ06HA28G. The Government has certain rights in the 
invention. 
BACKGROUND OF THE INVENTION 
20 
Thirty years of investigations into the molecular genetics 
and signaling of cancer cells have revealed cancer to be a 
genetic disease. The prevailing carcinogenesis paradigm 
asserts that cancer originates from a single cell which, 
through a series of well-defined mutations and selected clonal 25 
expansions, ultimately transforms into a cancer cell. Intense 
study has identified three critical gene classes which contrib-
ute to the carcinogenesis process: oncogenes, tumor-suppres-
sor genes and DNA repair genes, sometimes referred to as 
stability genes. Beyond the abnormal regulation of these clas- 30 
sic cancer genes, a number of additional processes which are 
common across cancer types have been identified as hall-
marks of the disease. These include sustained angiogenesis, 
tissue invasion and metastasis, and unlimited replicative 
capacity. Cancer cells also exhibit genomic instability, where 35 
the progeny of cancer cells express increasing levels of chro-
mosomal aberrations and allelic imbalance. Genomic insta-
bility generates the vast genotypic and phenotypic diversity 
found in all tumors, and it is the major obstacle in cancer 
treatment. 40 
Despite these major inroads into elucidating the carcino-
genesis process, there still remain large gaps in scientists' 
understanding of how mutations actually drive cell transfor-
mation and the subsequent cancer progression. Although 
gene mutations clearly contribute to cancer, no single mutated 45 
gene or combination of mutated genes occur in all or even in 
the majority of cancers. Moreover, it is not gene mutations, 
but primarily chromosome-level aberrations that occur in 
cells following transformation to the cancer state. Although it 
has long been assumed that cancers arise from mutated dif- 50 
ferentiated cells, there is now considerable interest in deter-
mining if instead it is mutated stem cells that are at the origin 
of cancer. Stem cells and cancer cells exhibit common prop-
erties such as the ability to continuously self-renew and dif-
ferentiate. Although genomic instability is ubiquitous across 55 
cancers, the mechanisms that drive this instability are still 
undetermined. Inhibition of DNA repair or stability genes, 
alterations in mitosis genes, aberrant centromeres, aneup-
loidy, teleomere dysregulations and, for virus-linked cancers, 
virus-induced fusion of genetically-mutated cells, have all 60 
been suggested as causes of the instability. Finally, given that 
gene mutations and particularly chromosome aberrations 
decrease the fitness of a cell, it is not understood how cancer 
cell populations are able to sustain and proliferate in the face 
of the high degree of chromosomal damage per cell. 65 
Although conventional treatments for neoplasia typically 
reduce the size of tumors, such responses can be transient. 
The invention provides tumor-initiating cell compositions, 
methods for producing a tumor-initiating cell, the use of such 
cells for the identification of agents useful for the treatment or 
prevention of neoplasia and neoplasia relapse following che-
motherapy or radiation therapy, as well as anti-neoplasia vac-
cines, and for the treatment of diseases and disorders associ-
ated with a deficiency in cell number. 
The invention provides an isolated cell selected for having 
undergone at least one spontaneous cell-cell fusion, or a 
descendant of said cell, wherein said cell is self-renewing. 
Such cells can be used for the methods taught herein. 
The invention further provides a tumor-initiating cell 
selected as having undergone spontaneous cell-cell fusion or 
a descendant of said cell. Tumor-initiating cells of the inven-
tion give rise to a neoplasia in vitro or in vivo under suitable 
growth conditions. Further, the tumor initiating cells of the 
invention exhibit one or more characteristic features as dem-
onstrated herein. These characteristics include, but are not 
limited to, aneuploidy, increased cellular proliferation rate 
relative to a corresponding reference cell, periodically 
increased expression of VEGF, k-ras, myc, MMP-9, CD44 or 
Bcl-2 relative to a corresponding reference cell, periodically 
reduced expression of CDKn2A and p53 relative to a corre-
sponding reference cell, formation of a colony in soft agar in 
vitro, and formation of a tumor in vivo. 
The tumor initiating cells of the invention can be generated 
by the spontaneous fusion between a neoplastic cell and a 
neoplastic cell, a non-neoplastic cell and a neoplastic cell, or 
a non-neoplastic cell and a non-neoplastic cell. Cells for 
fusion can be obtained from essentially any source including, 
but not limited to immortalized cell lines, normal cells from a 
subject for example a subject identified as being prone to or 
having neoplasia. Normal or neoplastic cells can be obtained 
from a subject being prone to or having neoplasia. Cells for 
use in the invention can be any type of cell that does not 
normally undergo spontaneous cell fusion in the absence of 
disease, for example, a fibroblast or epithelial cell. Cells that 
undergo spontaneous fusion in the absence of disease include 
muscle cells, macrophages, and gametes in the formation of a 
zygote. The fused cells of the invention do not include cells 
that have undergone chemically induced fusion, as in the case 
of hybridomas, or virally induced fusion. 
The invention also provides an isolated cell population of 
cells selected for having undergone at least one spontaneous 
cell-cell fusion or a descendant of such a cell. The cells are 
cultured under conditions sufficient to promote further 
fusion, wherein at least one cell of said population is a self-
renewing tumor-initiating cell. For example, the cells are 
cultured at a relatively high density. In an embodiment, at 
least about 50-75% of the cell population are tumor-initiating 
cells or highly tumorogenic cells. In some embodiments at 
least, 80%, 85%, 90%, or 95% of the cells are tumor initiating 
US 8,679,835 B2 
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cells or highly tumorogenic cells. Further, the tumor initiating 
cells in the population exhibit one or more characteristic 
features as demonstrated herein. These characteristics 
include, but are not limited to, aneuploidy, increased cellular 
proliferation rate relative to a corresponding reference cell, 
periodically increased expression of VEGF, k-ras, myc, 
MMP-9, CD44 or Bcl-2 relative to a corresponding reference 
cell, periodically reduced expression of CDKn2A and p53 
relative to a corresponding reference cell, formation of a 
colony in soft agar in vitro, and formation of a tumor in vivo. 
In an embodiment, at least about 50% of the cells are aneup-
loid and show increased expression of an oncogene selected 
from the group consisting of k-ras, myc and Bcl-2, and show 
decreased expression of CDKn2A and p53 relative to a cor-
responding reference cell. In an embodiment, the expression 
of genes associated with hyperproliferation and neoplasia are 
synchronously differentially expressed within the popula-
tion. Synchronously and differentially expressed markers 
include, but are not limited to, Myc, K-ras, Bcl-2, p53, 
CDKn2a, CD44, SPP1, and VEGF relative to acorresponding 
reference population. In an embodiment, at least 50%, 60%, 
70%, 80%, or 90% of the cells synchronously differentially 
express at least 2, 3, 4, 5, 6, 7, or 8 of the markers. 
The population of tumor initiating cells provided by the 
invention are highly tumorigenic. For example, the popula-
tion of cells enriched for having undergone cell fusion has a 
tumor producing efficiency that is at least about 10-fold 
greater than a reference cell. Highly tumorogenic cells can 
also be identified by their ability to consistently form tumors 
from a small number of injected cells in a short period of time. 
For example, the populations of cells enriched for cells that 
have undergone fusion, can form tumors upon injection of at 
least about 10-500 cells of the population forms a tumor of 
about I cm diameter in at least about 50% of nude mice within 
about 2-6 weeks. The populations of cells enriched for cells 
that have undergone fusion can also form tumors in immune 
competent mice. 
The population of tumor initiating cells of the invention 
can be generated by the spontaneous fusion between a neo-
plastic cell and a neoplastic cell, a non-neoplastic cell and a 
neoplastic cell, or a non-neoplastic cell and a non-neoplastic 
cell. Cells for fusion can be obtained from essentially any 
source including, but not limited to immortalized cell lines, 
normal cells from a subject for example a subject identified as 
being prone to or having neoplasia. Normal or neoplastic cells 
can be obtained from a subject being prone to or having 
neoplasia. Cells for use in the invention can be any type of cell 
that does not normally undergo spontaneous cell fusion in the 
absence of disease, for example, a fibroblast or epithelial cell. 
Cells that undergo spontaneous fusion in the absence of dis-
ease include muscle cells, macrophages, and gametes in the 
formation of a zygote. The fused cells of the invention do not 
include cells that have undergone chemically induced fusion, 
as in the case of hybridomas, or virally induced fusion. 
The invention provides a method for the generation of 
highly tumorogenic cells in culture enriched for cells that 
have undergone fusion and culturing the cells at a relatively 
high density to allow the cells to further undergo spontaneous 
fusion to produce multinucleate cells, and subsequently par-
tition off mononuclear cells from the multinucleate cell. In an 
embodiment, the isolated population of cells selected for 
having undergone at least one spontaneous cell-cell fusion, or 
a descendant of such a cell, are preferably conditions suffi-
cient to promote further fusion include culturing the cells at a 
density of about 80%, 85% or 90% confluence. In a preferred 
embodiment, the cells are cultured under standard growth 
conditions for the specific cell line (e.g., tissue culture media, 
growth factors, antibiotics). In a preferred embodiment, the 
cells are grown in the absence of agents that promote cell 
fusion (e.g., chemical agents, viruses) and are not trans-
formed with oncogenes or other agents that can promote 
5 aneuploidy (e.g., mitogens, DNA damaging agents). 
Cells that have undergone fusion can be identified by any 
method. In an embodiment, cells having undergone fusion are 
identified by the use of vital dyes such as cytoplasmic vital 
dyes or membrane vital dyes. In an alternate embodiment, the 
l0 
cells having undergone fusion are identified by direct obser-
vation of cells that have more than one nucleus and the nuclei 
are not the result of a single cell division, i.e., the cell is not in 
G2 or M. Cells containing three or more nuclei, e.g., 3, 4, 5, 6, 
15 7, 8, 9, 10, or more nuclei, can be identified as having under-
gone fusion. Cells can be selected by automated methods, for 
example using fluorescence activated cell sorting. In an 
embodiment, the cells can be selected manually. 
The invention provides cells made by the methods of the 
20 invention. Cells made by the methods of the invention have 
one or more of the following characteristics. They are self-
renewing, are capable of forming tumors in immune compe-
tent and immune incompetent mice, and are resistant to expo-
sure to radiation and/or chemotherapeutic agents. Further, the 
25 cells made by the methods of the invention exhibit one or 
more characteristic features as demonstrated herein. These 
characteristics include, but are not limited to, aneuploidy, 
increased cellular proliferation rate relative to a correspond-
ing reference cell, periodically increased expression of 
30 VEGF, k-ras, myc, MMP-9, CD44 or Bcl-2 relative to a 
corresponding reference cell, periodically reduced expres-
sion of CDKn2A and p53 relative to a corresponding refer-
ence cell, formation of a colony in soft agar in vitro, and 
formation of a tumor in vivo. In an embodiment, at least about 
35 50% of the cells are aneuploid and show increased expression 
of an oncogene selected from the group consisting of k-ras, 
myc and Bcl-2, and show decreased expression of CDKn2A 
and p53 relative to a corresponding reference cell. In an 
embodiment, the expression of genes associated with hyper- 
40 proliferation and neoplasia are synchronously differentially 
expressed within the population. Synchronously and differ-
entially expressed markers include, but are not limited to, 
Myc, K-ras, Bcl-2, p53, CDKn2a, CD44, SPPI, and VEGF 
relative to a corresponding reference population. In an 
45 embodiment, at least 50%, 60%, 70%, 80%, or 90% of the 
cells synchronously differentially express at least 2, 3, 4, 5, 6, 
7, or 8 of the markers. 
The invention further provides compositions including a 
population of tumor initiating cells made by the methods of 
50 the invention. In a preferred embodiment, the population is an 
isolated and/or enriched population of tumor initiating cells. 
The invention further provides methods of use of the cells 
of the invention. In embodiment, the invention provides a 
method for identifying an agent for the treatment or preven- 
55 tion of a neoplasia, hyperplasia or a hyperproliferative disor-
der using the cells of the invention. The method includes 
contacting a tumor-initiating cell or cell population with an 
agent; and detecting a decrease in cell fusion, survival, and/or 
proliferation relative to an untreated control cell or cell popu- 
60 lation. 
The invention further provides a method for the identifica-
tion of anti-neoplastic agents by identifying agents that 
inhibit cell fusion. The method includes contacting a popula-
tion of cells cultured under conditions sufficient to induce 
65 spontaneous cell-cell fusion with an agent; and detecting a 
reduction in cell-cell fusion relative to an untreated control 
population. In the method, a reduction in multinucleate cell 
US 8,679,835 B2 
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number in the treated population identifies an agent that 	 disorders associated with cell insufficiency by administering 
inhibits cell-cell fusion. For example, the agent may increase 	 the differentiated cells of the invention to a subject in need 
cell death. 	 thereof. The invention further includes a composition includ- 
The invention further provides methods for the identifica- 	 ing a differentiated cell of the invention formulated for 
tion of agents that inhibit the partitioning of cells containing 5 administration to a subject. 
single nuclei from the multinucleate cell. The method 
	
Definitions 
includes maintaining the multinucleate cell in culture under 	 "Aneuploid" or "aneuploidy" refers to a cell having an 
conditions sufficient to generate mononucleate cells from a 	 abnormal number of chromosomes relative to a correspond- 
multinucleate cell, and identifying agents that result in a 	 ing reference cell. Most cells that are not undergoing cell 
reduction in the generation of said cells relative to a corre-  io division are diploid (2N). Cells in the G2 or M phase of 
sponding control culture. 	 growth can have 4N chromosomes. 
The invention also provides methods for selecting a thera- 	 By "anti-fusion agent' is meant an agent that can reduce 
peutic regimen for a subject, including generating a popula- 	 the frequency or rate of cell-cell fusion. In particular, an 
tion of cells enriched for cells having undergone cell fusion 	 anti-fusion agent inhibits any step in the process of cell 
from a subject having a neoplastic disease and culturing them 15 fusion. In one embodiment, an anti-fusion agent acts by pre- 
under the methods of the invention to generate a population of 	 venting the fusion of cells to produce multinucleate cells orby 
tumor initiating cells, contacting the cell population with one 	 preventing the fusion of multinucleate cells to create tumor- 
or more agents, such as chemotherapeutic agents, and detect- 	 initiating orhighly tumorogenic cells having a singlenucleus. 
ing a decrease in cell survival, proliferation, or cell-cell fusion 	 In another embodiment, an anti-fusion agent acts by killing 
relative to an untreated control cell or cell population; and 20 cells undergoing cell-cell fusion. 
identifying the agent as effective in a therapeutic regimen for 	 By "cell-cell fusion" is meant the melding of two or more 
said subject. The method can be used for identifying initial 	 cells to form a multinucleate cell. A cell that has recently 
therapeutic agents, monitoring for continued response of the 	 undergone fusion is identified by the presence of two or more 
neoplasia to therapeutic agents, or identifying agents useful in 	 nuclei within a single cytoplasm, is identified using a detect- 
the treatment of a relapse. In an embodiment, the cells are 25 able marker (e.g., quantum dots) to identify a single cyto- 
derived from normal cells of the subject. In an embodiment, 	 plasm resulting from cell fusion, or is identified using any 
the cells are derived from the neoplasia of the subject. In an 	 other method known in the art and described herein. Cells 
embodiment, the cells are a combination of normal and neo- 	 descended from a fused progenitor cell may contain a single 
plastic cells from the subject. 	 nucleus that has split off from a multinucleate cell. Sponta- 
The method further provides immunogenic compositions so neous cell-cell fusions described herein do not include cell 
for the treatment or prevention of a neoplasia in a subject 	 fusions associated with virally induced cell fusions, with 
using non-viable cells of the invention in an excipient for 	 hybridoma cell fusions, or with cell fusions that occur during 
administration to a subject. In an embodiment, the composi- 	 normal development. Specifically excluded from the defini- 
tion further includes an adjuvant. In an embodiment, the cells 	 tion of cells that arise during spontaneous cell-cell fusion are 
are derived from the subject to whom the immunogenic com-  35 macrophages, myofibrils, or other cells that normally fuse in 
position is to be administered. In an embodiment, the cells are 	 mammals under non-disease conditions. Spontaneous cell- 
derived from a subject other than the individual to whom the 	 cell fusions of the invention are generated in the absence of a 
immunogenic composition is to be administered. In an 	 virus. Virally fused cells are specifically excluded from the 
embodiment, the subject has or is prone to neoplasia. The 	 definition of cells that arise during spontaneous cell-cell 
method can be used for inducing an immune response in a 40 fusion. 
subject against a neoplasia for the prevention or treatment of 	 The term "detectable" refers to an agent that when linked 
neoplasia. Such an immunotherapy can be used in conjunc- 	 with a nucleic acid molecule or protein of interest, or present 
tion with the administration of other anti-neoplastic agents, 	 in the cytoplasm or membrane not specifically attached to any 
e.g., chemotherapy, or radiation therapy, and be administered 	 protein or nucleic acid, facilitates detection. Detection is via 
prior to, concurrent with, or following chemotherapy or radia-  45 any means known in the art, including spectroscopic, photo- 
tion therapy. 	 chemical (e.g., luciferase, GFP), biochemical, immu- 
The invention further provides a method of immortalizing 	 nochemical, chemical means, or direct observation. For 
a primary cell in culture by selecting at least two cells as 	 example, useful labels include radioactive isotopes, magnetic 
having undergone spontaneous cell-cell fusion in a primary 	 beads, metallic beads, colloidal particles, fluorescent dyes, 
cell culture; and culturing the selected cells under conditions 50 electron-dense reagents, enzymes (e.g., horseradish peroxi- 
that promote further cell-cell fusion, thereby generating an 	 dase, alkaline phosphatase), biotin, digoxigenin, or haptens. 
immortalized cell. In an embodiment, the selected cells are 	 In particular embodiments, a detectable agent is one that can 
multinucleate. In an embodiment, the cells are maintained in 	 be readily observed, preferably in a quantitative manner, such 
culture for sufficient time to allow partitioning of the multi- 	 as a fluorescent tag that has a specific wavelengths of absorp- 
nucleate cells in culture to generate a population having at 55 tion and emission to allow detection of the compound asso- 
least 50% mononucleate aneuploid cells. 	 ciated with the detectable label. Detectable labels include 
The invention further includes a non-human animal, pref- 	 vital dyes for use with living cells, wherein the dye has little 
erably a non-human mammal having at cell or a population of 	 or no effect on cell viability, growth, and function. 
tumor-initiating cells of the invention. In an embodiment, the 	 As used herein, "descended from", "descended from a 
cells are present in sufficient number to allow for formation of 60 progenitor cell', and the like is understood as a cell that is 
a tumor in the mammal. 	 produced by mitosis, or meiosis, or a result of the separation 
The invention also includes the use of the tumor initiating 	 of at least one nucleus and some cytoplasm from a multi- 
cells of the invention to generate a differentiated cell by 	 nucleate cell. 
administration of growth factors or other agents to promote 	 As used herein, an "enriched population" or "population 
differentiation. The exact factors to be used depend on the 65 enriched for" cells having a desired characteristic comprises 
type of differentiated cell desired. The invention further 	 at least about 50% of cells having the characteristic that 
includes methods for amelioration or treatment of diseases or 	 defines the population. An enriched population preferably has 
US 8,679,835 B2 
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at least 70%, at least 75%, at least 80%, at least 85%, at least 	 or uncontrolled hyperproliferation or reduced cell death or 
90%, at least 95%, or at least 99% cells having the particular 	 apoptosis (e.g., a cancer cell, cells immortalized in culture, a 
phenotype, genotype, or other characteristic that defines the 	 transformed cell). 
population. 	 As used herein, "selecting" is understood as identifying 
By "free of viruses" or "virus-free" is understood as con-  5 and isolating or enriching for a cell having a desired charac- 
taining no detectable virus. Preferably, a culture that is virus- 	 teristic. The selected members can be isolated from their 
free contains no detectable fusogenic virus, by any standard 	 original environment and can be pooled. In one embodiment, 
detection method, including diagnostic methods, PCR or 	 cells are selected for having undergone fusion. Alternatively, 
other nucleic acid based method; western blot, ELISA, or 	 or in addition, selection can be performed based on the 
other immune based method, viral culture methods, or any io expression or the absence of expression of one or more pro- 
other methods known in the art. 	 teins. Protein markers for which cells may be selected 
As used herein, a "tumor-initiating cell' is a cell that has 	 include, but are not limited to, CD44, CD24, B38.1, CD2, 
undergone cell-cell fusion, or a descendant of such a cell that 	 CD3, CD10, CD14, CD16, CD31, CD45, CD64, CD140b, 
is capable of generating a neoplasia under appropriate con- 	 and ESA. A cell can be selected for being "positive" for a 
ditions in vitro or in vivo or which is capable of self-renewal. 15 marker, "low" for a marker, or "negative" for a marker, or for 
A cell that has undergone cell fusion has at least one of the 	 being positive, low, or negative for any of a combination of a 
following characteristics: has 2 nuclei wherein the nuclei did 	 number of markers. Cells that are positive exhibit detectable 
not arise from a single cell division and that typically divide 	 levels of a marker. Where the level of a marker in a cell is 
asynchronously; or has at least 3 nuclei, preferably at least 4, 	 described as increased or decreased, the level is measured 
5, 6, 7, 8, 9, or 10 nuclei; or has been observed directly to 20 relative to the levels present in a reference cell (e.g., an 
undergo cell fusion; or observed indirectly to have undergone 	 untreated control cell). Methods for selecting cells are well 
cell fusion by use of markers (e.g., GFP, RFP) or vital dyes. 	 known and include fluorescence activated cell sorting (FACS) 
As used herein, a "highly tumorogenic cell' exhibits at 	 and manual cell selection. The specific method of selection is 
least about a 10-fold increase in tumorogenicity as compared 	 not a limitation of the instant invention. Selection can be 
to a corresponding reference cell. Preferably, a highly 25 performed based on visual identification of cells having the 
tumorogenic cell exhibits at least about a 20-fold, 50-fold, or 	 desire properties, i.e., multinucleate cells. Selection can be 
100-fold increase in tumorogenicity as compared to a corre- 	 performed for cells that may or may not have fused based on 
sponding reference cell. For example, a highly tumorogenic 	 the mixing or absence of mixing of detectable cytoplasmic 
cell produces a tumor of 1 cm diameter in at least about 50%, 	 markers or labels (e.g., vital dyes, fluorescent proteins such as 
60%, 70%, 80% or more of nude mice from 1000 cells, 500 30 green FP and red FP), the amount of nuclear staining with 
cells in less than 8 wks, 6 wks, 4 wks, 3, wks, 2, wks, 1 wk; or 	 more fluorescence indicative of more nuclei, or the size of 
100 cells, 75 cells, 50 cells, 25 cells, 10 cells, or 5 cells in less 	 cells. 
than about 12 weeks, 10 weeks, 8 weeks, 6 weeks, or even as 	 By "population" is meant at least 2 cells. In a preferred 
little as 3 or 4 weeks. 	 embodiment, population is at least 5, 10, 50, 100, 500, 1000, 
A highly tumorogenic cell has a high tumor producing 35 or more cells. 
efficiency or a high colony producing efficiency, preferably as 	 By "obtain" is meant purchasing, synthesizing, or other- 
compared to a control cell. As used herein, "tumor producing 	 wise acquiring. 
efficiency", "efficiency of tumor production", and the like are 	 As used herein, a percent confluence is understood as the 
determined by the number of cells required to produce a 	 amount of surface area of a tissue culture dish or other con- 
tumor in a specific percentage of animals within a specific 40 tainer that is covered by adherent cells. Cells can be grown at 
time frame. For example, if 1000 of a first class of cells can 	 essentially any density, depending on cell type. 
produce tumors in 80% of animals at 2 months, and 100 of a 	 As used herein "periodically increased expression" or 
second class of cells can produce tumors in 80% of animals at 	 "periodically reduced expression" or "periodically modu- 
2 months, the second class of cells are 10-fold more efficient 	 lated expression" refers to a cyclic alteration in the level of a 
than the first class of cells in producing tumors. Similarly, 45 polypeptide or nucleic acid molecule over some period of 
efficiency can be based on the percent of animals in which a 	 time. Typically, the level of the polypeptide or nucleic acid 
tumor is produced when the cell number is held constant. 	 molecule varies synchronously in at least about 25%, 50%, 
Similarly, the number of colonies formed on soft agar from a 	 75%, or even 100% of the population. 
first class of cells can be compared to the number of colonies 	 As used herein, "synchronous" is understood to mean coor- 
formed on soft agar from a second class of cells. 	 5o dinated. Synchronous can refer to cell division, i.e., cells that 
As used herein, "multinucleate cell' is understood as a cell 	 cycle synchronously, or expression of specific markers at 
having more than one nucleus. For example, at least about 2, 	 different splits (i.e., p8, p9, etc), or both. 
3, 4, 5, 6, 7, 8, 9, or more nuclei. 	 By "agents typically present in cell culture" is meant 
A "mononuclear cell' or a "cell having a single nucleus" 	 agents that are generally required for cell survival in vitro. 
has one nucleus. A mononuclear cell can be aneuploid. 	 55 Such agents include growth media (e.g., DMEM, F12, MEM, 
As used herein, a "normal cell' is a control cell. In particu- 	 RPMI available commercially), growth factors in the form of 
lar, a normal cell is derived from a healthy tissue. Preferably, 	 purified growth factors or animal serum (e.g., bovine serum, 
the normal cell does not include any known mutations that 	 fetal bovine serum, horse serum), antibiotics (e.g., penicillin, 
predispose the cell to transformation, and does not display 	 streptomycin, tetracycline), and nutrients (e.g., sugar). It is 
apparent hyperplasia, abnormal or uncontrolled hyperprolif-  60 understood that the agents present in the media will depend 
eration, or reduced cell death or apoptosis (e.g., a non-cancer 	 upon the cell type. `Agents not typically in media" include 
cell). In particular embodiments, a "normal cell' is not a 	 agents that induce mutations or cell fusion, infectious agents, 
naturally occurring, non-disease associated multinucleate 	 agents that induce DNA damage, agents that induce cell cycle 
cell, such as a myofibril, a macrophage, or bone marrow 	 arrest in non-confluent cultures. 
derived stem cells, or a naturally occurring, non-disease asso-  65 	 By "isolated" is meant a material that is free to varying 
ciated fused cell such as a gamete. As used herein, a neoplas- 	 degrees from components which normally accompany it as 
tic cell is a cell that displays apparent hyperplasia or abnormal 
	
found in its native state. "Isolate" denotes a degree of sepa- 
US 8,679,835 B2 
9 
ration from original source or surroundings. For example, an 
isolated cell can be removed from an animal and placed in a 
culture dish or another animal. Isolated is not meant as being 
removed from all other cells. A polypeptide or nucleic acid is 
isolated when it is about 80% free, 85% free, 90% free, 95% 5 
free from other cellular material, or culture medium when 
produced by recombinant techniques, or substantially free of 
chemical precursors or other chemicals when chemically syn-
thesized. An "isolated polypeptide" or "isolated polynucle-
otide" is, therefore, a substantially purified polypeptide or io 
polynucleotide, respectively. 
The terms "polypeptide," "peptide" and "protein" are used 
interchangeably herein to refer to a polymer of amino acid 
residues. The terms apply to amino acid polymers in which 
one or more amino acid residue is an artificial chemical 15 
mimetic of a corresponding naturally occurring amino acid, 
as well as to naturally occurring amino acid polymers and 
non-naturally occurring amino acid polymer. 
By "reference" is meant a standard or control condition. 
Unless otherwise indicated, a particular nucleic acid 20 
sequence also implicitly encompasses conservatively modi-
fied variants thereof (e.g., degenerate codon substitutions) 
and complementary sequences, as well as the sequence 
explicitly indicated. Specifically, degenerate codon substitu-
tions may be achieved by generating sequences in which the 25 
third position of one or more selected (or all) codons is sub-
stituted with mixed-base and/or deoxyinosine residues 
(Batter et al., Nucleic Acid Res., 19:5081 (1991); Ohtsuka et 
al., J. Boil. Chem. 260:2605-2608 (1985); Rossolini et al., 
Mol. Cell. Probes, 8:91-98 (1994)). The term nucleic acid is 30 
used interchangeably with gene, cDNA, mRNA, oligonucle-
otide, and polynucleotide. 
The terms "identical" or percent "identity," in the context 
of two or more nucleic acids or polypeptide sequences, refer 
to two or more sequences or subsequences that are the same or 35 
have a specified percentage of amino acid residues or nucle-
otides that are the same (e.g., 60% identity, optionally 65%, 
70%,75%, 80%, 85%, 90%, or 95% identity over a specified 
region), when compared and aligned for maximum corre-
spondence over a comparison window, or designated region 40 
as measured using one of the following sequence comparison 
algorithms or by manual alignment and visual inspection. 
Such sequences are then said to be "substantially identical." 
This definition also refers to the compliment of a test 
sequence. Optionally, the identity exists over a region that is 45 
at least about 50 amino acids ornucleotides in length, ormore 
preferably over a region that is 75-100 amino acids or nucle-
otides in length. 
For sequence comparison, typically one sequence acts as a 
reference sequence, to which test sequences are compared. 50 
When using a sequence comparison algorithm, test and ref-
erence sequences are entered into a computer, subsequence 
coordinates are designated, if necessary, and sequence algo-
rithm program parameters are designated. Default program 
parameters can be used, or alternative parameters can be 55 
designated. The sequence comparison algorithm then calcu-
lates the percent sequence identities for the test sequences 
relative to the reference sequence, based on the program 
parameters. 
By "analog" is meant a molecule that is not identical, but 60 
has analogous functional or structural features. 
By "small molecule" is meant a compound having a 
molecular weight of no more than about 1500 daltons, 1000 
daltons, 750 daltons, 500 daltons. A small molecule is not a 
nucleic acid or polypeptide. 65 
As used herein, the term "polymerase chain reaction" 
(PCR) refers to the methods of U.S. Pat. Nos. 4,683,195,  
10 
4,683,202, and 4,965,188, all of which are hereby incorpo-
rated by reference, directed to methods for increasing the 
concentration of a segment of a target sequence in a mixture 
of genomic DNA without cloning or purification. As used 
herein, the terms "PCR product" and "amplification product" 
refer to the resultant mixture of compounds after two or more 
cycles of the PCR steps of denaturation, annealing and exten-
sion are complete. These terms encompass the case where 
there has been amplification of one or more segments of one 
or more target sequences. 
As used herein, the term "recombinant DNA molecule" as 
used herein refers to a DNA molecule, which is comprised of 
segments of DNA joined together by means of molecular 
biological techniques. 
As used herein, a nucleic acid sequence, even if internal to 
a larger oligonucleotide, also may be said to have 5' and 3' 
ends. In either a linear or circular DNA molecule, discrete 
elements are referred to as being "upstream" or 5' of the 
"downstream" or 3' elements. This terminology reflects the 
fact that transcription proceeds in a 5' to 3' fashion along the 
DNA strand. The promoter and enhancer elements which 
direct transcription of a linked gene are generally located 5' or 
upstream of the coding region. However, enhancer elements 
can exert their effect even when located 3' of the promoter 
element and the coding region. Transcription termination and 
polyadenylation signals are located 3' or downstream of the 
coding region. 
By "detecting" or "detection" and the like is meant the 
process of performing the steps for determine if an analyte is 
present. The amount of analyte present may be none or below 
the level of detection of the method. 
As used herein, a "theranostic" is understood to describe 
the process of diagnostic therapy for individual patients to 
tailor a treatment for them based on the test results. The 
method includes determining if and which drug will work 
best for a given individual, and/or a monitoring method to 
determine changes in the therapeutic needs of the patient, 
e.g., due to the development of drug resistance. In an embodi-
ment, a tumor-initiating cell of the invention is generated for 
a subject. Tumor-initiating cells are produced using normal 
cells, cells derived from a hyperplasia, or cells derived from a 
neoplasia (e.g., tumor). 
By "ameliorate" is meant decrease, suppress, attenuate, 
diminish, arrest, or stabilize the development or progression 
of a disease. 
As used herein, the terms "treat," treating," "treatment," 
and the like refer to reducing or ameliorating a disorder and/or 
symptoms associated therewith. It will be appreciated that, 
although not precluded, treating a disorder or condition does 
not require that the disorder, condition or symptoms associ-
ated therewith be completely eliminated. More than one dose 
may be required for prevention of a disease or condition. 
As usedherein, the terms "prevent," "preventing," "preven-
tion," "prophylactic treatment" and the like refer to reducing 
the probability of developing a disorder or condition in a 
subject, who does not have, but is at risk of or susceptible to 
developing a disorder or condition. More than one dose may 
be required for prevention of a disease or condition. 
By "alteration" is meant a positive or negative alteration. In 
one embodiment, the alteration is in the expression level or 
biological activity of a gene or polypeptide as detected by 
standard art known methods such as those described herein. 
As used herein, an alteration includes a 10% change in 
expression levels, preferably a 25% change, more preferably 
a 40% change, and most preferably a 50% or greater change 
in expression levels. 
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The term "neoplasia" or "hyperproliferative disorder" 	 quencher dye at the 3' end, thereby eliminating the FRET 
includes malignancies characterized by excess cell prolifera- 	 (Fluorescence Resonance Energy Transfer, the reduction in 
tion or growth, or reduced cell death. In specific embodi- 	 fluorescence intensity owing to the decrease in the energy 
ments, the term "cancer" includes but is not limited to carci- 	 level of the reporter dye caused by the resonance of the two 
nomas, sarcomas, leukemias, and lymphomas. The term 5 fluorescent dyes) effect produced by the spatial proximity 
"cancer" also includes primary malignant tumors, e.g., those 	 between the two dyes, and increasing the fluorescence inten- 
whose cells have not migrated to sites in the subject's body 	 sity of the reporter dye that has been controlled by the 
other than the site of the original tumor, and secondary malig- 	 quencher dye. The target nucleic acid can be selectively quan- 
nant tumors, e.g., those arising from metastasis, the migration 	 tified and detected in real-time by measuring the increase of 
of tumor cells to secondary sites that are different from the io the fluorescence intensity. 
site of the original tumor. Tumors include solid tumors (i.e., 	 The phrase "pharmaceutically acceptable carrier" is art 
non-blood tumors) and blood tumors. 	 recognized and includes a pharmaceutically acceptable mate- 
As used herein, "obtaining" is understood as purchase, 	 rial, composition or vehicle, suitable for administering com- 
procure, manufacture, or otherwise come into possession of 	 pounds used in the methods described herein to subjects, e.g., 
the desired material. 	 15 mammals. The carriers include liquid or solid filler, diluent, 
Cells and/or subjects may be treated and/or contacted with 	 excipient, solvent or encapsulating material, involved in car- 
one or more anti-neoplastic treatments including, surgery, 	 rying or transporting the subject agent from one organ, or 
chemotherapy, radiotherapy, gene therapy, immune therapy 	 portion of the body, to another organ, or portion of the body. 
or hormonal therapy, or other therapy recommended or pro- 	 Each carrier must be "acceptable" in the sense of being com- 
scribed by self or by a health care provider. 	 20 patible with the other ingredients of the formulation and not 
The term "subject" includes organisms which are capable 	 injurious to the patient. Some examples of materials which 
of suffering from cancer or other disease of interest who could 	 can serve as pharmaceutically acceptable carriers include: 
otherwise benefit from the administration of a compound or 	 sugars, such as lactose, glucose and sucrose; starches, such as 
composition of the invention, such as human and non-human 	 corn starch and potato starch; cellulose, and its derivatives, 
animals. Preferred human animals include human patients 25 such as sodium carboxymethyl cellulose, ethyl cellulose and 
suffering from or prone to suffering from cancer or associated 	 cellulose acetate; powdered tragacanth; malt; gelatin; talc; 
state, as described herein. The term "non-human animals" of 	 excipients, such as cocoa butter and suppository waxes; oils, 
the invention includes all vertebrates, e.g., mammals, e.g., 	 such as peanut oil, cottonseed oil, safflower oil, sesame oil, 
rodents, e.g., mice, and non-mammals, such as non-human 	 olive oil, corn oil and soybean oil; glycols, such as propylene 
primates, e.g., sheep, dog, cow, chickens, amphibians, rep-  30 glycol; polyols, such as glycerin, sorbitol, mannitol and poly- 
tiles, etc. A human subject can be referred to as a patient. 	 ethylene glycol; esters, such as ethyl oleate and ethyl laurate; 
A method for "predicting" or "diagnosing" as used herein 	 agar; buffering agents, such as magnesium hydroxide and 
refers to a clinical or other assessment of the condition of a 	 aluminum hydroxide; alginic acid; pyrogen-free water; iso- 
subject based on observation, testing, or circumstances. 	 tonic saline; Ringer's solution; ethyl alcohol; phosphate 
The term "differential" or "differentially" generally refers 35 buffer solutions; and other non-toxic compatible substances 
to a statistically significant different level in the specified 	 employed in pharmaceutical formulations. 
property or effect. Preferably, the difference is also function- 	 The language "therapeutically effective amount" or a 
ally significant. Thus, "differential binding or hybridization" 
	
"therapeutically effective dose" of a compound is the amount 
is a sufficient difference in binding or hybridization to allow 	 necessary to or sufficient to provide a detectable improve- 
discrimination using an appropriate detection technique. 40 ment in of at least one symptom associated or caused by the 
Likewise, "differential effect" or "differentially active" in 	 state, disorder or disease being treated. The therapeutically 
connection with a therapeutic treatment or drug refers to a 	 effective amount can be administered as a single dose or in 
difference in the level of the effect or activity that is distin- 	 multiple doses over time. Two or more compounds can be 
guishable using relevant parameters and techniques for mea- 	 used together to provide a "therapeutically effective amount" 
suring the effect or activity being considered. Preferably the 45 to provide a detectable improvement wherein the same 
difference in effect or activity is also sufficient to be clinically 	 amount of either compound alone would be insufficient to 
significant, such that a corresponding difference in the course 	 provide a therapeutically effective amount. 
of treatment or treatment outcome would be expected, at least 	 As used herein, the terms "effective" and "effectiveness" 
on a statistical basis. 	 includes both pharmacological effectiveness and physiologi- 
The polymerase chain reaction (PCR) is a widely known 50 cal safety. Pharmacological effectiveness refers to the ability 
method for amplifying nucleic acids. Of the PCR techniques, 	 of the treatment to result in a desired biological effect in the 
RT-PCR (Reverse Transcription-PCR), competitive RT-PCR 	 patient. Physiological safety refers to the level of toxicity, or 
and the like are used for detecting and quantifying a trace 	 other adverse physiological effects at the cellular, organ and/ 
amount of mRNA, and show their effectiveness. 	 or organism level (often referred to as side-effects) resulting 
Inrecent years, areal-time quantitative detection technique 55 from administration of the treatment. On the other hand, the 
using PCR has been established (TagMan PCR, Genome 	 term "ineffective" indicates that a treatment does not provide 
Res., 6 (10), 986 (1996), ABI PRISM?M Sequence Detection 	 sufficient pharmacological effect to be therapeutically useful, 
System, Applied Biosystems). This technique measures the 	 even in the absence of deleterious effects, at least in the 
amount of nucleic acids using a particular fluorescent-labeled 	 unstratified population. (Such a treatment may be ineffective 
probe (TagMan probe). More specifically, this technique uti-  60 in a subgroup that can be identified by the expression profile 
lizes the following principles: For example, a fluorescent- 	 or profiles.) "Less effective" means that the treatment results 
labeled probe having a reporter dye at the 5' end and a 	 in a therapeutically significant lower level of pharmacologi- 
quencher dye at the 3' end is annealed to the target DNA, and 	 cal effectiveness and/or a therapeutically greater level of 
the DNA is subjected to normal PCR. As the extension reac- 	 adverse physiological effects, e.g., greater liver toxicity. 
tion proceeds, the probe is hydrolyzed from the 5' end by the 65 	 Thus, in connection with the administration of a drug, a 
5'-3' exonuclease activity possessed by DNA polymerase. As 	 drug which is "effective against" a disease or condition indi- 
a result, the reporter dye at the 5' end is separated from the 	 cates that administration in a clinically appropriate manner 
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results in a beneficial effect for at least a statistically signifi-
cant fraction of patients, such as a improvement of symptoms, 
a cure, a reduction in disease load, reduction in tumor mass or 
cell numbers, extension of life, improvement in quality of life, 
or other effect generally recognized as positive by medical 
doctors familiar with treating the particular type of disease or 
condition. 
In reference to response to a treatment, the term "toler-
ance" refers to the ability of a patient to accept a treatment, 
based, e.g., on deleterious effects and/or effects on lifestyle. 
Frequently, the term principally concerns the patients per-
ceived magnitude of deleterious effects, such as nausea, 
weakness, dizziness, and diarrhea, among others. Such expe-
rienced effects can, for example, be due to general or cell-
specific toxicity, activity on non-target cells, cross-reactivity 
on non-target cellular constituents (non-mechanism based), 
and/or side effects of activity on the target cellular substitu-
ents (mechanism based), or the cause of toxicity may not be 
understood. In any of these circumstances one may identify 
an association between the undesirable effects and variances 
in specific genes or responses of the cells from the subject to 
contact with an agent ex vivo. 
Also in other embodiments, the method of selecting a 
treatment includes eliminating a treatment, where the pres-
ence or absence of certain profiles or responses of the 
enriched population of tumor-initiating cells from the subject 
to contact with an agent is indicative that the treatment will be 
ineffective or contra-indicated, e.g., would not reduce tumor 
size, would not stop tumor growth, and/or metastasis. In other 
preferred embodiments, in cases in which undesirable side-
effects may occur or are expected to occur from a particular 
therapeutic treatment, the selection of a method of treatment 
can include identifying both a first and second treatment, 
where the first treatment is effective to treat the disease or 
condition, and the second treatment reduces a deleterious 
effect of the first treatment. 
Usually, the treatment will involve the administration of a 
compound preferentially active or safe inpatients with certain 
profiles or responses of the enriched population of tumor-
initiating cells from the subject to contact with an agent ex 
vivo. The administration may involve a combination of com-
pounds. Thus, in preferred embodiments, the method 
involves identifying such an active compound or combination 
of compounds, where the compound is less active or is less 
safe or both when administered to a patient having a different 
profile. 
Also in some embodiments, the method of selecting a 
treatment involves selecting a method of administration of a 
compound, combination of compounds, or pharmaceutical 
composition, for example, selecting a suitable dosage level 
and/or frequency of administration, and/or mode of adminis-
tration of a compound. The method of administration can be 
selected to provide better, preferably maximum therapeutic 
benefit. In this context, "maximum" refers to an approximate 
local maximum based on the parameters being considered, 
not an absolute maximum. 
Also in this context, a "suitable dosage level' refers to a 
dosage level that provides a therapeutically reasonable bal-
ance between pharmacological effectiveness and deleterious 
effects. Often this dosage level is related to the peak or aver-
age serum levels resulting from administration of a drug at the 
particular dosage level. 
Described herein, according to one aspect, are methods of 
predicting responsiveness of a tumor to therapeutic treatment 
by determining the response of the enriched population of 
tumor-initiating cells from the subject to an agent. 
14 
Ranges provided herein are understood to be shorthand for 
all of the values within the range. For example, a range of 1 to 
50 is understood to include any number, combination of num-
bers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 
5 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 
25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 
42, 43, 44, 45, 46, 47, 48, 49, or 50. 
Unless specifically stated or obvious from context, as used 
herein, the term "or" is understood to be inclusive. 
10 Unless specifically stated or obvious from context, as used 
herein, the terms "a", "an", and "the" are understood to be 
singular or plural. 
The recitation of a listing of chemical groups in any defi- 
15 ration of a variable herein includes definitions of that variable 
as any single group or combination of listed groups. The 
recitation of an embodiment for a variable or aspect herein 
includes that embodiment as any single embodiment or in 
combination with any other embodiments or portions thereof. 
20 Any compositions or methods provided herein can be com-
bined with one or more of any of the other compositions and 
methods provided herein. 
BRIEF DESCRIPTION OF THE DRAWINGS 
25 
FIGS. 1A-1E relate to spontaneous cell fusion in vitro. 
Cultures of primary murine lung fibroblasts (MLF), Lewis 
lung carcinoma (LLC) cells and co-cultures were labeled, 
cultured for twenty-four hours and then sorted for fusion 
30 events. FIG. lA shows confocal microscope images of MLF-
MLF, MLF-LLC, and LLC-LLC fused cells. The presence of 
red (Qtracker® 655, Invitrogen) and green (Qtracker(k 525, 
Invitrogen) quantum dots (Qdots) within a single cytoplasm 
identified fused cells. Nuclei are stained with To-Pro®-3 (In- 
35 vitrogen) and given a blue pseudocolor. All photos are recon-
structed z-stack images. Scale bar is 10 mm. The MLF-MLF 
cell fusion (left) is detected at an early stage, arrows point to 
Qdots being exchanged through the filopodia linking the two 
cells. Fusion of cells in different cell cycle phases is detected. 
4o Note both interphase nuclei and prophase nuclei within the 
same cell, LLC-LLC (right) and MLF-LLC (right). FIG. 1B 
shows FACS data from sorting of fused cells. Representative 
flow cytometry dot plots for the populations. FIG. 1C pro-
vides histograms showing the percentage of cell-cell fusions 
45 during twenty-four hours. Data is compiled from three sepa-
rate biological replicate sorts with primary lung fibroblasts 
from different mice. Solid bars indicate % of cells detected 
which exhibited both red and green Qdots: 12.9±5.2% MLF-
MLF, 24.8±14.6 for LLC-LLC, and 16.4±2.5 for MLF-LLC. 
5o The dashed bars take into account the fact that for the MLF-
MLF and LLC-LLC cultures, twice as many cell-cell fusions 
must occur than are detectable by this methodology. MLF-
LLC fusions are all directly detectable. FIG. 1D provides 
histograms showing the percentage of double-labeled cells 
55 detected after 24 hours. Data was compiled from three sepa-
rate biological replicate sorts, in the case of the MLF using 
primary lung fibroblasts from different mice. Solid bars indi-
cate % of cells detected which exhibited both red and green 
Qdots: 12.9%±5.2 (25.8±10.4% after compensation for cal- 
60 culated unseen green-green/red-red exchanges striped bar) 
double-labeled MLF, 24.8%±14.7 (49.6%±29.4) double-la-
beled LLC, and 29.4±0.2% (58.8%±0.4) double-labeled 
MLF-MLFp25 cells. FIG. lE is a schematic depicting the 
isolation and subsequent culturing of cells undergoing spon- 
65 taneous cell-cell mixing in vitro. Red and green cells (labeled 
with Qdots) were co-cultured for 24 hours and then sorted for 
cells undergoing horizontal cell-cell exchange events (here 
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depicted as yellow). Following further in vitro culturing the 
cells were injected into mice to assess tumorigenicity of the 
different populations. 
FIGS. 2A-2D show the production of fused cells as func-
tion of passage in vitro. FIG. 2A shows morphological 
changes in fused cells as detected via immunofluorescent 
staining of F-actin (red) with nuclear stain To-Pro®-3. Fused 
cells from early passages form syncytia (blue). Scale bar is 10 
mm. MLF-MLF p4 exhibits organized F-actin stress fibers, 
not seen in MLF-LLC passages. For MLF-MLF cells trans-
formation occurs around p13, accompanied by dramatic 
changes in both nuclei and F-actin (as compared to MLF p13 
cells). Severed actin is detected along with the shape change 
occurring at that same passage. By MLF-MLFp17 cells have 
a phenotype strongly resembling the tumor line LLC. This 
occurs for MLF-LLC cells by p12. FIG. 2B shows measure-
ments of average cell and nuclear area for MLF, LLC, and 
MLF-MLF p8, p10, p12, p13, p16, and p24 populations. 
These measures oscillate as a function of passage, consistent 
with cell-cell fusions and the emergence of smaller cells in 
which there has been a reassortment and repackaging of the 
nuclear material. The ratio settles to about the same value as 
that of the original LLC cells. FIG. 2C shows increasing rates 
of cell proliferation for fused fibroblasts (MLF-MLF) vs. 
non-fused (MLF) fibroblasts and increasing cell proliferation 
rates for MLF-MLF as a function of passage in culture (i.e. 
p8, p17 and p29). This is analogous to the increase in prolif-
eration rate seen during the progression of tumor cells (Rubin 
2007). FIG. 2D shows Hoffman modulation contrast image of 
population of MLF-MLFp13 undergoing transformation in 
culture as compared to MLFp7 or p31 cells. The transformed 
morphology of the vast majority of the MLF-MLFp13 popu-
lation is noted. Black scale bar is 50 µm. 
FIGS. 3A and 3B show that fused fibroblasts undergo 
transformation in vitro. FIG. 3A shows the results of a soft 
agar transformation assay. Cultures of MLF, MLF-MLF pl 
and MLF-MLF p7 show no transformed cell colonies, while 
MLF-MLF p17 and LLC show high transformation. Quanti-
fication indicates MLF-MLF p17 had 1137+-66 colonies, 
considerably more than the 776±515 scored for LLC and 0 
colonies for MLF, MLF-MLF pl and MLF-MLF p7 cultures. 
All dishes were seeded at 5000 cells, separate biological and 
three technical replicates were pooled. FIG. 3B shows a cyto-
genetic analysis of karyotype for cell populations via 
M-FISH for MLF-MLF p8 and MLF-MLF p17. MLF-MLF 
p8 showed extensive aneuploidy. MLF-MLF p17 had aneup-
loidy, a high degree of allele losses and gains and a significant 
number of translocations. 
FIGS. 4A and 4B show that fused fibroblasts induce inva-
sive malignant tumors in vivo. FIG. 4A shows representative 
tumors in C57/13 16 mice after injection of 10 6 MLF-MLF p8 
or MLF-MLF p17 cells. Scale bars are 0.5 cm. Discrete 
multiple tumor nodules were characteristic of the MLF-MLF 
p17 tumors. Histological sections from MLF-MLF p8 and 
MLF-MLF p17 tumors stained with H&E demonstrate inva-
sion of tumor cells into muscle tissue. Black scale bar for 
H&E is 100 µm. FIG. 4B shows tumor growth plotted for 
MLF-MLF p8, n=4 (blue), MLF-MLF p17, n=10 (red) and 
LLC, n=5 (black) populations in C57/136 mice. Nonfused 
MLFs, n=10 (solid green) and MLFs loaded with Qdots®, 
n=10 (open green), were implanted as controls. For MLF-
MLF p8, 50% (2/4) of the implants formed malignant tumors 
after a lag period of greater than 25 days. For MLF-MLFp 17, 
100% (10/10) grew malignant tumors with essentially no lag 
period, 2 days, the same as the murine epithelial Lewis lung 
carcinoma line. 
FIG. 5 shows staining MLF-MLF p8 and MLF-MLF p17 
with a panel of antibodies for cancer related proteins. Col-
umn: H&E; EMA (Epithelial Membrane Antigen), EGFR 
(Epidermal Growth Factor Receptor), anti-apoptotic proto- 
5 oncogene Bcl-2; and tumor suppressor p53. Note absence of 
EMA in these tumors is taken to be an indicator of their 
stromal cell origin, while the presence of significant EMA 
tumor staining from a site in mouse 26 is taken to be an 
indicator of their epithelial cell origin, although the tumor in 
io mouse 26 originated from the same non-genetically altered 
lung fibroblasts. Considerable EGFR and Bcl-2 are detected 
in these tumors. Both these proteins are highly expressed in 
lung cancers. The black scale bars are 20 M. 
FIGS. 6A-6D show a molecular characterization of the 
15 transformation process. Protein and RNA of genes associated 
with carcinogenesis for fused fibroblasts, as a function of 
passage. FIGS. 6A and 6D shows orchestrated cyclic gene 
regulation detected for the classic genes associated with can-
cer, which include the oncogenes Myc, Kras, and Bcl-2; the 
20 tumor suppressors p53 and CDKn2a; the metastasis genes 
CD44 and SPPI (OPN); and the angiogenesis gene VEGF, as 
measured by RT-PCR as a function of passage after fusion. 
Both CD44 and SPPI (OPN) are also associated with normal 
cell-cell fusion. A synchronized regulation of cancer genes 
25 over the whole population was observed consequent to trans-
formation. No such regulation was seen for these same genes 
in the control unsorted MLF population as a function of 
passage. FIGS. 6B and 6C shows immunofluorescent staining 
for CD44 (green) and MMP9 (green) and OPN (red) for 
30 MLF-MLF cells. Staining of Lewis lung carcinoma cells, 
LLC, is shown for reference. Nuclei stained withTo-Pro®-3. 
Scale bars are 10 mm. Low to negligible levels of CD44 and 
MMP-9 were seen in cells of the early MLF-MLF passages 
but high levels of both were detected in later passages. 
35 FIGS. 7A-7D shows the results of in vivo dilution assay to 
detect % of functional cancer stem cells in the MLF-MLF 
population (p25 cells) by measuring tumor growth in immune 
competent mice. Various numbers of MLF-MLF p25 cells 
were injected into p25 competent mice to promote tumor 
40 formation. FIG. 7A shows a plot of the first time and average 
lag time for tumor onset as a function of number of injected 
MLF-MLF p25 cells. The results are seen to be nearly linear 
on the log plot. FIGS. 7B and 7C show plots of tumor growth 
(volume) for MLF-MLFp25 and MLF-MLFp24 cells: 10 6 
45 cells (n=12), 5000 cells (n=12), 500 cells (n=10), 50 cells 
(n=10), and 5 cells (n=10) were injected into C571316 mice. 
The table shows both the numbers of mice at each dilution 
that had visible subcutaneous tumor burden and the numbers 
of mice that were sacrificed to date due to tumor burden, 
50 subcutaneous or internal. Note for some mice injected with 
only 5 or 50 cells, subcutaneous tumors appeared and then 
regressed. FIG. 7D shows a plot of the average lag time for 
tumor onset as a function of number of injected MLF-MLF 
p25 cells. The results are seen to be nearly linear on the log 
55 plot and closely fit the equation y -62.42-9.56x log 10(x), 
where y is the average lag time to tumor onset and x is the 
number of cells injected (red dashed line) (R2 -0.997). 
FIGS. 8A-8D demonstrates that human prostate epithelial 
cell populations undergo cell-cell fusion and fused human 
60 prostate epithelial cells are transformed. FIG. 8A shows the 
karyotype of the primary human adult prostate epithelial 
cells, confirming a normal composition. FIG. 8B shows flow 
cytometry dot plots. Cultures of the karyotypically normal 
prostate epithelial cell population were labeled with red 
65 (Qtracker 655) or green (Qtracker 525) quantum dots, co-
cultured for 24 hours and then sorted for double-labeled cells, 
indicative of cell-cell exchange events. Left plot shows the 
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uniformity of co-cultured cell population. Right plot shows 
cells as function of red or green Qtracker and the gating for 
double positives, Epi-Epi, cells (Gate R2=19,06%). FIG. 8C 
shows confocal microscopic images of prostate epithelial 
co-cultures. FIG. 8C,PanelsAandB show the presence of red 5 
and green quantum dots within a single cytoplasm identified 
cells actively involved in cytoplasmic exchange. FIG. 8C, 
panels C and D show cell structure filaments stained with 
F-actin (red) including both quantum dots. Blue corresponds 
to nuclei stained with To-Pro-3. Scale bar is 10 µm. FIG. 8D 10 
shows bright field microscopic images of prostate epithelial 
cell cultures. FIG. 8D, panel a is an image of the original 
prostate epithelial cell population pre-sort (passage 4). FIG. 
8D, panels b-f are representative images of double-labeled, 15 
Epi-Epi, post-sort (passage 2) exhibiting altered cellular and 
population morphology and characteristic of transformed cell 
population in vitro. Scale bar 200 µm. 
FIG. 9 depicts passage history for human prostate cancer 
cells in vitro and the first three generations in vivo. Schematic 20 
depicts primary prostate epithelial cells labeled with green 
(Qtracker 525) or red (Qtracker 655) quantum dots mixed in 
culture (24 hr), then sorted for the doubled-labeled cell popu-
lation (Epi-Epi). Either 50,000 or 100,000 dual-labeled cells 
were implanted subcutaneously in adult nude or SCID mice. 25 
The description of tumor site (e.g. prostate, lung, lymph 
nodes, etc.) along with mouse type is given. Serial implants of 
tumor fragments mouse-to-mouse are depicted using the 
smaller mouse symbols. Arrows emanate from the tumor type 
transplanted. Shading indicates sacrificed animal due to 30 
tumor burden. To date, tumors have been serially passaged 
through eight generations of mice with tumor burden devel-
oping at multiple sites, attesting to the sustained tumorigenic 
capacity of these cancers. 35 
FIG. 10 depicts tumor tissue with respective histology. 
FIG. 10, panel a shows a subcutaneous tumor on nude mouse 
injected with 50,000 transformed cells. Upper arrow points to 
site of subcutaneous injection and lower arrow to tumor. FIG. 
10, panel al is a histological image of a tumor slice stained 40 
with hemotoxylin and eosin (H&E) revealing well-differen-
tiated adenocarcinoma morphology. FIG. 10, panel b is an 
image of calcified lymph node (lower arrow) present close to 
prostate region and distinctly enlarged prostate coagulating 
gland (upper arrow). FIG. 10, panel bl is a histological image 45 
of prostate tissue from FIG. 10, panel b stained with H&E 
showing cancer cells invading mouse prostate. FIG. 10, panel 
c shows a solid tumor mass found near abdomen. FIG. 10, 
panel cl is a histological image stained with H&E showing 
cancer cells infiltrating intestine lumen. FIG. 10, panel d 50 
shows that subcutaneous injection of 100,000 fused cells led 
to growth of internal tumor mass near chest cavity. FIG. 10, 
panel dl is a histological image of H&E staining of the tumor 
in FIG. 10, panel d. FIG. 10, panel e shows an enlarged 
prostate from tumor burden (arrow). FIG. 10, panels el, e2, 55 
and e3 are histological images of H&E staining showing 
human prostate cancer cells invading and fully integrating 
into the mouse prostate. FIG. 10, panel f shows examples of 
metastatic kidney tumor (note size and discoloration). FIG. 
10, panel fl is a histological image of H&E staining of the 60 
tumor in FIG. 10, panel f. FIG. 10, panel g shows lung tumor 
after serial in vivo passing. FIG. 10, panel gl is a histological 
image of H&E staining of the tumor in FIG. 10, panel g. FIG. 
10, panel h show kidneys, spine (left arrow) and infiltrated 
lymph node (right arrow). FIG. 10, panel Irl is a histologically 65 
image of H&E staining showing cancer cells infiltrating bone. 
FIG. 10, panel i shows metastasis in liver. FIG. 10, panel it is  
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a histological image of H&E staining showing invading 
tumor cells in liver. Tissue/organs/animal scale bar: 3 mm. 
H&E scale bar: 100 µm. 
FIGS. 11A-11E demonstrate that PSA detection confirms 
human prostate cancer in a mouse model. FIG. 11A shows 
immunohistochemical detection of human PSA protein. FIG. 
11A, panels a, b, and c show that high PSA expression (3-4) 
was detected in cancer cells infiltrating the mouse prostate. 
Clean staining PSA detected only in tumor cells which had 
invaded the prostate region after subcutaneous injection on 
the mouse back. FIG. 11A, panel d shows PSA expression in 
subcutaneous tumor. FIG. 11A, panels e and f shows PSA 
expression in lung tumor. Scale bar: 50 µm. FIG. 11B shows 
fluorescence in situ hybridization (FISH) on prostate tumor 
tissue sections. FISH was performed onfrozen tissue sections 
with a probe for human PSA (green). The nuclei of the cells 
were stained with To-Pro-3 (blue). The first row demonstrates 
no detection in lung tissue from a control mouse that was 
injected with single-labeled post-sort Epi cells. No tumors 
were detected at sacrifice or by histology in any of the control 
mice. The next three rows demonstrate positive PSA detec-
tion in mouse tumors that originated from transformed, Epi-
Epi cells. The white scale bar represents 10 M. FIG. 11C 
shows immunofluorescent staining on frozen tissue. The first 
row demonstrates no antibody staining for PSA in lung tissue 
from a control mouse injected with single-labeled post-sort 
Epi cells. The next three rows demonstrate positive PSA (red) 
in mouse tumor tissue that originated from the transformed 
double-labeled Epi-Epi p2 cells. Nuclei were stained with 
To-Pro-3 (blue). The white scale bar represents 20 µm. FIG. 
11D depicts upregulation of PSA mRNA detected along with 
downregulation of NKX3-A mRNA and PAWR mRNA in 
Epi-Epi cells in vitro undergoing transformation in vitro. 
RT-PCR analysis was conducted as a function of in vitro 
passage for the human prostate epithelial cells, both pre and 
post sort. RT-PCR analysis demonstrated that following their 
sorting and subsequent culturing the double-labeled cells, 
Epi-Epi, increased expression of PSA to >10x over that of the 
original unsorted population. PSA upregulation was seen to 
coincide with the downregulation of the well-known prostate 
tumor suppressor genes, NKX3-A and PAWR. No upregula-
tion of PSA or downregulation of the tumor suppressor genes 
was seen for the control single-labeled Epi cell populations. 
Rather these control population cells showed a transient 
decrease in PSA and increase in the tumor suppressor genes. 
The data are normalized to the prostate epithelial cell popu-
lation before sorting. FIG. 11E depicts Western blot analysis 
detecting human PSA in tissue taken from tumor-bearing 
mice but not from control mice. Anti-human PSA western of 
cell lysates from liver of control mice (injected with Epi cells 
from the single-labeled sort) (lane 1), tumor-infiltrated pros-
tatic lymph node (lane 2), and lung tumor (lane 3). 
DETAILED DESCRIPTION OF THE INVENTION 
The invention provides tumor-initiating cell compositions, 
methods for producing a tumor-initiating cell, and the use of 
such cells for the identification of agents useful for the treat-
ment or prevention of neoplasia and for the treatment or 
prevention of relapse following chemotherapy or radiation 
therapy. Desirably, tumor-initiating cells of the invention are 
self-renewing and stem-cell like. Accordingly, the invention 
further provides methods for driving the differentiation of a 
tumor-initiating cell of the invention towards a differentiated 
phenotype. 
The invention is based, at least in part, on the discovery that 
selection and culturing of cells created in cell-cell fusion 
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events generates one or more neoplastic cells. Such cells are 	 cells obtained from healthy tissue or from a neoplasia biopsy 
capable of producing neoplasia in vitro or in vivo. As 	 from a subject. The cells from biopsy are expanded in culture. 
described in more detail below, the selection of cells that have 	 Such cells are isolated using techniques known to those 
undergone spontaneous cell fusion among primary adult 	 skilled in the art. For example, a tissue or organ can be 
murine fibroblasts or human prostate epithelial cells in vitro 5 disaggregated mechanically and/or treated with digestive 
was sufficient to create a population of cells that induced 	 enzymes and/or chelating agents that weaken the connections 
high-grade malignant tumors in vivo with 100% efficiency. 	 between neighboring cells making it possible to disperse the 
Despite the absence of viral, genetic or other manipulations, 	 tissue into a suspension of individual cells without appre- 
these cells exhibited the classic hallmarks of cancer. Careful 	 ciable cell breakage. Enzymatic dissociation can be accom- 
characterization of mouse fibroblasts selected in this way io plished by mincing the tissue and treating the minced tissue 
revealed changes characteristic of cancer, including aneup- 	 with digestive enzymes (e.g., trypsin, chymotrypsin, collage- 
loidy; chromosome-level aberrations, upregulated oncogenes 	 nase, elastase, hyaluronidase, DNase, pronase, and dispase). 
(myc, k-ras, EGFR, Bcl-2), downregulated tumor suppressor 	 Mechanical disruption can be accomplished by scraping the 
genes (CDKn2a), upregulated invasion, metastasis and 	 surface of the organ, the use of grinders, blenders, sieves, 
angiogenic genes (MMP9, CD44, OPN, VEGF), genomic 15 homogenizers, pressure cells, or sonicators. For a review of 
instability, and a continuously increasing proliferation rate. 	 tissue disruption techniques, see Freshney, (Culture of Ani- 
Strikingly, the dysregulation of oncogenesis genes 	 mal Cells. A Manual of Basic Technique, 2d Ed., A. R. Liss, 
occurred simultaneously with the transformation event. 	 Inc., New York, Ch. 9, pp. 107-126, 1987). 
These results indicate that a classic cancer cell genotype need 
	
Once a tissue has been reduced to a suspension of indi- 
not arise through selection acting on random mutations, but go vidual cells, the suspension can be fractionated into subpopu- 
rather can arise as part of a deterministic, programmed 
	
lations. This may be accomplished using standard techniques 
genomic response to spontaneous cell fusion events. In sum, 	 (e.g., cloning and positive selection of specific cell types or 
spontaneous cell-cell fusions can initiate and drive the essen- 	 negative selection, i.e., the destruction of unwanted cells). 
tial aspects of carcinogenesis, including transformation, pro- 	 Selection techniques include separation based upon differen- 
gression, invasion, metastasis and self renewal thereby pro-  25 tial cell agglutination in a mixed cell population, freeze-thaw 
viding further mechanistic understanding of cancer 	 procedures, differential adherence properties of the cells in 
induction. 	 the mixed population, filtration, conventional and zonal cen- 
Spontaneous cell-cell fusion as provided herein is not 	 trifugation, unit gravity separation, countercurrent distribu- 
driven by viruses, synthetic agents, or inserted heterologous 	 tion, electrophoresis and fluorescence-activated cell sorting. 
genetic material (e.g., oncogenes). As described herein, the 3o For a review of clonal selection and cell separation tech- 
fusion process is driven by the selection of cells that have 	 niques, see Freshney, Culture of Animal Cells. A Manual of 
undergone fusion. If desired, such cells can be grown under 	 Basic Techniques, 2d Ed., A. R. Liss, Inc., New York, Ch. 11 
conditions that sufficient to promote multiple rounds of 	 and 12, pp. 137-168, 1987). The use of autologous cells, is 
fusion, thereby generating multinucleate cells. These multi- 	 preferred. As described herein, such cells are used for the 
nucleate cells are precursors of tumor-initiating mononuclear 35 selection of individualized therapeutic agents for the subject 
cells. Tumor-initiating cells of the invention are used to gen- 	 from whom the cells are derived or from another subject. 
erate animal models of metastatic cancer and cancer in nude 	 Alternatively, such cells are used for the production of anti- 
mice, as well as in non-immune compromised animals. 	 neoplasia vaccines for the subject from whom the cells are 
Methods for Generating Tumor-Initiating Cells 	 derived or from another subject. Methods oftherapy selection 
Tumor-initiating cells of the invention are generated by 4o and for vaccine production are described below. 
establishing primary cells in culture and selecting those that 	 Based on results reported herein, tumor-initiating cells are 
have undergone fusion according to the methods described 	 more resistant to chemotherapeutic agents, radiation, and 
herein or any other method known in the art. In one embodi- 	 other insults due to their ability to recombine to correct 
ment, such cells are grown in culture at a relatively high 	 genetic damage induced by the insults. Therefore, it should be 
density (plating at about 80% confluence) or under other 45 possible to identify a subpopulation of tumor-initiating cells 
conditions sufficient to promote further cell-cell fusion 	 by their resistance to insults. Cells are cultured at a suffi- 
events. In a preferred embodiment, cells are identified as 	 ciently high density (at least 80% confluent) preferably for 
having fused by detecting the exchange of soluble cytoplas- 	 sufficient time to allow for more than one round of cell fusion, 
mic markers, such as Qdots® which are vital dyes that do not 	 at least about 24 hours, preferably about 48 to 72 hours. Cells 
induce cell fusion, or cells can be derived from transgenic 5o are then subjected to an insult sufficient to kill most of the 
animals, such as mice, that express fluorescent proteins, such 	 cells. Dead cells are removed, and the remaining viable cells 
as green fluorescent protein (GFP) or red fluorescent protein 	 are transferred to a culture of high density (e.g., at least about 
(RFP) in a tissue of interest. In one alternative embodiment, 	 80% confluent). 
detectable markers incorporated in the cell membrane can be 	 Cells that have undergone fusion can be identified based on 
used. Cells with at least two distinct detectable markers are 55 marker expression. As disclosed herein, tumor-initiating cells 
co-cultured for preferably at least about eight and more pref- 	 of the invention undergo a program of synchronous expres- 
erably for at least about twenty-four hours. Cells having the 	 sion and non-expression of specific cell markers (e.g., 
two distinct markers are identified as having fused. Cells are 	 increased expression of classic oncogenes, such as myc, 
also identified as having fused if they have two nuclei that are 	 k-ras, EGFR, Bcl-2, decreased expression of tumor suppres- 
not a result of mitosis or meiosis. Cells having at least three 60 sor gene CDKn2a, increased expression of invasion, metasta- 
nuclei have clearly undergone cell fusion. 	 sis and angiogenic genes MMP9, CD44, OPN, VEGF). If 
While the examples provided herein specifically describe 	 desired, cells are co-cultured at sufficiently high density to 
methods for selecting tumor-initiating cells from fibroblast 	 promote further fusion events. In one embodiment, cells are 
and epithelial cultures, the invention is not so limited. Cells 	 cultured for sufficient time to allow for more than one round 
for use in the methods of the invention can be isolated from a 65 of cell fusion, and selected for expression and/or non-expres- 
number of sources, including, for example, from a tissue of a 	 sion of cell markers. Appropriate markers can be selected 
patient. In one embodiment, the isolated cells are autologous 	 based on the data in FIG. 6. 
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Fluorescent labels allow for the sorting of cells that have 
fused using a fluorescent activated cell sorter (FACS) 
machine. Cells can also be sorted manually. The specific 
method of sorting and isolation is not a limitation of the 
invention. The isolated subpopulation of cells are plated at a 5 
high density of at least about 80% confluent to promote fur-
ther cell fusion. 
The isolation of the subpopulation of cells results in a 
culture that is both synchronous in the expression of markers, 
and therefore not surprisingly synchronous in the progression l0 
of a series of morphological changes, from mononucleate, to 
multinucleate, to cytoskeletal collapse, to mononuclear cells 
with high nuclear to cytoplasmic ratio. 
Screening Assays 	 15 
The invention provides for the selection of tumor-initiating 
cells. Such cells may be used to identify novel therapeutic 
agents for the treatment of neoplasia. Without wishing to be 
bound by theory, cell-cell fusion may be the original step that 
gives rise to a neoplasia or to a neoplastic precursor cell. 20 
Accordingly, compositions of the invention are useful to iden-
tify agents that reduce the generation, proliferation, and/or 
survival of such cells. 
As reported herein, tumor-initiating cells progress through 
a series of phenotypic stages in culture. Interruption of the 25 
process at any step will likely disrupt the formation of tumor-
initiating cells. Methods for screening agents for therapeutic 
activity are well known in the art. It is understood that initial 
screening methods in vitro typically lead to the further testing 
of compounds both in vitro and in vivo. Screening assays can 30 
be combined to characterize agents with potential therapeutic 
activity. Agents can be selected based on functional or struc-
tural homology (e.g., chemotherapeutic agents, kinase inhibi-
tors), combinatorial chemistry libraries, natural compound 
libraries, approved drug libraries, peptide libraries, etc. 35 
Agents can also be rationally selected based on their known 
function. Osteopontin, for example, is likely to be useful to 
inhibit production of a tumor-initiating cell because of its 
biological activity as an inhibitor of cell fusion. In all screen-
ing assays, agents are preferably tested in duplicate or tripli- 40 
cate and appropriate controls, preferably both positive and 
negative, are run to allow for determining relative activity of 
the agent. The ability to design proper controls is within the 
ability of those of skill in the art. 
In vivo, tumor cells may not synchronously proceed 45 
through the steps observed herein to generate tumor-initiating 
cells or a synchronous program of marker expression. There-
fore, an effective therapeutic intervention may, if desired, 
include administration of a combination of compounds that 
disrupt different steps in the process. Similarly, administra- 50 
tion of an agent to disrupt the formation of tumor-initiating 
cells in combination with one or more known chemothera-
peutic agents may also be useful. 
The invention provides for the generation of isolated cul-
tures enriched for cells that are synchronous as they proceed 55 
through the steps of cell fusion, multinucleate cell formation, 
and partitioning into mononuclear cells. Isolated cultures of 
tumor-initiating cells are prepared, and agents are added to 
the cultures at discrete time points prior to fusion, prior to 
partition of mononuclear cells from the multinucleate cell, or 60 
after partition of mononuclear cells from the multinucleate 
cell. It is noted that the formation of tumor-initiating cells can 
be accomplished by specifically killing the multinucleate 
cells or the mononuclear cells partitioned from the multi-
nucleate cell. Agents that prevent fusion by killing the initial 65 
cell population prior to fusion may also be useful. The exact 
times for administration of agents and detection of changes in 
growth or other phenotypic or genotypic changes can be 
readily determined by those of skill in the art. 
Agents can also be tested for their ability to reduce tumoro-
genicity of cells in either a soft agar growth assay or a tumoro-
genicity assay in animals, such as rats or mice. Such methods 
are described herein and well known to those of skill in the art. 
Screening forAgents that Inhibit Cell Fusion or the Growth of 
the Descendants of Such Cells 
Cell-cell fusion results in the generation of highly tumoro-
genic and metastatic cells. Such cells may be responsible for 
tumor resistance to chemotherapeutic agents or to radio-
therapy. However, chemotherapeutic agents have necessarily 
been tested for activity against bulk tumor because no meth-
ods for isolating cancer stem cells. Using the tumor-initiating 
cells of the invention, therapeutic and prophylactic agents can 
now be tested for the ability to disrupt cell fusion, the ability 
to inhibit production of mononuclear cells from a multinucle-
ate cell, and/or to inhibit the generation of tumor-initiating 
and/or metastatic cells of the invention. Agents can also be 
tested for their ability to kill rare tumor-initiating cells that are 
resistant to conventional chemotherapeutic agents and radia-
tion therapy. Such agents can include single agents or librar-
ies of compounds with or without structural of functional 
similarities. 
Cells that have undergone fusion are identified using cyto-
plasmic vital dyes, by nuclear staining to identify cells with at 
least 4N DNA content or multinucleate cells that are not in the 
G2 or M phase of the cell cycle, or by direct observation of the 
cells. In one embodiment, cells are sorted using a FACS 
machine and plated into multiwell plates at a density of at 
least 80% to promote cell fusion. 
To identify agents that inhibit cell fusion, agents are added 
to the wells at or around the time of plating, or at the latest 
prior to the initiation of cell fusion. The agent is preferably 
applied to wells in duplicate or triplicate with appropriate 
control wells (e.g., vehicle control, positive control) for com-
parison. Appropriate time frames can vary between cell types 
and be readily determined by empirical observation. The 
amount of cell fusion is determined, for example, by direct 
observation or by FACS analysis after the desired time period 
after exposure to the agent (e.g., about 12 hours, 24 hours, 48 
hours, 72 hours or longer). In one embodiment, compounds 
are administered at a dose that does not kill the cells, but 
instead inhibits fusion. Compounds found to inhibit fusion 
can be tested and characterized, for example, for the ability to 
reduce the formation of colonies on soft-agar or to reduce 
tumor formation in mice. Agents found to inhibit cell fusion 
are useful in treating or preventing the progression of hyper-
plasia to more severe disease or hyperproliferative disorders. 
Agents that may inhibit fusion include, but are not limited to, 
CD44 antagonists, CD 133, and osteopontin. 
To identify agents that kill fused, multinucleate cells, cells 
able to undergo fusion are selected at plated at a density of at 
least about 80% confluency and allowed to undergo fusion 
until at least about 50% of the cells are multinucleate prior to 
contacting the cells with the agent. The agent is preferably 
applied to wells in duplicate or triplicate with appropriate 
control wells (e.g., vehicle control, positive control) for com-
parison. Appropriate time frames can vary between cell types 
and be readily determined by empirical observation. The 
amount of viable multinucleate cells are determined for 
example by direct observation or FACS analysis after the 
desired time period after exposure to the agent (e.g., about 12 
hours, 24 hours, 48 hours, 72 hours or longer). Wells are also 
observed for the generation of mononucleate cells in response 
to the agent. Agents found to kill fused cells or prevent for-
mation of single nucleate cells from the fused cell can be 
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tested and characterized further for example for the ability to 
reduce the formation of colonies on soft-agar or to reduce 
tumor formation or halt tumor growth in mice. Agents may or 
may not be useful in killing the bulk of tumor cells in animal 
models; however, upon killing of the most tumorogenic cells, 5 
the tumor should cease to grow and eventually die. 
To identify agents that kill mononucleate cells derived 
from multinucleate cells, cells able to undergo fusion are 
selected at plated at a density of at least about 80% conflu-
ency, allowed to undergo fusionuntil at least about 80% of the io 
cells are multinucleate, and subsequently produce multi-
nucleate cells prior to contacting the cells with the agent. The 
agent is preferably applied to wells in duplicate or triplicate 
with appropriate control wells (e.g., vehicle control, positive 
control) for comparison. Appropriate time frames can vary 15 
between cell types and be readily determined by empirical 
observation. The amount of viable cells are determined for 
example by direct observation or FACS analysis after the 
desired time period after exposure to the agent (e.g., about 12 
hours, 24 hours, 48 hours, 72 hours or longer). Agents found 20 
to kill mononucleate cells from fused cells can be tested and 
characterized further for example for the ability to reduce the 
formation of colonies on soft-agar or to reduce tumor forma-
tion or halt tumor growth in mice. Agents may or may not be 
useful in killing the bulk of tumor cells in animal models; 25 
however, upon killing of the most tumorogenic cells, the 
tumor should cease to grow and eventually die. 
Therapy Selection 
The highly tumorogenic cells provided herein can be gen-
erated from normal or from neoplastic cells. It is known that 30 
different cancers respond to different therapeutic agents, or 
combinations of agents, differently depending on the specific 
characteristics of the tumor, and the genetic makeup of the 
subject in whom the tumor is present. Tests have been devel-
oped to characterize tumors, including, for example, the 35 
Oncotype DX by Genomic Health, which contains sixteen 
genes associated with breast cancer and five control genes. 
This test can predict the likelihood of cancer recurrence and 
provide information regarding which chemotherapeutic 
interventions are likely to be most useful. However, such a 40 
test can only look at the bulk properties of the tumor and 
cannot provide information on highly tumorogenic cells that 
may be present in the population. 
Normal and/or abnormal cells are obtained from an indi-
vidual diagnosed with cancer. Primary cultures are generated 45 
using methods appropriate to the specific cell type to be 
cultured. Rates of generation of fused cells can be compared 
between the normal cells in culture and the abnormal cells in 
culture. A higher rate of generation of fused cells in the 
culture may suggest increased malignancy of the tumor. 50 
Normal and/or abnormal cells that have been grown in 
culture to obtain an enriched population of tumor-initiating 
cells can be tested for response to a panel of approved che-
motherapeutic agents. Depending on the stage of the tumor in 
the subject, different compounds can be tested at different 55 
phases of the culturing of the cells for the ability to inhibit 
fusion and/or kill cells. Chemotherapeutic agents that can be 
tested include, but are not limited to alkylating and alkylating-
like agents such as nitrogen mustards (Chlorambucil, Chlo-
rmethine, Cyclophosphamide, Ifosfamide, Melphalan, Ben- 60 
damustine, Uramustine), nitrosoureas (Carmustine, 
Fotemustine, Lomustine, Streptozocin); platinum (alkylat-
ing-like): (Carboplatin, Cisplatin, Oxaliplatin, Triplatin tet-
ranitrate, Satraplatin), alkyl sulfonates (Busulfan, Treosul-
fan); hydrazines (Procarbazine, Dacarbazine, 65 
Temozolomide); and aziridines (ThioTEPA); antimetabolites 
such as folic acid analogs (Aminopterin, Methotrexate, Pem- 
etrexed, Raltitrexed); purine analogs (Cladribine, Clofara-
bine, Fludarabine, Mercaptopurine, Pentostatin, Thiogua-
nine); and pyrimidine analogs (Capecitabine, Cytarabine, 
Decitabine, Fluorouracil, Floxuridine, Gemcitabine); spindle 
poison/mitotic inhibitor Taxane (Docetaxel, Larotaxel, Pacli-
taxel); Vinca (Vinblastine, Vincristine, Vindesine, Vinorel-
bine); cytotoxic/antitumor antibiotics of the anthracycline 
family (Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, 
Mitoxantrone, Pixantrone, Valrubicin); streptomyces (Acti-
nomycin, Bleomycin, Mitomycin, Plicamycin); Hydrox-
yurea; topoisomerase inhibitors Camptotheca (Camptoth-
ecin, Topotecan, Irinotecan, Rubitecan); Podophyllum: 
(Etoposide, Teniposide); Cl monoclonal antibodies; receptor 
tyrosine kinase (Cetuximab, Panitumumab, Trastuzumab); 
CD20 (Rituximab, Tositumomab); and other chemotherapeu-
tic agents (Alemtuzumab, Bevacizumab, Gemtuzumab) Pho-
tosensitizers Aminolevulinic acid, Methyl aminolevulinate, 
Porfimer sodium, Verteporfin Tyrosine kinase inhibitors Axi-
tinib, Bosutinib, Cediranib, Dasatinib, Erlotinib, Gefitinib, 
Imatinib, Lapatinib, Lestaurtinib, Nilotinib, Semaxanib, Sor-
afenib, Sunitinib, Vandetanib Cyclin-dependent kinase 
inhibitor Seliciclib Other retinoids (Alitretinoin, Tretinoin), 
Fusion protein (Aflibercept)-Altretamine, Amsacrine, 
Anagrelide, Arsenic trioxide, Asparaginase (Pegaspargase), 
Bexarotene, Bortezomib, Celecoxib, Denileukin diftitox, 
Elesclomol, Estramustine, Irofulven, Ixabepilone, Masopro-
col, Mitotane, Oblimersen, Testolactone, Tipifarnib, Trabect-
edin. 
Response of the enriched tumor-initiating cell population 
to the agent in culture is likely predictive of the response of 
the tumor in vivo. The usefulness of the method can be tested 
in animal models of cancer. 
Anti-Neoplasia Vaccines 
Anti-neoplasia vaccines are useful as therapeutics for the 
treatment of specific types of cancer. Advantageously, these 
vaccines may be tailored to treat the cancers of particular 
individuals, by generating vaccines that target specific tumor 
antigens expressed on a tumor in a subject. Anti-neoplasia 
vaccines of the invention are particularly useful because they 
provide for the targeting of tumor-initiating cells that are 
responsible for neoplasia relapse. Anti-neoplasia vaccines 
typically contain inactivated tumor cells or tumor antigens 
that stimulate a patient's immune system. The immune sys-
tem responds to this stimulation by generating immunore-
sponsive cells that target the neoplasia. In particular embodi-
ments, anti-neoplasia vaccines of the invention desirably 
target tumor-initiating cells, thereby preventing relapses of 
the neoplasia. Unlike vaccines for other diseases that prevent 
the occurrence of the disease, anti-neoplasia vaccines are 
typically administered after a subject has been identified as 
having a neoplasia. 
Anti-neoplasia cell vaccines are produced using the cellu-
lar compositions of the invention, which are generated as 
described herein. In particular, a tumor-initiating cell is pro-
duced by isolating fibroblasts, epithelial cells, or other cells 
from a subject and/or isolating a tumor cell from the subject. 
In one approach, primary cells are isolated and cultured in 
vitro. Cells that have undergone cell-cell fusion in vitro are 
selected according to a methods described herein (e.g., using 
quantum dots, identifying cells having one or more nuclei). If 
desired, the cells are cultured at high density to promote 
further fusion events. Preferably, the cells are cultured at high 
density, and passaged between at least about 3-25 times (e.g., 
3, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 
23, 24, 25). Cells generatedby this process arehighly tumoro-
genic. The cells are killed and injected into the patient where 
the tumor-initiating cell antigens stimulate an immune 
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response. Desirably, the immune system targets the small 
population of tumor-initiating cells that carry one or more 
antigens that was displayed on the dead cells. In other 
embodiments, selected cells are cultured together with iso-
lated tumor cells, and tumor cell-normal cell (e.g., fibrobast, 
epithelial cell) fusions are selected. In still other embodi-
ments, tumor cell-tumor cell fusions are selected. 
In particular embodiments, cells of the invention synchro-
nously express particular antigens, which allows for the 
analysis of protein expression at various points during the 
fusion process. Identification of antigens expressed prior to or 
during fusion allows for the production of a vaccine that 
prevents cell fusion. 
The methods provided herein can also be used for the 
generation of a vaccine for specific treatment of neoplasias in 
individuals. Cells are obtained from normal or neoplastic 
cells from the individual and cultured to identify markers 
present on tumor-initiating cells. Rapid methods of screening 
for recombinant antibodies, such as single chain humanized 
antibodies, can be performed to select an agent appropriate 
for treatment of cancer in a specific individual. 
Antigen vaccines use tumor-specific antigens proteins 
displayed on a tumor cell to stimulate the immune system. 
By injecting these antigens systemically or into the neoplastic 
area of the patient, the immune system produces antibodies or 
cytotoxic T lymphocytes to attack neoplastic cells that carry 
that specific antigen. Multiple antigens can be used in this 
type of vaccine to vary the immune system response. 
Typically vaccines are prepared in an injectable form, 
either as a liquid solution or as a suspension. Solid forms 
suitable for injection may also be prepared as emulsions, or 
with the polypeptides encapsulated in liposomes. The cells 
are injected in any suitable carrier known in the art. Suitable 
carriers typically comprise large macromolecules that are 
slowly metabolized, such as proteins, polysaccharides, poly-
lactic acids, polyglycolic acids, polymeric amino acids, 
amino acid copolymers, lipid aggregates, and inactive virus 
particles. Such carriers are well known to those skilled in the 
art. These carriers may also function as adjuvants. 
Adjuvants are immuno stimulating agents that enhance 
vaccine effectiveness. Effective adjuvants include, but are not 
limited to, aluminum salts such as aluminum hydroxide and 
aluminum phosphate, muramyl peptides, bacterial cell wall 
components, saponin adjuvants, and other substances that act 
as immuno stimulating agents to enhance the effectiveness of 
the composition. 
Vaccines are administered in a manner compatible with the 
dose formulation. By an effective amount is meant a single 
dose, or a vaccine administered in a multiple dose schedule, 
that is effective for the treatment or prevention of a disease or 
disorder. Preferably, the dose is effective to inhibit the growth 
of a neoplasm. The dose administered will vary, depending on 
the subject to be treated, the subject's health and physical 
condition, the capacity of the subject's immune system to 
produce antibodies, the degree of protection desired, and 
other relevant factors. Precise amounts of the active ingredi-
ent required will depend on the judgment of the practitioner. 
Test Compounds and Extracts 
In general, agents that inhibit cell-cell fusion, that increase 
cell death or otherwise reduce the proliferation or survival of 
a tumor-initiating cell of the invention are identified from 
large libraries of natural product or synthetic (or semi-syn-
thetic) extracts or chemical libraries or from polypeptide or 
nucleic acid libraries, according to methods known in the art. 
Those skilled in the field of drug discovery and development 
will understand that the precise source of test extracts or 
compounds is not critical to the screening procedure(s) of the 
26 
invention. Alternatively, virtually any number of unknown 
chemical extracts or compounds can be screened using the 
methods described herein. Examples of such extracts or com-
pounds include, but are not limited to, plant-, fungal-, 
5 prokaryotic- or animal-based extracts, fermentation broths, 
and synthetic compounds, as well as the modification of 
existing polypeptides. 
Libraries of natural polypeptides in the form of bacterial, 
fungal, plant, and animal extracts are commercially available 
10 from a number of sources, including Biotics (Sussex, UK), 
Xenova (Slough, UK), Harbor Branch Oceangraphics Insti-
tute (Ft. Pierce, Fla.), and PharmaMar, U.S.A. (Cambridge, 
Mass.). Such polypeptides can be modified to include a pro- 
15 tein transduction domain using methods known in the art and 
described herein. In addition, natural and synthetically pro-
duced libraries are produced, if desired, according to methods 
known in the art, e.g., by standard extraction and fractionation 
methods. Examples of methods for the synthesis of molecular 
20 libraries can be found in the art, for example in: DeWitt et al., 
Proc. Natl. Acad. Sci. U.S.A. 90:6909,1993; Erb et al., Proc. 
Nad. Acad. Sci. USA 91:11422, 1994; Zuckermann et al., J. 
Med. Chem. 37:2678, 1994; Cho et al., Science 261:1303, 
1993; Carrell et al., Angew. Chem. Int. Ed. Engl. 33:2059, 
25 1994; Carell et al., Angew. Chem. Int. Ed. Engl. 33:2061, 
1994; and Gallop et al., J. Med. Chem. 37:1233, 1994. Fur-
thermore, if desired, any library or compound is readily modi-
fied using standard chemical, physical, or biochemical meth-
ods. 
30 Numerous methods are also available for generating ran-
dom or directed synthesis (e.g., semi-synthesis or total syn-
thesis) of any number of polypeptides, chemical compounds, 
including, but not limited to, saccharide-, lipid-, peptide-, and 
35 nucleic acid-based compounds. Synthetic compound librar-
ies are commercially available from Brandon Associates 
(Merrimack, N.H.) andAldrich Chemical (Milwaukee, Wis.). 
Alternatively, chemical compounds to be used as candidate 
compounds canbe synthesized from readily available starting 
40 materials using standard synthetic techniques and method-
ologies known to those of ordinary skill in the art. Synthetic 
chemistry transformations and protecting group methodolo-
gies (protection and deprotection) useful in synthesizing the 
compounds identified by the methods described herein are 
45 known in the art and include, for example, those such as 
described in R. Larock, Comprehensive Organic Transforma-
tions, VCH Publishers (1989); T. W. Greene and P. G. M. 
Wins, Protective Groups in Organic Synthesis, 2nd ed., John 
Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and 
5o Fieser's Reagents for Organic Synthesis, John Wiley and 
Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents 
for Organic Synthesis, John Wiley and Sons (1995), and 
subsequent editions thereof. 
Libraries of compounds may be presented in solution (e.g., 
55 Houghten, Biotechniques 13:412-421, 1992), or on beads 
(Lam, Nature 354:82-84, 1991), chips (Fodor, Nature 364: 
555-556, 1993), bacteria (Ladner, U.S. Pat. No. 5,223,409), 
spores (Ladner U.S. Pat. No. 5,223,409), plasmids (Cull et al., 
Proc Nad Acad Sci USA 89:1865-1869, 1992) or on phage 
60 (Scott and Smith, Science 249:386-390, 1990; Devlin, Sci-
ence 249:404-406, 1990; Cwirla et al. Proc. Nad. Acad. Sci. 
87:6378-6382,1990; Felici, J. Mol. Biol. 222:301-310,1991; 
Ladner supra.). 
In addition, those skilled in the art of drug discovery and 
65 development readily understand that methods for dereplica- 
tion (e.g., taxonomic dereplication, biological dereplication, 
and chemical dereplication, or any combination thereof) or 
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the elimination of replicates or repeats of materials already 	 tion and preparation of such compositions are well known to 
known for their activity should be employed whenever pos- 	 those skilled in the art of pharmaceutical formulation. For- 
sible. 	 mulations can be found in Remington: The Science and Prac- 
When a crude extract is found to have anti-neoplastic activ- 	 tice of Pharmacy, supra. 
ity further fractionation of the positive lead extract is neces-  5 	 Compositions for parenteral use may be provided in unit 
sary to isolate molecular constituents responsible for the 	 dosage forms (e.g., in single-dose ampoules), or in vials con- 
observed effect. Thus, the goal of the extraction, fraction- 	 taining several doses and in which a suitable preservative may 
ation, and purification process is the careful characterization 	 be added (see below). The composition may be in the form of 
and identification of a chemical entity within the crude extract 	 a solution, a suspension, an emulsion, an infusion device, or a 
that is useful as a neoplasia therapeutic. Methods of fraction-  io delivery device for implantation, or it may be presented as a 
ation and purification of such heterogenous extracts are 	 dry powder to be reconstituted with water or another suitable 
known in the art. If desired, compounds shown to be useful as 	 vehicle before use. Apart from the active agent that reduces or 
therapeutics are chemically modified according to methods 	 ameliorates neoplasia, the composition may include suitable 
known in the art. 	 parenterally acceptable carriers and/or excipients. The active 
Pharmaceutical Therapeutics 	 15 therapeutic agent(s) may be incorporated into microspheres, 
The invention provides a simple means for identifying 	 microcapsules, nanoparticles, liposomes, or the like for con- 
compositions (including nucleic acids, peptides, small mol- 	 trolled release. Furthermore, the composition may include 
ecule inhibitors, and antibodies) useful as therapeutics for the 	 suspending, solubilizing, stabilizing, pH-adjusting agents, 
treatment or prevention of a neoplasia. Accordingly, a chemi- 	 tonicity adjusting agents, and/or dispersing, agents. Control 
cal entity discovered to have medicinal value using the meth-  20 release dosage forms are known in the art. 
ods described herein is useful as a drug or as information for 	 As indicated above, the pharmaceutical compositions 
structural modification of existing compounds, e.g., by ratio- 	 according to the invention may be in the form suitable for 
nal drug design. Such methods are useful for screening agents 	 sterile injection. To prepare such a composition, the suitable 
having an effect on a variety of neoplasias associated with 	 active agent(s) are dissolved or suspended in a parenterally 
viral infections. 	 25 acceptable liquid vehicle. Among acceptable vehicles and 
For therapeutic uses, the compositions or agents identified 	 solvents that may be employed are water, water adjusted to a 
using the methods disclosed herein may be administered sys- 	 suitable pH by addition of an appropriate amount of hydro- 
temically, for example, formulated in a pharmaceutically- 	 chloric acid, sodium hydroxide or a suitable buffer, 1,3-bu- 
acceptable buffer such as physiological saline. Preferable 	 tanediol, Ringer's solution, and isotonic sodium chloride 
routes of administration include, for example, subcutaneous, 30 solution and dextrose solution. The aqueous formulation may 
intravenous, interperitoneally, intramuscular, or intradennal 	 also contain one or more preservatives (e.g., methyl, ethyl or 
injections that provide continuous, sustained levels of the 	 n-propyl p-hydroxybenzoate). In cases where one of the com- 
drug in the patient. Treatment of human patients or other 	 pounds is only sparingly or slightly soluble in water, a disso- 
animals will be carried out using a therapeutically effective 	 lution enhancing or solubilizing agent can be added, or the 
amount of a therapeutic identified herein in a physiologically- 35 solvent may include 10-60% w/w of propylene glycol or the 
acceptable carrier. Suitable carriers and their formulation are 	 like. 
described, for example, in Remington's Pharmaceutical Sci- 	 Solid Dosage Forms For Oral Use 
ences by E. W. Martin. The amount of the therapeutic agent to 	 Formulations for oral use include tablets containing the 
be administered varies depending upon the manner of admin- 	 active ingredient(s) in a mixture with non-toxic phannaceu- 
istration, the age and body weight of the patient, and with the 40 tically acceptable excipients. Such formulations are known to 
clinical symptoms of neoplasia. Generally, amounts will be in 	 the skilled artisan. Excipients may be, for example, inert 
the range of those used for other agents used in the treatment 	 diluents or fillers (e.g., sucrose, sorbitol, sugar, mannitol, 
of other diseases associated with neoplasia. 	 microcrystalline cellulose, starches including potato starch, 
The administration of a compound for the treatment of a 	 calcium carbonate, sodium chloride, lactose, calcium phos- 
neoplasia may be by any suitable means that results in a 45 phate, calcium sulfate, or sodium phosphate); granulating and 
concentration of the therapeutic that, combined with other 	 disintegrating agents (e.g., cellulose derivatives including 
components, is effective in ameliorating, reducing, or stabi- 	 microcrystalline cellulose, starches including potato starch, 
lizing a neoplasia. The compound may be contained in any 	 croscannellose sodium, alginates, or alginic acid); binding 
appropriate amount in any suitable carrier substance, and is 	 agents (e.g., sucrose, glucose, sorbitol, acacia, alginic acid, 
generally present in an amount of 1-95% by weight of the 50 sodium alginate, gelatin, starch, pregelatinized starch, micro- 
total weight of the composition. The composition may be 	 crystalline cellulose, magnesium aluminum silicate, car- 
provided in a dosage form that is suitable for parenteral (e.g., 	 boxymethylcellulose sodium, methylcellulose, hydroxypro- 
subcutaneously, intravenously, intramuscularly, or intraperi- 	 pyl methylcellulose, ethylcellulose, polyvinylpyrrolidone, or 
toneally) administration route. The pharmaceutical composi- 	 polyethylene glycol); and lubricating agents, glidants, and 
tions may be formulated according to conventional phanna-  55 antiadhesives (e.g., magnesium stearate, zinc stearate, stearic 
ceutical practice (see, e.g., Remington: The Science and 	 acid, silicas, hydrogenated vegetable oils, or talc). Other 
Practice of Pharmacy (20th ed.), ed. A. R. Gennaro, Lippin- 	 pharmaceutically acceptable excipients can be colorants, fla- 
cott Williams & Wilkins, 2000 and Encyclopedia ofPharma- 	 voring agents, plasticizers, humectants, buffering agents, and 
ceutical Technology, eds. J. Swarbrick and J. C. Boylan, 	 the like. 
1988-1999, Marcel Dekker, New York). 	 60 The tablets may be uncoated or they may be coated by 
Parenteral Compositions 	 known techniques, optionally to delay disintegration and 
The pharmaceutical composition may be administered 	 absorption in the gastrointestinal tract and thereby providing 
parenterally by injection, infusion or implantation (subcuta- 	 a sustained action over a longer period. The coating may be 
neous, intravenous, intramuscular, intraperitoneal, or the 	 adapted to release the active drug in a predetermined pattern 
like) in dosage forms, formulations, or via suitable delivery 65 (e.g., in order to achieve a controlled release formulation) or 
devices or implants containing conventional, non-toxic phar- 	 it may be adapted not to release the active drug until after 
maceutically acceptable carriers and adjuvants. The formula- 	 passage of the stomach (enteric coating). The coating may be 
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a sugar coating, a film coating (e.g., based on hydroxypropyl 	 and the two levels are compared to monitor the course of 
methylcellulose, methylcellulose, methyl hydroxyethylcellu- 	 disease or the efficacy of the therapy. In certain preferred 
lose, hydroxypropylcellulose, carboxymethylcellulose, acry- 	 embodiments, a pre-treatment level of Marker in the subject is 
late copolymers, polyethylene glycols and/or polyvinylpyr- 	 determined prior to beginning treatment according to this 
rolidone), or an enteric coating (e.g., based on methacrylic 5 invention; this pre-treatment level of Marker can then be 
acid copolymer, cellulose acetate phthalate, hydroxypropyl 	 compared to the level of Marker in the subject after the treat- 
methylcellulose phthalate, hydroxypropyl methylcellulose 	 ment commences, to determine the efficacy of the treatment. 
acetate succinate, polyvinyl acetate phthalate, shellac, and/or 	 Methods for Inducing the Differentiation of a Tumor-Initiat- 
ethylcellulose). Furthermore, a time delay material, such as, 	 ing Cell 
e.g., glyceryl monostearate or glyceryl distearate may be io 	 As reported herein, spontaneous cell-cell fusions can ini- 
employed. Control release dosage forms are known in the art. 	 tiate and drive the essential aspects of carcinogenesis, includ- 
The solid tablet compositions may include a coating 	 ing transformation, progression, invasion, metastasis and self 
adapted to protect the composition from unwanted chemical 	 renewal. Given that the tumor-initiating cells of the invention 
changes, (e.g., chemical degradation prior to the release of the 	 are self-sustaining and stem-cell like, it is likely that they can 
active anti-neoplasia therapeutic substance). The coating may 15 be driven to form a variety of differentiated cell types. 
be applied on the solid dosage form in a similar manner as that 	 Accordingly, the invention provides for the treatment of dis- 
described in Encyclopedia of Pharmaceutical Technology, 	 eases and disorders associated with a deficiency in cell num- 
supra. 	 ber. Many diseases associated with a deficiency in cell num- 
At least two anti-tumor intitiating cell agent or anti-cell 
	
ber are characterized by an increase in cell death. Such 
fusion agent and an anti-neoplasia therapeutics may be mixed 20 diseases include, but are not limited to, neurodegenerative 
together in the tablet, or may be partitioned using methods 	 disorders, stroke, myocardial infarction, ischemic injury, or 
routine in the art. 	 hepatic insufficiency. Injuries associated withtrauma can also 
Therapeutic Methods 	 result in a deficiency in cell number in the area sustaining the 
Agents identified as acting as agents that inhibit cell-cell 	 wound. Methods of the invention ameliorate such diseases, 
fusion or that otherwise increase cell death or reduce the 25 disorders, or injuries by generating cells that can supplement 
survival or proliferation of a tumor-initiating cell are useful 	 the deficiency. Such cells are generated by driving the differ- 
for preventing or ameliorating a neoplastic disease. In one 	 entiation of a tumor-initiating cell of the invention towards a 
therapeutic approach, an agent identified as described herein 	 differentiated phenotype. 
is administered to the site of a potential or actual disease- 	 In various embodiments, the tumor-initiating cells of the 
affected tissue or is administered systemically. The dosage of 30 invention are driven to differentiate in vitro using any agent 
the administered agent depends on a number of factors, 	 that promotes the differentiation of a stem cell. Exemplary 
including the size and health of the individual patient. For any 	 agents include, but are not limited to, any one or more of 
particular subject, the specific dosage regimes should be 	 activin A, adrenomedullin, acidic FGF, basic fibroblast 
adjusted over time according to the individual need and the 	 growth factor, angiogenin, angiopoietin-1, angiopoietin-2, 
professional judgment of the person administering or super-  35 angiopoietin-3, angiopoietin-4, angiostatin, angiotropin, 
vising the administration of the compositions. 	 angiotensin-2, bone morphogenic protein 1, 2, or 3, cadherin, 
The therapeutic methods of the invention (which include 	 collagen, colony stimulating factor (CSF), endothelial cell- 
prophylactic treatment) in general comprise administration of 	 derived growth factor, endoglin, endothelin, endostatin, 
a therapeutically effective amount of a composition described 	 endothelial cell growth inhibitor, endothelial cell-viability 
herein, such as a anti-neoplasia vaccine of the formulae 40 maintaining factor, ephrins, erythropoietin, fibronectin, 
herein to a subject (e.g., animal, human) in need thereof, 	 granulocyte macrophage colony stimulating factor (GM- 
including a mammal, particularly a human. Such treatment 	 CSF), hepatocyte growth factor, human growth hormone, 
will be suitably administered to subjects, particularly 	 IFN-gamma, LIE, insulin, insulin-like growth factor-1 or -2 
humans, suffering from, having, susceptible to, or at risk for 	 (IGF), interleukin (IL)-I or 8, platelet derived endothelial 
a disease, disorder, or symptom thereof. Determination of 45 growth factor (PDGF), retinoic acid, trans-retinoic acid, stem 
those subjects "at risk" can be made by any objective or 	 cell factor (SCF), TNF-alpha, TGF-beta, VEGF-A, VEGF-B, 
subjective determination by a diagnostic test or opinion of a 	 VEGF-C, VEGF-D, VEGF-E, VEGF, and VEGF164. Agents 
subject or health care provider (e.g., genetic test, enzyme or 	 comprising growth factors are known in the art to differentiate 
protein marker, Marker (as defined herein), family history, 	 stem cells. Such agents are expected to be similarly useful for 
and the like). The compounds herein may be also used in the 50 inducing the differentiation of a tumor-initiating cell. In an 
treatment of any other disorders in which neoplasia or hyper- 	 embodiment, such agents are used to promote differentiation 
plasia may be implicated. 	 oftumorogenic cells to increase susceptibility to chemothera- 
In one embodiment, the invention provides a method of 	 peutic agents. 
monitoring treatment progress. The method includes the step 	 Differentiated cells are identified as differentiated, for 
of determining a level of diagnostic marker (Marker) (e.g., 55 example, by the expression of markers, by cellular morphol- 
any target delineated herein modulated by a compound 	 ogy, or by the ability to form a particular cell type (e.g., 
herein, a protein or indicator thereof, etc.) or diagnostic mea- 	 ectodermal cell, mesodermal cell, edodermal cell, adipo- 
surement (e.g., screen, assay) in a subject suffering from or 	 cyte, myocyte, neuron). Those skilled in the art can readily 
susceptible to a disorder or symptoms thereof associated with 
	
determine the percentage of differentiated cells in a popula- 
neoplasia, in which the subject has been administered a thera-  60 tion using various well-known methods, such as fluorescence 
peutic amount of a compound herein sufficient to treat the 	 activated cell sorting (FACS). Preferable ranges of purity in 
disease or symptoms thereof. The level of Marker determined 	 populations comprising differentiated cells are about 50 to 
in the method can be compared to known levels of Marker in 	 about 55%, about 55 to about 60%, and about 65 to about 
either healthy normal controls or in other afflicted patients to 	 70%. More preferably the purity is about 70 to about 75%, 
establish the subject's disease status. In preferred embodi-  65 about 75 to about 80%, about 80 to about 85%; and still more 
ments, a second level of Marker in the subject is determined 	 preferably the purity is about 85 to about 90%, about 90 to 
at a time point later than the determination of the first level, 	 about 95%, and about 95 to about 100%. Purity cells or their 
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progenitors can be determined according to the marker profile 
within a population. Dosages can be readily adjusted by those 
skilled in the art (e.g., a decrease in purity may require an 
increase in dosage). 
Differentiated cells of the invention can be provided 5 
directly to a tissue or organ of interest (e.g., by direct injec-
tion). In one embodiment, cells of the invention are provided 
to a site where an increase in the number of cells is desired, for 
example, due to disease, damage, injury, or excess cell death. 
Alternatively, cells of the invention canbe provided indirectly 10 
to a tissue or organ of interest, for example, by administration 
into the circulatory system. If desired, the cells are delivered 
to a portion of the circulatory system that supplies the tissue 
or organ to be repaired or regenerated. 15 
Advantageously, cells of the invention engraft within the 
tissue or organ. If desired, expansion and differentiation 
agents can be provided priorto, during or after administration 
of the cells to increase, maintain, or enhance production or 
differentiation of the cells in vivo. Compositions of the inven- 20 
tion include pharmaceutical compositions comprising differ-
entiated cells or their progenitors and a pharmaceutically 
acceptable carrier. Administration can be autologous or het-
erologous. For example, cells obtained from one subject, can 
be administered to the same subject or a different, compatible 25 
subject. Methods for administering cells are known in the art, 
and include, but are not limited to, catheter administration, 
systemic injection, localized injection, intravenous injection, 
intramuscular, intracardiac injection or parenteral adminis-
tration. When administering a therapeutic composition of the 30 
present invention (e.g., a pharmaceutical composition), it will 
generally be formulated in a unit dosage injectable form 
(solution, suspension, emulsion). 
Formulations 
Cellular compositions of the invention comprising differ - 35 
entiated cells can be conveniently provided as sterile liquid 
preparations, e.g., isotonic aqueous solutions, suspensions, 
emulsions, dispersions, or viscous compositions, which may 
bebufferedto a selectedpH. Liquid preparations arenormally 
easier to prepare than gels, other viscous compositions, and 40 
solid compositions. Additionally, liquid compositions are 
somewhat more convenient to administer, especially by injec-
tion. Viscous compositions, on the other hand, can be formu-
lated within the appropriate viscosity range to provide longer 
contact periods with specific tissues. Liquid or viscous com- 45 
positions can comprise carriers, which can be a solvent or 
dispersing medium containing, for example, water, saline, 
phosphate buffered saline, polyol (for example, glycerol, pro-
pylene glycol, liquid polyethylene glycol, and the like) and 
suitable mixtures thereof. 50 
Sterile injectable solutions can be prepared by incorporat-
ing the cells (e.g., differentiated cells) utilized in practicing 
the present invention in the required amount of the appropri-
ate solvent with various amounts of the other ingredients, as 
desired. Such compositions may be in admixture with a suit- 55 
able carrier, diluent, or excipient such as sterile water, physi-
ological saline, glucose, dextrose, or the like. The composi-
tions can also be lyophilized. The compositions can contain 
auxiliary substances such as wetting, dispersing, or emulsi-
fying agents (e.g., methylcellulose), pH buffering agents, 60 
gelling or viscosity enhancing additives, preservatives, fla-
voring agents, colors, and the like, depending upon the route 
of administration and the preparation desired. Standard texts, 
such as "REMINGTON'S PHARMACEUTICAL SCI-
ENCE", 17th edition, 1985, incorporated herein by reference, 65 
may be consulted to prepare suitable preparations, without 
undue experimentation. 
Various additives which enhance the stability and sterility 
of the compositions, including antimicrobial preservatives, 
antioxidants, chelating agents, and buffers, can be added. 
Prevention of the action of microorganisms can be ensured by 
various antibacterial and antifungal agents, for example, 
parabens, chlorobutanol, phenol, sorbic acid, and the like. 
Prolonged absorption of the injectable pharmaceutical form 
can be brought about by the use of agents delaying absorp-
tion, for example, aluminum monostearate and gelatin. 
According to the present invention, however, any vehicle, 
diluent, or additive used would have to be compatible with the 
differentiated cells or their progenitors. The compositions can 
be isotonic, i.e., they can have the same osmotic pressure as 
blood and lacrimal fluid. The desired isotonicity of the com-
positions of this invention may be accomplished using 
sodium chloride, or other pharmaceutically acceptable agents 
such as dextrose, boric acid, sodium tartrate, propylene glycol 
or other inorganic or organic solutes. Sodium chloride is 
preferred particularly for buffers containing sodium ions. 
Viscosity of the compositions, if desired, can be main-
tained at the selected level using a pharmaceutically accept-
able thickening agent. Methylcellulose is preferred because it 
is readily and economically available and is easy to work 
with. Other suitable thickening agents include, for example, 
xanthan gum, carboxymethyl cellulose, hydroxypropyl cel-
lulose, carbomer, and the like. The preferred concentration of 
the thickener will depend upon the agent selected. The impor-
tant point is to use an amount that will achieve the selected 
viscosity. Obviously, the choice of suitable carriers and other 
additives will depend on the exact route of administration and 
the nature of the particular dosage form, e.g., liquid dosage 
form (e.g., whether the composition is to be formulated into a 
solution, a suspension, gel or another liquid form, such as a 
time release form or liquid-filled form). 
A method to potentially increase cell survival when intro-
ducing the cells into a subject is to incorporate cells or their 
progeny (e.g., in vivo, ex vivo or in vitro derived cells) of 
interest into a biopolymer or synthetic polymer. Depending 
on the subject's condition, the site of injection might prove 
inhospitable for cell seeding and growth because of scarring 
or other impediments. Examples of biopolymer include, but 
are not limited to, cells mixed with fibronectin, fibrin, fibrino-
gen, thrombin, collagen, and proteoglycans. This could be 
constructed with or without included expansion or differen-
tiation factors. Additionally, these could be in suspension, but 
residence time at sites subjected to flow would be nominal. 
Another alternative is a three-dimensional gel with cells 
entrapped within the interstices of the cell biopolymer admix-
ture. Again, expansion or differentiation factors could be 
included with the cells. These could be deployed by injection 
via various routes described herein. 
Those skilled in the art will recognize that the polymeric 
components of the compositions should be selected to be 
chemically inert and will not affect the viability or efficacy of 
the differentiated cells or their progenitors as described in the 
present invention. This will present no problem to those 
skilled in chemical and pharmaceutical principles, or prob-
lems can be readily avoided by reference to standard texts or 
by simple experiments (not involving undue experimenta-
tion), from this disclosure and the documents cited herein. 
Dosages 
One consideration concerning the therapeutic use of dif-
ferentiated cells of the invention or their progenitors is the 
quantity of cells necessary to achieve an optimal effect. In 
general, doses ranging from 1 to 4x10 7 cells may be used. 
However, different scenarios may require optimization of the 
amount of cells injected into a tissue of interest. Thus, the 
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quantity of cells to be administered will vary for the subject 	 injury or disease. Alternatively, compositions can be provided 
being treated. In a preferred embodiment, between 10 4 to 108 , 	 indirectly to the organ of interest, for example, by adminis- 
more preferably 10 5 to 107, and still more preferably, 1, 2, 3, 	 tration into the circulatory system. Compositions can be 
4, 5, 6, 7x107 stem cells of the invention can be administered 	 administered to subjects in need thereof by a variety of 
to a human subject. 	 5 administration routes. Methods of administration, generally 
Fewer cells can be administered directly a tissue where an 	 speaking, may be practiced using any mode of administration 
increase in cell number is desirable. Preferably, between 10 2 
	
that is medically acceptable, meaning any mode that produces 
to 106, more preferably 10 3 to 105, and still more preferably, 	 effective levels of the active compounds without causing 
104 differentiated cells or their progenitors can be adminis- 	 clinically unacceptable adverse effects. Such modes of 
tered to a human subject. However, the precise determination io administration include intramuscular, intra-cardiac, oral, rec- 
of what would be considered an effective dose may be based 	 tal, topical, intraocular, buccal, intravaginal, intracisternal, 
on factors individual to each subject, including their size, age, 	 intracerebroventricular, intratracheal, nasal, transdermal, 
sex, weight, and condition of the particular subject. As few as 	 within/on implants, e.g., fibers such as collagen, osmotic 
100-1000 cells can be administered for certain desired appli- 	 pumps, or grafts comprising differentiated cells, etc., or 
cations among selected patients. Therefore, dosages can be 15 parenteral routes. The term "parenteral" includes subcutane- 
readily ascertained by those skilled in the art from this dis- 	 ous, intravenous, intramuscular, intraperitoneal, intragonadal 
closure and the knowledge in the art. 	 or infusion. A particular method of administration involves 
The skilled artisan can readily determine the amount of 	 coating, embedding or derivatizing fibers, such as collagen 
cells and optional additives, vehicles, and/or carrier in com- 	 fibers, protein polymers, etc. with therapeutic proteins. Other 
positions and to be administered in methods of the invention. 20 useful approaches are described in Otto, D. et al., J. Neurosci. 
Typically, any additives (in addition to the active stem cell(s) 	 Res. 22: 83 and in Otto, D. and Unsicker, K. J. Neurosci. 10: 
and/or agent(s)) are present in an amount of 0.001 to 50% 	 1912. 
(weight) solution in phosphate buffered saline, and the active 	 In one approach, differentiated cells derived from cultures of 
ingredient is present in the order of micrograms to milli- 	 the invention are implanted into a host. The transplantation 
grams, such as about 0.0001 to about 5 wt %, preferably about 25 can be autologous, such that the donor of the cells is the 
0.0001 to about 1 wt %, still more preferably about 0.0001 to 	 recipient of the transplanted cells; or the transplantation can 
about 0.05 wt % or about 0.001 to about 20 wt %, preferably 	 be heterologous, such that the donor of the cells is not the 
about 0.01 to about 10 wt %, and still more preferably about 	 recipient of the transplanted cells. Once transferred into a 
0.05 to about 5 wt %. Of course, for any composition to be 	 host, the re-differentiated cells are engrafted, such that they 
administered to an animal or human, and for any particular 3o assume the function and architecture of the native host tissue. 
method of administration, it is preferred to determine there- 	 In another approach, differentiated cells derived from cul- 
fore: toxicity, such as by determining the lethal dose (LD) and 	 tures of the invention are implanted into a host. The trans- 
LD51 in a suitable animal model e.g., rodent such as mouse; 	 plantation can be autologous, such that the donor of the cells 
and, the dosage of the composition(s), concentration of com- 	 is the recipient of the transplanted cells; or the transplantation 
ponents therein and timing of administering the 35 can be heterologous, such that the donor of the cells is not the 
composition(s), which elicit a suitable response. Such deter- 	 recipient of the transplanted cells. The differentiated cells are 
minations do not require undue experimentation from the 	 then engrafted, such that they assume the function and archi- 
knowledge of the skilled artisan, this disclosure and the docu- 	 tecture of the native host tissue. Differentiated cells and the 
ments cited herein. And, the time for sequential administra- 	 progenitors thereof can be cultured, treated with agents and/ 
tions can be ascertained without undue experimentation. 	 40 or administered in the presence of polymer scaffolds. If 
If desired, cells of the invention are delivered in combina- 	 desired, agents described herein are incorporated into the 
tion with (prior to, concurrent with, or following the delivery 	 polymer scaffold to promote cell survival, proliferation, 
of) agents that increase survival, increase proliferation, 	 enhance maintenance of a cellular phenotype. Polymer scaf- 
enhance differentiation, and/or promote maintenance of a 	 folds are designed to optimize gas, nutrient, and waste 
differentiated cellular phenotype. In vitro and ex vivo appli-  45 exchange by diffusion. Polymer scaffolds can comprise, for 
cations of the invention involve the culture of differentiated 	 example, a porous, non-woven array of fibers. The polymer 
cells or their progenitors with a selected agent to achieve a 	 scaffold can be shaped to maximize surface area, to allow 
desired result. Cultures of cells (from the same individual and 	 adequate diffusion of nutrients and growth factors to the cells. 
from different individuals) can be treated with expansion 	 Taking these parameters into consideration, one of skill in the 
agents prior to, during, or following differentiation to 5o art could configure a polymer scaffold having sufficient sur- 
increase the number of differentiated cells. Similarly, differ- 	 face area for the cells to be nourished by diffusion until new 
entiation agents of interest can be used to generate a differ- 	 blood vessels interdigitate the implanted engineered-tissue 
entiated cell from a tumor-initiating cell. Differentiated cells 	 using methods known in the art. Polymer scaffolds can com- 
can then be used for a variety of therapeutic applications (e.g., 	 prise a fibrillar structure. The fibers can be round, scalloped, 
tissue or organ repair, regeneration, treatment of an ischemic 55 flattened, star-shaped, solitary or entwined with other fibers. 
tissue, or treatment of myocardial infarction). If desired, dif- 	 Branching fibers can be used, increasing surface area propor- 
ferentiated cells of the invention are delivered in combination 	 tionately to volume. 
with other factors that promote cell survival, differentiation, 	 Unless otherwise specified, the term "polymer" includes 
or engraftment. Such factors, include but are not limited to 	 polymers and monomers that can be polymerized or adhered 
nutrients, growth factors, agents that induce differentiation, 60 to form an integral unit. The polymer can be non-biodegrad- 
products of secretion, immunomodulators, inhibitors of 	 able or biodegradable, typically via hydrolysis or enzymatic 
inflammation, regression factors, hormones, or other biologi- 	 cleavage. The term "biodegradable" refers to materials that 
cally active compounds. 	 are bioresorbable and/or degrade and/or break down by 
Delivery Methods 	 mechanical degradation upon interaction with a physiologi- 
Compositions of the invention (e.g., cells in a suitable 65 cal environment into components that are metabolizable or 
vehicle) can be provided directly to an organ of interest, such 	 excretable, over a period of time from minutes to three years, 
as an organ having a deficiency in cell number as a result of 	 preferably less than one year, while maintaining the requisite 
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structural integrity. As used in reference to polymers, the term 
"degrade" refers to cleavage of the polymer chain, such that 
the molecular weight stays approximately constant at the 
oligomer level and particles of polymer remain following 
degradation. 
Materials suitable for polymer scaffold fabrication include 
polylactic acid (PLA), poly-L-lactic acid (PLLA), poly-D-
lactic acid (PDLA), polyglycolide, polyglycolic acid (PGA), 
polylactide-co-glycolide (PLGA), polydioxanone, polyglu-
conate, polylactic acid-polyethylene oxide copolymers, 
modified cellulose, collagen, polyhydroxybutyrate, polyhy-
droxpriopionic acid, polyphosphoester, poly(alpha-hydroxy 
acid), polycaprolactone, polycarbonates, polyamides, poly-
anhydrides, polyamino acids, polyorthoesters, polyacetals, 
polycyanoacrylates, degradable urethanes, aliphatic polyes-
ter polyacrylates, polymethacrylate, acyl substituted cellu-
lose acetates, non-degradable polyurethanes, polystyrenes, 
polyvinyl chloride, polyvinyl flouride, polyvinyl imidazole, 
chlorosulphonatedpolyolifins, polyethylene oxide, polyvinyl 
alcohol, Teflon®, nylon silicon, and shape memory materials, 
such as poly(styrene-block-butadiene), polynorbomene, 
hydrogels, metallic alloys, and oligo(e-caprolactone)diol as 
switching segment/oligo(p-dioxyanone)diol as physical 
crosslink. Other suitable polymers can be obtained by refer-
ence to The Polymer Handbook, 3rd edition (Wiley, N.Y., 
1989). 
Kits 
The invention provides kits for the practice of the methods 
of the invention. The kit can include, for example, an enriched 
population of tumor-initiating cells for growth in culture and 
instructions for use. The cells can be used to practice any of 
the methods of the invention including drug screening and the 
generation of models of cancer in mammals. 
The practice of the present invention employs, unless oth-
erwise indicated, conventional techniques of molecular biol-
ogy (including recombinant techniques), microbiology, cell 
biology, biochemistry and immunology, which are well 
within the purview of the skilled artisan. Such techniques are 
explained fully in the literature, such as, "Molecular Cloning: 
A Laboratory Manual", second edition (Sambrook, 1989); 
"Oligonucleotide Synthesis" (Gait, 1984); `Animal Cell Cul-
ture" (Freshney, 1987); "Methods in Enzymology" "Hand-
book of Experimental Immunology" (Weir, 1996); "Gene 
Transfer Vectors for Mammalian Cells" (Miller and Calos, 
1987); "Current Protocols in Molecular Biology" (Ausubel, 
1987); "PCR: The Polymerase Chain Reaction", (Mullis, 
1994); "Current Protocols in Immunology" (Coligan, 1991). 
These techniques are applicable to the production of the poly-
nucleotides and polypeptides of the invention, and, as such, 
may be considered in making and practicing the invention. 
Particularly useful techniques for particular embodiments 
will be discussed in the sections that follow. 
The following examples are put forth so as to provide those 
of ordinary skill in the art with a complete disclosure and 
description of how to make and use the assay, screening, and 
therapeutic methods of the invention, and are not intended to 
limit the scope of what the inventors regard as their invention. 
This invention is further illustrated by the following 
examples, which should not be construed as limiting. 
EXAMPLES 
Example I 
Cell-Cell Exchange In Vitro 
The question of whether fusion of normal primary cells, 
without transgenic alteration, can create allelic imbalances 
and other molecular repartitionings sufficient to transform 
these cells into cancer cells was investigated. That is, can 
cell-cell fusion, in and of itself, lead to carcinogenic cell 
transformation, without the need to invoke specific gene 
5 mutations. If fusion can transform normal cells into cancer 
cells, then further fusion events between tumor cells or 
between tumor and host cells may be what drives and sustains 
cancer progression. To these ends, the ability of primary 
murine lung fibroblasts (MLF) and murine Lewis lung carci- 
io noma cells (LLC) to undergo cell-cell fusion was investigated 
in vitro. The cytoplasm of cells was labeled with different 
colored Qdots® to detect cell-cell exchanges and fusions. 
These particular constructs, designed for cell labeling in 
vitro, are taken up in the cytoplasm, by endocytosis, and 
15 remain there once internalized. They have been reported not 
to induce fusion events and to be non-toxic to live cells 
(Murasawa et al. 2005, Gopalakrishnan et al. 2006). This 
cytoplasmic marking system was also used in lieu of reporter 
constructs to minimize interference with cellular chromo- 
20 some integrity. 
In these experiments, high levels of cell-cell exchanges and 
fusions were observed among murine lung fibroblasts (MLF) 
cells, among LLC cells, and between MLF and LLC cells 
following 24 hour culturing (FIGS. 1A-1D). Replicate MLF 
25 cultures were labeled with red and green with Qdots, respec-
tively, and co-cultured. Following 24 hours of co-culture the 
cell population was sorted for double-labeled (red/green) 
cells. These cells are referred to as "MLF-MLF" cells, as they 
contain cytoplasmic material from at least two MLF cells, 
30 either with the accompanying nuclei (e.g., cell fusion or cell 
engulfment) or without (cytoplasm transfer only). 
The findings demonstrated that spontaneous cell "unions" 
of these various sorts are frequent in MLF cultures. The sorted 
cells exhibited morphological features indicative of fusion, 
35 including the presence of two or even three nuclei within one 
cytoplasm. Inspection of the degree of DNA condensation 
within nuclei indicated that cells often fused while in different 
phases of their respective cell cycles, confirming that the 
presence of two nuclei was not a consequence of nuclear 
4o division (FIG. 1A, fusion of a prophase cell with an inter-
phase cell). Cytoskeletal-mediated activity analogous to that 
observed during developmental fusion was also detected, 
specifically, the extension of filopodia linking fusing cells 
(FIG. 1A). In a small number of fused cells, an entire cell 
45 appeared inside the second cell. Such cells are consistent with 
what has been described by Overholtzer et al. (2007) as ento-
sis. Countering the idea that cell-cell fusion is a rare event, the 
level of fusion detected in these cultures was considerable 
(25.8%±I0.4 MLF-MLF, 49.6%±29.2 LLC-LLC, and 
50 16.4%±2.5 MLF-LLC) (FIGS. 1B and 1C). 
Additionally, it is noted when these MLF-MLFp25 cells 
where assayed for the degree of cell-cell exchange within the 
population using the Qdot double-labeled cell assay 
described above, an average of 58.8%±0.4% double-labeled 
55 cells was detected (FIG. 1D). This observation indicates that 
the MLF-MLFp25 cell population has, during passage, tran-
sitioned to one where cells are uniformly engaged in very 
high cell-cell exchange activity. This result contrasted with 
the 25.8%±I0.4% detected from the original MLF population 
6o and the 49.6%±29.2% detected with LLC cells. Not only 
were more cell-cell exchanges in the MLF-MLFp25 cell 
population significantly detected than in the original MLF 
population, but the tight reproducibility of the results com-
pared to both MLF and LLC showed that MLF-MLFp25 were 
65 a highly regulated population of cells. 
The results demonstrate that a significant amount of mate-
rial exchange among cells is ongoing, at least in culture, even 
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over short periods. These data demonstrate that spontaneous 	 changes accompanied alterations in the molecular fingerprint 
cell-cell exchange and fusion of single cells in tissue culture 	 (FIG. 613), indicating a massive synchronized transformation 
can be a common occurrence. This suggests that when cells in 	 of the population. 
vivo are liberated from the proper three dimensional tissue 	 Cells transitioned from an extended and adherent pheno- 
constraints and extracellular matrix attachments that nor-  5 type (and often multinucleate cells) to a spherical, lightly- 
mally prevent such interactions, the role of cell-cell fusion 	 adherent morphology, reminiscent of stem cell cultures. The 
might also be significant. The prospect that basement mem- 	 population-wide nature of the transformation was in sharp 
brane detachment might facilitate cell fusion adds an addi- 	 contrast to the well-documented spontaneous transforma- 
tional mechanistic consideration to the important body of 	 tions frequently noted within murine cell populations, which 
literature reporting that the aberrant three dimensional archi-  10 are focal and occur at very low frequency (e.g., 10 focal 
tecture can modulate carcinogenic conversion (Bissell et al. 	 transformants per 100,000 NIH-3T3 cells, Chow et al., 1994). 
2005, Rubin 2006, Wang et al. 1998, Kass et al. 1994, Over- 	 Accompanying the changes in size and shape of the emergent 
holtzer et al. 2007). Taken together, the data suggest cell-cell 	 cells was a pronounced alteration in the cell cytoskeleton, 
exchange is a fundamental means of dynamic communication 	 with the disruption and eventual loss of filamentous actin by 
between cells that are allowed to comingle, which can be 15 passage thirteen (FIG. 2A). This loss of filamentous actin is 
amplified inappropriately to generate aberrant unstable cells, 	 consistent with the actin disruption that has been observed in 
including overtly fused cells, triggering an overall carcino- 	 cells following tumorigenic conversion (Folger and Pardee 
genesis program. 	 1999). 
It is also known that disruption of filamentous actin pre-
Example 2 	 20 vents fusion of macrophages (deFife and Tenney 1999). In the 
present study, actin disruption may function in an analogous 
Cell-Cell Fusion Gives Rise to Transformed 	 manner by preventing further fusion and/or enhancing an 
Fibroblasts 	 "anti-fusion" or a "fission" process, resulting in the predomi- 
nately multinucleate cell population giving way to a popula- 
The isolation of a pure population of double-labeled cells, 25 tion of small, round, mononucleate cells (FIGS. 2A, 213, 2D). 
actively engaged in cell-cell exchange, proved important to 	 As shown in FIG. 2A, the MLF-MLFpl7 cells no longer 
establishing the relationship between cell fusion and cell 	 resembled the MLF cells from which they were derived but 
transformation. Given that the sorted fused cells were, for the 	 phenotypically and morphologically resembled the murine 
most part tetraploid, further cell-cell fusions between these 	 epithelial lung tumor (LLC) cells. Similar morphological 
cells enabled up to a geometric increase in cell ploidy. In this 30 conversions occurred in the MLF-LLC cells by p12, at which 
way, complex cell fusion events (involving three or more 	 time they were indistinguishable from the original LLC cells. 
nuclei within a cell) that might normally occur over much 	 No such morphological transitions occurred in the MLF 
longer time scales, or not at all, were accelerated. Isolating 	 populations over the more than 30 passages in culture (FIGS. 
cells that had fused within the last 24 hours assured the 	 2A, 2D, and 6A-6D). Without being bound to a particular 
presence of fusion competent cells and also synchronized the 35 theory, the striking morphologic transition to epithelial-like 
cells with respect to that fusion event (once cells fuse there is 	 mononucleated cells detected for the MLF-MLF cell popula- 
a relaxation time before cells are again fusion competent). 	 tions shows that transformations in vivo could easily go unde- 
To characterize this transformation, a detailed investiga- 	 tected, and an essential population-level role in initiating 
tion into the structural, functional, and molecular response of 	 carcinogenesis could be overlooked. 
the population of these double-labeled cells as a function of 40 	 Quantification of the average nuclear area/cellular area for 
passage after the initial exchanges was undertaken (FIGS. 	 the MLF-MLF cells is shown as a function of passage (FIG. 
2A-2D, 3A and 313, 4A and 413, 6A-6D). Double-labeled cell 	 213). As observed over p8, p10, p12, p13, p16, and p24, the 
populations were tracked in vitro. LLC-LLC cultures grew 	 ratio of nuclear-to-cellular area oscillated with passage, mir- 
similarly to LLC cultures. By passage four (p4), MLF-MLF 	 roring the chromosome content variations expected from 
cultures were growing well and were more resistant to modu-  45 cycles of cell-cell fusions, followed by losses and repartition- 
lations in microenvironmental conditions than the MLFs 	 ings of nuclear material into smaller cells. At later passages, 
from which they were derived. A ubiquitous early stage in the 	 this ratio asymptotes to a value similar to that for LLC cells 
generation of the MLF-MLF, MLF-LLC and LLC-LLC fused 	 and is somewhat higher than that for the MLF cells from 
cells was the presence of multiple nuclei within the cell, i.e. 	 which they were derived (FIG. 213). 
the formation of syncytia and heterokaryons (Harris et al. 50 
1969, Ogle et al. 2005). Although most cells contained two 	 Example 3 
nuclei following the original sort, further culturing lead to 
subsequent fusions and the accumulation of additional nuclei 
	
Transformation of Fused Fibroblasts in Culture 
per cell. In later passages it was not uncommon to detect 5-6 
nuclei (e.g. FIG. 2a MLF-MLFp4, MLF-LLCp6). Popula-  55 	 To verify that spontaneously fused fibroblasts had indeed 
tions of fused fibroblasts, MLF-MLF, were tracked in vitro 	 undergone carcinogenic transformation the classic measures 
for over fifty passages. 	 of carcinogenic transformation employed by investigators 
Unlike primary MLF cultures, MLF-MLF cultures grew 	 were used to show creation of tumor cells with defined 
faster with continued passaging (FIG. 2C). MLF-MLF main- 	 genetic elements (Hahn et al. 1999), the ability of the cells to 
tained a flat, adherent "fibroblast-like" morphology up to 60 form colonies in soft agar in vitro (FIG. 3A) and to form 
passage thirteen (pl3). At p13 a dramatic shift occurred not 	 tumors in vivo (FIGS. 4A and 413). In the soft agar assay, no 
only in the form and character of the majority of cells (FIGS. 	 transformed cells were detected in pre-passage thirteen cul- 
2A, 213, 2D), evidenced by cellular and nuclear alterations 	 tures, but a dramatic emergence of a transformed cell popu- 
(FIG. 2A) sweeping structural changes e.g. increased 	 lation was observed in post-passage thirteen cultures. Addi- 
nuclear/cytoplasmic ratios (FIGS. 2A and 213, loss of fila-  65 tionally, as expected, the normal fibroblast (MLF) 
mentous actin (FIG. 2A), and adoption of a rounded, less 	 populations contained no transformed cells, whereas the lung 
adherent cell morphology (FIGS. 2A and 2D). These physical 	 tumor (LLC) populations contained large numbers of trans- 
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formed cells. About 60% more cell colonies were measured 	 observed "hallmarks" of cancer progression (Hanahan and 
for the MLF-MLFp17 population than for the aggressive 	 Weinberg 2000) are not dictated by, random mutations, fol- 
epithelial carcinoma line, LLC (FIG. 3A). This highly 	 lowed by in vivo pressures and selection of cell-level genetic 
tumorogenic phenotype was concurrent with a decrease in 	 attributes, but can arise, even in 2D culture, as orchestrated, 
expression of CD44 demonstrating that expression of CD44 5 programmed responses driven by cell-cell fusion events. 
is not essential to establishment of tumors or growth in soft 
	
Along with developing these molecular and behavioral 
agar. The MLF-MLF p17 cells also yielded on average about 	 hallmarks of cancer cells, the structure and phenotype of the 
60%more cell colonies in the soft agar assay than did the LLC 
	
fused-fibroblasts converged to exhibit standard pathological 
cells plated at the same density (FIG. 3A). Paralleling the 	 features used in the diagnosis of lung and other cancers. These 
reduced variance seen in the frequency of cell-cell exchange 10 included various cell and nuclear size and shape criteria, e.g. 
events among sorted MLF-MLFp25 cells vs LLC cells (FIG. 	 the expression of a high and variable nucleus/cell ratio and 
11)), the variance in ability to form colonies was much 	 abnormally sized and shaped nuclei (FIGS. 2A and 2B) 
reduced for the MLF-MLFp 17 when compared to that of the 	 (Franklin 2000, Zink et al. 2004). Central to the in vivo 
LLC line. 	 carcinogenic process is the onset of genomic instability fol- 
Since the same colony growth assay was used as a measure 15 lowing cell transformation. As anticipated, mFISH results 
of transformation efficacy in vitro, these results can be con- 	 verified the genomic instability of these cells. All MLF-MLF 
trasted with the studies using the defined genetic elements, 	 cultures exhibited aberrant, aneuploid, unstable genomes 
large-T, hTERT and ras, to engineer human cancer cells 	 which progressed to display the type of chromosome-level 
(Hahn et al. 1999). The MLF-MLFp17 populations demon- 	 aberrations and individual karyotypic diversity observed in 
strated 1137±66 colonies per 5000 cells plated (approx 23%), 20 solid tumors (Vogelstein and Kinzler 2004, Fabarius et al. 
whereas the human cells transfected with oncogenic genes 	 2003) (FIG. 313). Specifically, karyograms of five cells from 
yielded approx 150 colonies per 10,000 cells plated (<1.5%). 	 the MLF-MLFp8 culture exhibited chromosome numbers 
Notwithstanding differential difficulties in achieving trans- 	 ranging from 56-143 (haploid 20) and showed gains and 
formation in human vs. mouse cells, it remains that the level 
	
losses of specific homologues. For the MLF-MLFp17 cul- 
of transformation attained in these studies by simply modu-  25 ture, karyograms exhibited from 78-86 chromosomes, again 
lating cell population dynamics and isolating naturally fused 	 with considerable gains and losses of homologues, but now 
cells without genetic intervention—exceeded that realized by 	 accompanied by translocation-type chromosome aberrations 
a strategic transfection of oncogenic genes specifically 	 (FIG. 313). These findings are in line with data from human 
selected to accomplish that end. 	 cancers which are known to exhibit on the order of 60-90 
In the Hahn et al., 1999, classic transfection study, the 30 chromosomes per cell (haploid 23). The fact that in this 
human cells took 60 population doublings in culture post- 	 model, MLF-MLF chromosome number per cell increases 
transfection to obtain the less than 1.5% transformation. 	 and then converges to aneuploid values with lesser variance, 
Without being bound to any particular theory, events beyond 
	
is consistent with the multiple cell fusions and subsequent 
the oncogene transfections, including heightened cell-cell 	 repartitioning into smaller cellular contents, as seen in FIGS. 
exchanges, assisted in triggering cell destabilization and ulti-  35 2A-2D. In types of esophageal and colorectal cancers, tetra- 
mate transformation. It also heightens confidence that the cell 	 ploid cells are observed as an intermediate step in the devel- 
transformation model generated through the amplification of 	 opment of aneuploid tumor cells (Margolis 2005), which is 
normal cell processes, which lack the introduced mechanistic 	 consistent with cell-cell fusion of diploid cells proceeding 
biases inherent to genetic transfection, is well-positioned to 	 and contributing to the development of aneuploidy. 
reveal genetic, biochemical, and structural steps involved in 40 
the transition of normal cells to cancer cells that remain, to 	 Example 5 
date, not available through preconceived oncogene manipu- 
lation alone. 	 Spontaneously-Fused Fibroblasts Induce Malignant 
Tumors In Vivo 
Example 4 	 45 
Remarkably, when spontaneously fused, adult fibroblasts 
Production of Fused Fibroblasts In Vitro, Parallels 	 that had undergone no genetic manipulation were implanted 
Cancer-Cell Progression In Vivo 	 in mice, aggressive tumors resulted. Both MLF-MLFp8 and 
MLF-MLFp17 cells induced high-grade malignant tumors 
Strikingly, MLF-MLF cells were generated in vitro in a 50 (FIGS. 4A and 413). Parallel control experiments conducted 
manner analogous to the progression of cancer cell popula- 	 with unsorted, nonfused fibroblasts (MLF) from various pas- 
tions in vivo. Like spontaneously arising cancer, the sponta- 	 sages (MLFp-3, MLFp-2, MLFpO, MLFp9, MLF p19) with 
neously fused fibroblast populations: transformed (FIG. 3A); 	 and without Qdots®, were conducted, with subcutaneous 
developed genomic instability (FIG. 313); increased aneup- 	 injection of (FIG. la). The MLFpO populations tested were 
loidy (FIG. 313); acquired chromosome-level aberrations, 55 labeled with either the same concentration of Q dots used for 
including losses and gains of homologues and translocations 	 the sort (50 nM), or twice the concentration (100 nM). No 
(FIG. 313); increased cellular proliferation rate (FIG. 2C); and 	 tumor growth was detected for any of the mice in these control 
upregulated classic oncogenes, e.g. k-ras, myc and Bcl-2, 	 groups, up to 16 months after cell injection. FIGS. 4A and 4B 
while downregulating tumor suppressor genes and apoptosis 	 shows the growth curves and representative photos for MLF- 
genes, e.g. CDKn2A and p53 (FIG. 613). RNA and protein 60 MLFp8 and MLF-MLFp17 tumors. Tumor growth curves for 
studies revealed increases in invasion and metastasis-related 
	
Lewis lung carcinoma (LLC) studies conducted in parallel are 
genes e.g. MMP-9, CD44 (FIG. 6A) and upregulated angio- 	 shown for comparison. For the MLF-MLFp8 the frequency of 
genic genes e.g. VEGF (FIG. 613). All these classic charac- 	 tumor incidence was 50% (2/4) with a considerable lag period 
teristics of cancer developed simply as a function of passage 	 of about twenty days before tumor growth was detectable. By 
after enrichment of the fused cell population and mimic the 65 contrast, 100% (10/10) of animals injected with MLF- 
progressive development of these same characteristics in vivo 	 MLFp 17 had tumors detectable just two days after injection, 
during tumor progression. This suggests that many of the 	 with their rate of growth increasing to approach that of LLC. 
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These results are consistent with the high percentage of 
transformed cells in the p17 population, as detected by the 
soft agar assay in vitro (FIG. 3A). The fact that MLF-MLFp8 
populations, which exhibited no transformed cells in vitro, 
grew tumors in vivo after an extended lag time, is also con-
sistent with the in vitro results, when it is considered that the 
additional lag time to tumor appearance (18 days) roughly 
matched the number of days it took the p8 population to 
transform in vitro (as p13). The increase in tumor frequency 
and the much shortened lag period for MLF-MLFp17 dem-
onstrate how the tumorigenic potential of the MLF-MLF 
population naturally advances in vitro, analogous to the same 
process observed in tumors in vivo. 
All tumors grown from MLF-MLF p8 and p17 cells were 
malignant, as demonstrated by their invasion into the adjacent 
muscle tissue (FIGS. 4A and 413). In keeping with their fibro-
blast origin, the tumors appeared histologically comparable 
to high-grade sarcomas based on cellular organization and a 
general lack of epithelial membrane antigen (EMA) staining 
(FIG. 5, mouse 26 (M#26)). Yet surprisingly, malignant cells 
in distinct regions of p17 tumors stained positive for the 
carcinoma marker EMA (FIG. 5). Because the injected can-
cer cells were of stromal origin, without wishing to be bound 
by theory, this result would suggest that either mesenchymal-
epithelial transition (MET) or cell-cell fusions between stro-
mal and epithelial cells invivo had occurred. This raises again 
the issue of whether all cancers categorized as epithelial, 
actually originate from epithelial cells. 
Fusion may have significant implications for the observa-
tion that cells in carcinomas can express both epithelial and 
mesenchymal features, and that epithelial mesenchymal tran-
sitions, EMT, are observed in tumors (Trimboli et al. 2008). In 
general, the MLF-MLF tumors were highly proliferative, 
with little necrosis despite their large size. In contrast to the 
MLF-MLFp8 tumors, MLF-MLFp17 tumors appeared mul-
tilobular as if composed of an aggregate of smaller tumors 
originating from multiple cell foci (FIGS. 4A and 413). This 
observation supports the recent proposition that a defining 
characteristic of advanced malignancy may be the seeding of 
local metastases into which the tumor continually expands 
(Norton and Massague 2006, Enderling et al., submitted). 
In keeping with this macroscopic observation, pathological 
analysis confirmed the existence of multiple distinct sites 
with different malignant grades in some p17 tumors. Histo-
logical sections from both the p8 and p17 tumors exhibited 
considerable staining for the oncogenec anti-apoptosis pro-
tein Bcl-2 and the activated membrane receptor EGFR (FIG. 
5). These proteins, elevated in a vast number of tumor types, 
play central roles in the development and progression of lung 
and other cancers and are major therapeutic targets (Sitha-
nandam and Anderson 2008, Adams and Cory 2002). The 
switching on of these proteins further indicates the extent to 
which MLF-MLF cancers molecularly mimic spontaneously 
arising cancers, including carcinomas. All the p8 and p17 
tumors continued to grow malignant tumors in new animals 
when serially passaged mouse to mouse (9 times to date) and 
in all cases malignant tumors developed, indicating self-re-
newal capability. Despite continued passage (>50 passages) 
in vitro the transformed MLF-MLF populations remained 
tumorigenic. Injections of 500,000 MLF-MLFp58 cells 
yielded tumors in 2/2 mice (Table 1). Invasive cancers con-
sistently developed in the lungs when MLF-MLFp33 cells 
were administered by tail vein. Even single colonies of about 
1000 cells cloned from individual MLF-MLFp25 cells were 
determined to be tumorigenic in mice over many generations.  
5 	 Remarkably, the isolation and subsequent culturing of 
double-labeled cells was sufficient to orchestrate the synchro-
nous carcinogenic cell transformation observed (FIGS. 
2A-2D, 3A and 313), and trigger the synchronized regulation 
of individual genes, as measured over twenty-seven in vitro 
io passages. This strongly suggests an orchestrated program of 
gene regulation was turned on in the fused cells—one which 
provides a window to the carcinogenesis process up to, dur-
ing, and through transformation. The time-dependent regula-
tion of critical oncogenes and tumor suppressor genes in 
15 MLF-MLF cells, from passage four though nineteen is shown 
in FIG. 6A. A unique pattern in the transcription of these 
genes was observed. Around p13, dramatic upregulations 
were observed for the oncogenes myc, k-ras, and Bcl-2, each 
of which is associated with vast number of human cancers 
20 including many lung cancers (Salgia and Skarin 1998) (FIG. 
6A). Most prominently, myc expression in MLF-MLF p13 
cells was seen to be upregulated 1200-fold over that of MLF 
cells. myc was, by far, the most differentially regulated of the 
fifteen genes examined in these cells, with k-ras upregulated 
25 62x and Bcl-2 upregulated 150x. The tumor suppressor gene 
CDKn2a (p16) (Yaswen and Stampfer 2002, Stampfer and 
Yaswen 2003, Beausejour et al. 2003) was oppositely regu-
lated. CDKn2a was significantly downregulated through pl3, 
after which the transcription of this tumor suppressor was 
30 essentially shut off (FIG. 6A) and remained off (observed 
through p27). This is consistent with the fact that CDKn2A is 
a critical tumor suppressor that becomes methylated and 
silenced in cancers including LLC (FIG. 6A). 
In addition to the time-dependent up- and downregulation 
35 of oncogenes and tumor-suppressor genes observed, upregu-
lation of the major tumor angiogenesis factor, VEGF (vascu-
lar endothelial growth factor) (Ferrara et al. 2007, Hlatky et 
al. 1989) was demonstrated. As was the case for the onco-
genes examined, VEGF exhibited maximal upregulation 
4o around p 13. When additional genes prominent in tumor inva-
sion and metastasis were considered, these were also found to 
be upregulated in a time-dependent manner similar to VEGF 
and the set of oncogenes investigated (FIGS. 6A and 613). It is 
noteworthy that although the classic cancer-related genes 
45 investigated demonstrated a marked differential in transcrip-
tion around p13, this was not the case for all other genes 
examined. It may be concluded the differential regulation in 
these cultures at p13 was not a generalized, non-specific 
response of the cell population, but rather reflected the inte- 
50 grated molecular fingerprint of the transformation event. The 
culture model may thus offer a means of characterizing and 
dissecting the transformation process in a time-dependent 
manner up to and through cell transformation. 
The time-dependent pattern of gene transcription observed 
55 further underscores the fact that spontaneously fused fibro- 
blasts, under high density conditions, undergo a carcinogenic 
program which includes the up-regulation and down-regula- 
tion of genes analogous to that occurring in human and 
murine cancer cells in vivo. Invasion and metastasis genes 
60 investigated included: CD44 a membrane glycoprotein cen- 
tral in cell homing and adhesion (Sackstein et al. 2008); 
osteopontin (OPN, SPPI) a ligand of CD44 upregulated in 
lung, breast, colorectal, ovarian, melanoma, and other can- 
cers and correlated with metastatic potential (Coppola et al. 
65 2004); and the matrix metalloproteinase MMP9, whose 
elevated expression has been implicated in increased inva- 
sion, progression, metastasis and decreased patient survival, 
42 
Example 6 
Orchestrated Regulation of Cancer Genes 
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across a large spectrum of cancers and, importantly, is also a 
ligand of CD44 (Desai et al. 2007). Of particular importance 
with respect to the studies herein, CD44, OPN and MMP-9 
are also involved in normal cell-cell fusion processes during 
development. MMP-9 protein expression increased in MLF-
MLFp13 cells, and in parallel with the mRNA regulations, 
increased protein expressions for CD44 and OPN were also 
observed (FIGS. 6A-6D). Transcription of CD44 was noted 
to be upregulated 24-32 fold at p12. CD44 is of particular 
interest, not simply due to its involvement in tumor metasta-
sis, but because it has also been determined to be a marker for 
cancer stem cells in breast, prostate, colon (Fillmore 2008 
says as few as 100 CD44+/CD24/low/ESA+ cells make 
tumors), and head and neck tumors (Prince et al. 2007) also 
normal hematopoietic stem cell (Sackstein et al. 2008). Inter-
estingly, CD44 also plays an integral role in the normal pro-
cess of macrophage cell fusion (Cui et al. 2006). Vignery's lab 
has demonstrated that CD44 is highly and transiently 
expressed in macrophages under fusogenic conditions (Ster-
ling et al. 1998). 
On the other hand, osteopontin has been shown to prevent 
macrophage fusion (Sterling et al. 1998), suggesting that 
fusion may be a tightly-controlled process targeted to specific 
situations or times. In the MLF-MLF passages osteopontin 
transcription demonstrated periodic upregulation as a func-
tion of passage, in contrast to the essential lack of osteopontin 
transcription seen in all of the MLF passages. The regulation 
of OPN expression (observed out to MLF-MLF p33) expres-
sion provides information as to the dynamics of ongoing cell 
fusions during and beyond transformation. While MMP9 is 
well-known to be elevated in lung cancers (including LLC, 
FIGS. 6A-6D) and is correlated with poor clinical prognosis, 
it happens it is also highly expressed in both myocytes, 
formed by myoblast fusion, and in osteoclasts, formed by 
macrophage fusion (Pratap et al. 2005). Consistent with the 
observation of elevated MMP9 in cells formed by fusion, 
MMP9 levels were low in the primary fibroblasts (MLFs) but 
high in fused fibroblasts by passage 17 (FIG. 613). Without 
wishing to be bound by theory, it is likely that the elevated 
MMP-9, CD44, and OPN expression detected in tumor popu-
lations, in metastatic cancer cells, and in cancer stem cells are 
all connected with an ongoing cell-cell exchange and fusion 
process occurring during carcinogenesis and tumor progres-
sion. 
Example 7 
Cell-Cell Fusion Gives Rise to Cancer Stem Cells 
Fused MLF cells were tested for their ability to form cancer 
stem cells (CSCs). Without being bound to any particular 
theory, it was hypothesized that the intercellular exchanges 
and genomic mixing between fused MLF cells creates cancer 
stem cells (CSCs). As a functional test for CSCs, varying 
numbers (10 6, 5,000, 500, 50, and 5) of MLF-MLFp25 cells 
were injected in mice to determine the number of cells nec-
essary to initiate tumor growth (FIGS. 7B and 7C). As a 
departure from standard assays that attempt to determine the 
potency of cancer populations by first sorting for a series of 
cell surface markers (e.g. CD44+/CD24 -"'-/ESA+)70 and 
then injecting various dilutions of cells expressing those 
markers, MLF-MLFp25 cells were not pre-selected for mark-
ers. Even so, it was demonstrated that 5 MLF-MLFp25 cells 
were sufficient to produce malignant invasive tumors. It is 
believed that this is the lowest number of cells found to 
successfully produce tumors in such assays, and that the 
ability to produce tumors from this few cancer cells without 
44 
any pre-selection for surface markers is unprecedented. 
These results support the characterization of these cells as 
cancer stem cells. 
The number of injected MLF-MLFp25 cells vs the lag time 
5 before tumor detection was plotted (FIG. 713). The cell injec-
tion number (10 6, 5,000, 500, and 50) versus lag time is a 
straight line on a log plot (R 2=0.997). Aside from affirming 
the accuracy of the dilutions, this result demonstrated a new 
10 finding that the individual CSCs grew at the same rate inde-
pendent of number injected. This result suggests CSCs act 
more or less identically and independently in vivo over more 
than five orders of magnitude of injection sizes, supporting 
the assertion the cells are executing an orchestrated program 
15 o action. This result is also consistent with the observation in 
the cell fusion assays that MLF-MLFp25 cells are a tightly 
regulated population of cells, as indicated by the close repro-
ducibility of the results (FIG. 1D). Using the plot of the 
number of injected MLF-MLFp25 cells vs the lag time before 
20 tumor detection to extrapolate back to one cancer stem cell, it 
is estimated that such tumors would be detectable approxi-
mately 62 mouse days following the creation of the first 
cancer stem cell. If human tumors were first detected at the 
same size this period would translate to roughly six human 
25 years, a period fairly consistent with time scales derived from 
human cancer epidemiology. Furthermore, plotting the 
growth rates of tumors as function of injection size (shown in 
FIGS. 7A and 7D) showed that the MLF-MLF cells retained 
30 potency independent of injection size. Without being bound 
to a particular theory, this observation suggests that, once 
created, the fused cells can independently execute cancer 
growth programs. One important dependence on injection 
count was noted. Despite the fact that all cells were injected 
35 subcutaneously, tumor growth for 5 cells was preferentially 
internal, and produced more invasive and metastatic tumors 
overall. Table I summarizes the data for all the subcutaneous 
tumor injections of MLF-MLF and of MLF cells to date. No 
tumor growth was detected for any of the MLF cell injections 
40 in general, in two instances animals injected with MLF-
MLFp4 cells eventually developed internal tumor growth in 
the spleen after 482 days. In sum, transformation of the MLF-
MLF cell population resulted in a high fraction of functional 
cancer stem cells as evidenced by the fact that 5 cells, 
45 
unsorted for stem cell surface markers, induced tumor 
growth. In contrast, even sixteen months after injection of 
MLF passages in vivo, no tumors have been detected in any of 
the animals. 
50 
TABLE I 
Cells Injected Tumors 
MLFp-3 0/10 
MLFp-2 0/10 
55 	 MLFpO with 50 nM Qdots 015 
MLFpO with 100 nM Qdots 015 
MLFp9 0/3 
MLFp19 0/5 
MLF-MLF p4 2/10* 
MLF-MLFp8 2/4 
60 	 MLF-MLFp17 10/10 
MLF-MLFp24 (10 6 cells) 2/2 
MLF-MLFp24 (5000 cells) 2/2 
MLF-MLFp25 (10 6 cells) 10/10 
MLF-MLFp25 (5000 cells) 10/10 
MLF-MLFp25 (500 cells) 8/10 
65 	 MLF-MLFp25 (50 cells) 4/10 
MLF-MLFp25 (5 cells) 2/10 
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TABLE 1-continued 
Cells Injected 	 Tumors 
MLF-MLFp35 	 2/2 
MLF-MLFp58 (500,000 cells) 	 2/2 
*No subcutaneous tumors. Only internal tumor burden detected in the spleen 482 days after 
cells injected. 
Example 8 
Primary Human Fibroblasts for Tumor Initiating 
Precursor Cells and Progeny 
46 
lation organization overall. A range of varied cell shapes from 
extremely elongated to spherical were present. The mono-
layer character of the original epithelial culture was lost, with 
cell overgrowth evident, and three-dimensional (3D) colonies 
5 formed networks and connected via separate elongated cells 
and extended cellular processes. Individual linking cells were 
seen to span the distance between colonies (FIG. 8D). In 
contrast the control, single-labeled cell populations grown in 
parallel, did not demonstrate an abrupt transition in growth 
10 pattern, did not form 3D structures, and continued to propa-
gate in culture for one additional passage (to Epi p3) beyond 
that of the Epi-Epi cells. 
Example 10 
Primary normal human fibroblasts were obtained and 15 
grown in culture using the methods used to generate tumor- 	 Generation of an Animal Model of Metastatic 
initiating mouse fibroblasts. Primary human cells were 	 Cancer 
observed to undergo the same program of cell fusion and cell 
fission to release single nucleate cells in a time frame similar 	 Metastatic animal models of disease are difficult and 
to mouse fibroblasts. 	 20 incredibly time consuming to establish. Typically, the time 
for the development of metastases exceeds the lifespan of a 
Example 9 	 mouse (2-3 years). Moreover, the cost of maintaining animals 
for such an extended period of time is prohibitive. The use of 
Cell-Cell Fusion Observed In Vitro 	 highly tumorogenic cells of the invention allows for the reli- 
25 able generation of metastatic tumors in mouse, rat, and other 
Replicate cultures of primary human prostate epithelial 	 animal models. Moreover, using enriched populations of 
cells displaying a normal karyotype (FIG. 8A), were sepa- 	 highly metastatic cells, a known and reproducible number of 
rately labeled with either green (Qtracker 525) or with red 	 cells can be implanted in each animal to allow for compari- 
(Qtracker 655) quantum dots. The labeled cells were then 	 sons between animals. 
co-cultured for 24 hours. Following this co-culture period, the 30 	 Primary mouse fibroblasts are cultured to generate an 
cells were sorted into three distinct subpopulations: a double- 	 enriched population of tumor initiating cells. Highly tumoro- 
labeled green-red subpopulation, a single-labeled green sub- 	 genic cells are injected into immune competent mice or non- 
population; and a single-labeled red subpopulation (FIGS. 	 immune competent mice (e.g., nude mice, irradiated mice). 
8A-8D and 9A-9C). Sorting of the double-labeled cells pro- 	 Mice are monitored for the development of tumors at sites 
vided a means to isolate a subpopulation of cells that had 35 remote from the injection site. 
topologically merged and undergone horizontal exchange of 
	
Immunocompromised mice were subcutaneously injected 
cellular material, removing from the final isolate cells that 	 with either control (Epi) or the transformed (Epi-Epi p2) 
had not actively exchanged over the last 24 hrs. Red and green 	 cells. FIG. 9 shows a schematic of the fate of nude and SCID 
Q dots along with double nuclei within a single cytoplasm 	 mice subcutaneously injected with the transformed (Epi-Epi 
were observed in confocal images (z-stacks) of representative 40 p2) (50,000 cells or 100,000 cells, respectively). All mice 
cells in the double-labeled subpopulation several hours after 	 injected with Epi-Epi p2 cells developed malignant cancers. 
the cell sort (FIG. 8C). Cells containing both red and green Q 	 As is characteristic for human prostate cancers, the initial 
dots were observed, and among these, cells containing two 	 tumor growth was slow. The time of sacrifice was determined 
nuclei in different cycle phases. The appearance of aberrant, 	 by the physical condition of each individual animal rather 
multinucleate cells following sorting and isolation was inter-  45 than the size of any apparent tumor. 
preted as heralding the onset of abnormal nuclear transfers, 	 For standard tumor models, following the subcutaneous 
cell engulfinents, and/or cell fusion events presaging final 
	
injections of cancer cells, tumors typically develop as subcu- 
carcinogenic conversion. Notably a significant fraction of the 	 taneous masses at the injection site. Interestingly, when Epi- 
original primary population was seen to participate in 	 Epi p2 cancer cells were injected minimal or often no tumor 
exchange activity during a 24 hr period. Approximately 19% 5o developed at the site of injection. Instead, an unexpected 
of the cells were identified by the sort as double-labeled, 	 ability of the tumor cells to migrate away from the implant 
whereas 81% were identified as single-labeled (FIG. 813). 	 site and metastatically colonize internal sites was observed. 
Results from investigations with murine fibroblasts 	 Tumors grew at orthotopic and metastatic sites typical for 
selected for active exchange were subcultured at a moderately 	 prostate cancer, including prostate, bone, liver, lung, and 
high density, continued interactions between the cells could 55 lymph nodes. 
lead to a state of "population instability", resulting in carci- 	 In a nude mouse injected with 50,000 cells, a measurable 
nogenic transformation and the emergence of potent cancer 	 slow-growing subcutaneous tumor (392 mm 3 in 29 days) did 
cells. No such conversion was observed under the same cul- 	 appear. But, even in this case, the tumor developed not at the 
ture conditions without prior selection for exchange activity. 	 site of injection (caudally at the dorsal midline), but rather in 
For the current studies, primary human epithelial cells were 60 the genitourinary area (FIG. 10). A second nude mouse, also 
sorted and cultured following the methodology developed for 	 injected with 50,000 cells from the same cell aliquot, devel- 
the murine investigations. The double-labeled and single- 	 oped very minimal tumor at the site of injection yet displayed 
labeled epithelial subpopulations were cultured and pro- 	 widespread internal tumor dissemination. This animal exhib- 
cessed in parallel following the sort. The post-sort double- 	 ited cancer in the lymph nodes, near the right kidney; and had 
labeled cells, Epi-Epi p0, grew in vitro and were passaged 65 a liver metastasis, but most notably, cancer was present in the 
twice (to Epi-Epi p2) before growth arrest. This was followed 	 prostate area and the prostate itself (FIGS. 9, 10, and 11A- 
by a widespread alteration of cell morphology and of popu- 	 11E). The fact that human prostate cancer cells homed to the 
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normal uninjured mouse prostate after subcutaneous injec-
tion in the back of the animals, demonstrates a capability 
extending well beyond homing to sites of injury and may be 
reminiscent of that seen during embryogenesis and develop-
ment. Withoutbeing boundto any particular theory, this result 5 
also points to the conservation between mouse and man of a 
mechanism driving the homing of these cells to internal sites. 
Having established that these transformed prostate epithe-
lial cells, Epi-Epi p2, were indeed highly carcinogenic and 
demonstrating extraordinary homing ability, it was important 10 
to determine if the cancer populations had the ability to per-
petuate tumor growth indefinitely. To test this, tumors were 
passaged in vivo, animal to animal, over eight generations to 
date. Just as 100% of the mice injected with the transformed 
cells developed malignant tumors, the invivo serial passaging 15 
of tumor fragments (1 mm 3) over generations also resulted in 
100% of the animals developing malignant cancers (FIG. 9). 
To date, all tumor fragments passaged, regardless of the site of 
excision (e.g. prostate, lymph node, etc.), grew tumors in 
recipient immunocompromised animals. As expected, paral- 20 
lel studies with wild-type C571316 mice demonstrated no 
tumor growth. The tumors exhibited patterns ranging from 
well-differentiated and glandular to more primitive and stem-
cell-like (FIGS. 10 and 11A-11E). The majority displayed a 
more primitive morphology. In certain instances such varia- 25 
tion in morphology was displayed over different regions 
within the same tumor mass. Taken together these results 
demonstrate a capacity of these cells to self-renew and to 
variably differentiate in vivo, extending on the observation 
that sustained self-renewal capacity observed for murine can - 30 
cer cells generated by similar methods. 
Analogous to the findings seen for injected cancer cells, 
subcutaneous implantation of tumor fragments also resulted 
in homing of the cancers to internal sites. The subcutaneous 
implantation of a tumor fragment did not guarantee subcuta- 35 
neous tumor growth. Although some tumor implants did 
result in subcutaneous tumor growth, these tumors were also 
accompanied by cancers in the prostate and the prostate area, 
bone, lung, liver, kidney, and lymph nodes (FIGS. 9 and 10). 
Prostate cancer is well known to metastasize to bone, lymph 40 
nodes and, to a lesser extent, lungs and liver. Of patients with 
metastatic disease, about 50% have lung and about 25% have 
liver metastasis. Clinical prostate cancer metastasizing to the 
kidney is rarer, although known to occur. 
Prostate specific antigen, PSA, commonly used as a biom- 45 
arker for human prostate carcinoma, is lacking in mice. The 
fact that PSA is elevated in human prostate cancers but does 
not present in mice makes this protein an attractive candidate 
marker for tracking human prostate cancers and their 
metastasis in murine xenograft models. However, it has 50 
proven problematic to develop human prostate models that 
maintain PSA, even when starting from primary prostate 
cancers. The Epi-Epi p2 prostate cancer cells expressed 
elevated PSA in culture, but continued to express significant 
PSA as tumors in murine xenograft models. PSA levels were 55 
sustained or even increased following serial tumor passaging 
in vivo (FIG. 11A-11E). Elevated PSA was also detected in 
the tumors that developed directly from injections of the 
transformed prostate epithelial cells and in all subsequent 
generations of tumors resulting from in vivo passaging. 60 
Expression did not depend on tumor site, and Western blot 
and antibody staining demonstrated human PSA expression 
in subcutaneous, orthotopic (prostate) and internal (e.g. 
lymphnodes, lung, etc) tumors sites. The positive detection of 
the human mRNA, DNA and protein PSA in these tumor 65 
tissues confirmed both the human and the prostate origin of all 
the cancers (FIGS. 11-11C). 
The original population of karyotypically-normal prostate 
epithelial cells (FIG. 8) used expressed baseline levels of 
PSA, and it was not until the double-labeled subpopulation 
was selected and subcultured that PSA was seen to increase. 
RT-PCR analysis demonstrated that by post-sort passage 2 
(Epi-Epi p2), the double-labeled cell subpopulation increased 
expression of PSA to >10-fold over that of the original 
unsorted prostate epithelial population (FIG. 11D). The high 
rate of PSA increase observed may be considered in light of 
clinical findings that a high rate of PSA increase in serum, 
high PSA velocity, is an established indicator of aggressive 
prostate cancer, and a negative prognostic indicator for cancer 
survival. 
As expected, no increase in PSA expression was detected 
for the non-transforming, single-labeled control subpopula-
tion following the sort and subsequent culturing. In addition 
to highly upregulated expression of PSA, the transforming 
Epi-Epi subpopulation also exhibited significantly decreased 
expression of two well-known tumor suppressors common in 
prostate cancer. Both NKX3-A, an androgen-regulated 
homeobox gene, and PAWR (prostate apoptosis gene 4), a 
pro-apoptotic protein first identified in prostate cancer cells, 
were down-regulated. Again, the control sorted single-la-
beled cell subpopulation, Epi, displayed no such decrease in 
expression of these tumor suppressors. In fact, there was a 
transient increase in PAWR expression detected in the single-
labeled first passage cell population (Epi p1) after the sort. 
In sum, human epithelial cancers were created without 
imposed genetic manipulation from karyotypically normal 
adult cells. By altering the constitutive cell-cell exchange 
dynamic of the cell population through selection of cells 
exhibiting a high level of recent exchange activity, a remark-
ably efficient tumorigenic transformation was accomplished. 
Escalated cell-cell exchanges gave way to a carcinogenesis 
course, with the creation of unstable cells that spontaneously 
transformed to a stable cancer-cell state. A population of 
cancer cells emerged that was highly malignant, possessing 
self-renewal capacity and metastatic character. During trans-
formation in vitro the human prostate cancer cells upregu-
lated PSA and downregulated well-known prostate tumor 
suppressor genes were produced. The transformed cells were 
100% effective in developing malignant cancers in immuno-
compromised mice. The tumors exhibited high PSA expres-
sion and self renewal capacity was demonstrated by serial 
completely effective passage of tumors in vivo over eight 
generations to date. Most remarkable was the ability of the 
cells to spontaneously home to the prostate and to those sites 
that are established sites of metastasis in clinical prostate 
cancer patients. The fact that the reprogrammed human pros-
tate cells were able to home to normal, uninjured, mouse 
prostate, places the homing capacity of these cancer cells 
beyond that currently ascribed to adult stem cells and sug-
gests the triggering of programs related to homing in embryo-
genesis and development. 
These results indicate that cell-cell fusions among primary 
fibroblasts, without genetic manipulation, viral infections or 
other predisposing alterations, can trigger a carcinogenesis 
program that transforms primary cells into cancer cells and 
drives their malignant progression in vivo. The isolation, 
sequestering and passaging of fused cells at densities opti-
mized to promote further fusions gave rise to a population of 
cells that underwent a synchronized transformation. The 
transformation process itself was characterized by the break-
down of the actin cytoskeleton, the merging of nuclei, re-
sorting of chromatin and the reapportionment of nuclear and 
cytoplasmic material of the syncytial cells into smaller cells 
with a high nuclear to cytoplasmic ratio. The resulting cancer 
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cells were mononuclear, aneuploid cells that presented a clas-
sic cancer cell phenotype and genotype, both in vitro and in 
vivo. 
Strikingly, spontaneous fusion among adult fibroblasts 
brought about a synchronous transformation of the cell popu- 5 
lation, in turn triggering the programmed regulation of the 
well-established cancer genes. The results reported herein 
demonstrate that in cancer cells, the hallmark oncogenesis 
gene dysregulations generally thought to derive from selec-
tion pressures acting on random mutations over time are io 
likely the result of a well-orchestrated but inappropriately-
triggered genetic program. 
More specifically, the studies described herein suggest that 
the transformation event itself may be capitalizing on innate 
fusion-dependent programs meant to confer greater organs- 15 
mal fitness; for example, the fusion of bone-marrow-derived 
stem cells to sites of tissue damage to effect repair not other-
wise possible or in sexual reproduction itself, where the 
fusion of gametes serves to introduce robustness through 
genetic mixing. If the genetic dysregulation, e.g. increased 20 
oncogene and decreased tumor-suppressor expression, com-
mon to cancer cells is indeed a programmed response rather 
than the result of selection of random mutations, the thera-
peutic ramifications would be considerable. 
Tracking an aberrantly triggered cellular program that 25 
leads to cancer would greatly simplify and inform the search 
for therapeutic targets and strategies. Although many criti-
cally important and highly-regulated genes involved in cell 
transformation and subsequent tumor progression have been 
intensely investigated over decades, the vast majority of can - 30 
cer gene regulations are still unknown. This is particularly 
true of the myriad of lesser-magnitude cancer-associated 
genetic regulations still unstudied that may prove vital both 
for understanding and thwarting tumor growth. By allowing 
cell transformation to unfold without introducing predispos- 35 
ing genetic alterations, conditions may be more favorable for 
assessing the combined effect of these gene regulations. 
Beyond genetic considerations, the roles of membrane, 
cytoskeletal, and nuclear modulations during the transfonna-
tion event also assume a greater mechanistic importance in 40 
these investigations, insofar as membrane and nuclear activi-
ties define the reduction from syncytial to synkaryotic forms 
observed during transformation. 
A fusion-initiated process of cancer induction lies well 
outside the classic carcinogenesis paradigm, which asserts 45 
that cancer originates from a single cell that has acquired 
oncogenc mutations. Cancers do not result from a single 
mutated cell gone awry, but rather from a multilevel process 
linking intercellular-interactions, nuclear and cytoskeletal 
modifications, chromosomal aberrations and genomic mix- 50 
ing among cells. Primary mammalian cells in vitro, removed 
from the three-dimensional attachments which dictate coop-
erative interaction in vivo, can undergo significant levels of 
cell-cell fusions. It is likely that the propensity to fuse may be 
a general feature of the single-cell state, and that the cancer 55 
cell, no longer constrained to be a cooperating cell in a tissue, 
may invoke this single-cell program. If true, the three-dimen-
sional tissue organization of multi-cellular organisms would 
act to thwart cell-cell fusion and suppress the oncogenc 
process. From this perspective, a role for cell fusion in onco- 60 
genesis could lend additional mechanistic insight to numer-
ous studies that have demonstrated carcinogenesis suppres-
sion with the proper maintenance of tissue architecture, 
extracellular matrix attachments and 3-D contacts and con-
straints. The cooperative nature of an organized tissue may 65 
serve to suppress carcinogenesis by limiting the cell mobility 
needed for fusions to occur. 
At the other extreme, cell overgrowth may encourage cell-
cell fusion. This would be consistent with the transformation 
occurring in areas of hyperplasia in patients. It has been 
shown that activations of oncogenes associated with prolif-
eration and cell overgrowth are often the first oncogenc genes 
to be dysregulated, frequently leading to neoplasia andhyper-
plasia, but not directly to frank cancer and genomic instabil-
ity. Without wishing to be bound by theory, it may be that 
aberrant cell juxtapositions and tissue organization which 
occur within sites of hyperplasia are also permissive of cell-
cell fusion and act in concert with the well-documented 
genetic dyregulations to further promote oncogenesis. 
In sum, this work provides a unified carcinogenesis para-
digm linking both genetic and non-genetic processes. Know-
ing cell-cell interactions alone can orchestrate cancer gene 
dysregulations may help better define mechanistic linkages 
between tissue architecture, stromal-epithelial interactions, 
aneuploidy, and genomic instability. Cancer may be inter-
preted as an emergent process where loosening of cell-cell 
and tissue constraints and tissue architectural disruptions can 
directly regulate oncogenc signaling. This calls for linking 
current genetic and non-genetic investigations through a sys-
tems-wide approach to better dissect underlying carcinogen-
esis mechanisms and designing therapeutic strategies. In par-
ticular, the fact that profound modulations in membrane, 
nuclear and cytoskeletal characteristics of these cells was 
observed simultaneous with their transition from a multi-
nuclear to single nuclear state indicates that it would be fruit-
ful to invest more effort in establishing the role these subcel-
lular activities play in the transformation process. 
Results reported herein were obtained using the following 
methods and materials. 
Cell Culture. 
Lewis lung cell (LLC) murine lung carcinoma was 
obtained from American Type Culture Collection (Manassas, 
Va.). Lewis lung cells were cultured in DMEM, high glucose 
(Gibco Invitrogen Cell Culture, Carlsbad, Calif.) with 10% 
FBS (Gibco Invitrogen Cell Culture). Murine lung fibroblasts 
(MLF) were harvested from the lung of 40-60-day-old non-
tumorbearing mice as describedby Kumar et al. (1991). Mice 
were overdosed with 0.8 cc of Aver -tin (Sigma, St. Louis, 
Mo.). Lungs were removed and placed in 1xPBS in sterile 
conditions. Lungs were then diced into small chunks (1-2 
mm2) and spread out on 1-10 cm 2 plates. They were then 
covered with a minimal amount of DMEM, low glucose with 
10% FBS and 100 µg/ml of penicillin/streptomycin and 
placed gently in cell incubators. The media was gently 
replaced on the plates after 2 days. The MLF cell outgrowth 
from the chunks was trypsinzed when 80% confluent using 
0.05% Trypsin-EDTA (Gibco Invitrogen Cell Culture, Carls-
bad, Calif.) and placed back in culture. MLF cells were main-
tained in the same media used to isolate the cells. 
Human adult normal prostate epithelial cells and specified 
optimal growth media were obtained from Clonetics-Loma 
(PrEC, Cat #CC-2555). Cryovials were thawed at 37° C., 2 
min, cells seeded at 2500 cells/cm 2 in 25 cm2 and 75 cm2 
flasks (Corning, USA) incubated under 5% CO 2 . Cells passed 
at 80% confluence. 
Cocultures. 
For the studies with mouse lung cells, the following pro-
cedures were used. All primary cells were cocultured through 
passage 8. All cells were detached from flasks using standard 
methods. Cells were counted for each population with a 
hemocytometer, and were separated into three 15 ml centri-
fuge tubes. One tube was labeled with 50 nM of Qtracker® 
525 (Green) cell labeling dye (Invitrogen, Carlsbad, Calif.) 
and another with 45 nM of Qtracker® 655 cell labeling dye 
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(Red) (Invitrogen). The third tube, with 2x10 5 cells, was not 	 stored at —80° C. Quality and quantity of total RNA isolated 
labeled. All tubes were incubated at 37° C. in a cell incubator 	 was measured by using an Agilent 2100 bioanalyzer. 
for one hour and cells labeled with Qtrackers® were washed 	 cDNA Generation. 
three times with the appropriate media. After the final wash 
	
Total RNA from MLF, LLC, and different passages of 
all cells were resuspended in the appropriate media with 5 MLF-MLF was isolated using TRIzoI®. RNA integrity was 
supplements. Tubes labeled with no dye were plated in T25 	 confirmed by lab-on chip technology, using an Agilent 2100 
flasks. Approximately 2x10 5 cells with Qtracker® 525 and 	 bioanalyzer in combination with the RNA 6000 Lab Chip kit 
with Qtracker® 655 were plated in separate T25 flasks. 	 according to the manufacturer's instructions (Agilent Tech- 
Approximately 5x10 5 cells with Qtracker® 525 and 	 nologies, Boeblingen, Germany). cDNAs were synthesized 
Qtracker® 655 were combined and placed in T75 flasks in io from 1 µg total RNA using High Capacity cDNA Reverse 
triplicates. All flasks were incubated at 37C., 5% CO 2, for 24 
	
Transcription kit (ABI, Applied Biosystems) and stored at 
hours with the appropriate media. 	 —20° C. or —80° C. until use. 
For the studies with human prostate epithelial cells, the 	 Real-Time Quantitative PCR. 
following procedures were used. At four passages in culture, 	 Expression levels of RNA transcripts were quantitated by 
3x106 cells were placed in 15 ml centrifuge tubes with either 15 real-time PCR using a 7300 Real Time PCR System from 
50 nM of Qtracker 525 (Green) cell labeling dye (Molecular 	 Applied Biosystems. Complementary DNAs were mixed 
Probes, CA), or 45 nM of Qtracker 655 (Red) cell labeling 	 with TagMan universal PCR master mix (Applied Biosys- 
dye (Molecular Probes, CA). The third tube containing 2x10 5 	 tems) and primers (CDKn2a, Spp1, p53, WC, Bcl-2, Kras, 
cells with no Qtracker was used as an additional control. 	 CD44, and VEGFa) for mouse lung cell studies or primers 
Tubes were incubated 1 hours at 37° C. one hour, and cells 20 (PSA, NKX3-A and PAWR) for human epithelial prostate 
washed three times with appropriate media. Cells then resus- 	 cell studies before performing real-time PCR. PCR condi- 
pended in appropriate media with supplements. Cells (2x 10 5) 	 tions for all RT-PCRs were preformed as follows: denatur- 
from each of the three tubes were plated in three T25 flasks. 	 ation at 95° C. for 30 sec, annealing at 60° C. for 30 seconds 
Cells (5x105) from tubes with Qtracker 525 and with 	 and extension at 72° C. for 1 minute. In addition to profiling 
Qtracker 65 5 were combined for co-culture and placed in T75 25 all samples for the target sequence, samples were profiled for 
flasks in triplicate. All flasks were placed in a cell incubator at 	 18S (ribosomal RNA) expression as endogenous control. For 
37° C. with 5% CO 2 for 24 h. 	 each single well amplification reaction a threshold cycle (CT) 
Cell Sorting. 	 was observed in the exponential phase of amplification and 
Cells were washed once with 1 xPBS, trypsinized and sus- 	 the quantitation of relative expression levels was achieved 
pended into 15-m1 centrifuge tubes, and pelleted at room 30 using standard curves for both the target and endogenous 
temperature for 5 minutes (e.g., at 300xg). The supernatant 	 controls. All assays were performed in triplicate. 
was removed and cells were resuspended in approximately 	 Proliferation Assay. 
0.5 ml of the appropriate media in 5 ml polypropylene round- 	 The CyQUANT® Cell Proliferation Assay was performed 
bottom tubes (Becton Dickinson, Franklin Lakes, N.7.). Cells 	 using the standard protocol recommended by Invitrogen. For 
were sorted using a MoFlos (Dako, ne Cytomation) cell 35 the cell proliferation standard curve, a concentrated cell sus- 
sorter. Cells which detached from T25 flasks were used as 	 pension in medium with a density of 10 5 cells/ml was pre- 
controls to optimize the gates for the cell sorter. Double- 	 pared. Serial dilutions in the wells of a 96 well plate (black, 
labeled cells possessing both red and green Qtrackers were 	 clear bottom, Costar 3603) were performed such that 200 
collected and defined as functionally exchanging cells. 	 µvolumes of growth medium contain cell numbers ranging 
Single-labeled cells with either red or green Qtrackers alone 40 from 1000 to 20,000. A control well with no cells was also 
were collected and these populations used as controls for the 	 included. After 48-72 hours cells were centrifuged, the super- 
studies. A small portion of sorted cells were placed on cover 	 natant removed and the plates frozen at —80° C. overnight. 
slips that were treated with ECL cell attachment matrix (en- 	 The cells were thawed the next day, 200 ld of the 
tacin-collagen IV-laminin) from Upstate (Temecula, Calif.) 	 CyQUANTOGR dye/lysis buffer (Invitrogen) was added to 
for microscopy. The rest of the sorted cells were placed in the 45 each well and incubated for 2-5 min at room temperature. The 
appropriate sized flask for culture. 	 96-well plates were read at 485 nm on a Victor 2 fluorescence 
RNA Isolation. 	 plate reader to quantify total fluorescence from each well. 
RNA was isolated from cultures pre- and post-sort (e.g., 	 Nuclear and Cell Area Quantification. 
MLF, LLC, and MLF-MLF fused cells). Cells were placed in 	 Cells were prepared and stained on the same day for quan- 
TRIzol (Invitrogen) for 5 min at room temperature. Cells in 50 tification. Cells were detached from the flasks and 1 x10 7 cells 
TRIzol® were incubated for 5 minutes at room temperature. 	 (in form of a cell pellet) were resuspended in 4% paraform- 
Chloroform (0.2 ml per 1 ml of TRIzol(k) was added to each 	 aldehyde for 15 minutes at room temperature for fixation. 
sample (containing 0.5-1.0x10 6 cells) and incubated at room 	 Cells were washed once with 1 x Tris-buffered saline, pH 7.4 
temperature for 5 minutes. The samples were centrifuged at 	 (1 xTBS) and resuspended in Hoechst nuclear stain (Invitro- 
10,000xg for 15 minutes at 4° C. The aqueous phase which 55 gen) at a concentration 4 µg/ml in 1 ml of 1xTBS for 15 
contains the RNA was transferred to a clean 1.5 ml eppendorf 	 minutes at room temperature. Cells were washed once again 
tube. Isopropyl alcohol (0.5 ml per 1 ml of aqueous phase) 	 with 1 xTBS. Cells were then resuspended in 60 µl of 1 xTBS 
was gently added. Samples were incubated at room tempera- 	 and kept at 4° C. until ready to use. An ImageStream® cell 
ture for 10 minutes and centrifuged at 10,000xg for 10 min- 	 analysis system (Amnis, Seattle, Wash.) was used to image 
utes at 4° C. The supernatant was discarded and the RNA 6o and quantify 10,000 to 20,000 cells for each cell type. IDEAS 
pellet was washed once with 70-75% ethanol. The RNA from 	 ApplicationO software was used to analyze the nuclear and 
the cells (e.g., MLF, LLC, and MLF-MLF cells) was resus- 	 cell area for each cell type. 
pended in 10 µl RNase-free water. The RNA from human 	 Soft Agar Assay. 
prostate epithelial cells was resuspended in 5 µl in RNase-free 	 1% Agar (DNA grade) in 1xPBS was autoclaved and 
water. The RNA from LLC-LLC cells was resuspended in 65 cooled to 40° C. in a water bath. An equal volume of the 
100 µl in RNase-free water. 1 µl from each sample was put 	 appropriate 2x media and the 1% agar was mixed to give 
aside for RNA integrity testing. The rest of the RNA was 	 0.5%.4 ml of the new agar mix was poured in 60 mmx15 mm 
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cell culture dish from Corning (Corning, N.Y.) and allowed to 
set. 0.7% agar in 1 xPBS was autoclaved and allowed to cool 
to 40° C. 5000 cells/plate is needed for this assay, so cells 
were prepared at a concentration of 2x10 5 cells/ml. 0.1 ml of 
cell solution or 20,000 cells were placed in a 15 ml centrifuge 
tube and 3 ml of the appropriate 2x media was added to the 
tube. 3 ml of 0.7% agar was mixed with 3 ml of the cells in the 
15 ml tube. 1.5 ml of the cell and agar solution was added to 
each culture dish containing 0.5% agar prepared earlier. The 
assay was incubated at 37° C. in a cell incubator for 10 to 14 
days. Cultures were stained with 0.005% Crystal Violet 
(Sigma-Aldrich) for 1 hour and colonies were quantified 
using a dissecting microscope. 
mFISH. 
For the studies with mouse lung cells, the following pro-
cedures were used. Slides were made using a single-cell 
suspension in 3:1 methanol:acetic acid fixative, then dehy-
drated. Metaphase chromosome preparations were pretreated 
and denatured in a series of solutions including saline sodium 
citrate and sodium hydroxide. Chromosome preparations 
were then dehydrated and air dried. A 10 µl aliquot of Mouse 
m-FISH probe cocktail (Metasystems, Altlussheim, Ger-
many) was denatured at 75° C., quickly cooled, and prehy-
bridized at 37° C. for 30 minutes. The probe was added to the 
slide, coverslipped and sealed with rubber cement for incu-
bation over the course of 4 days at 37° C. Posthybridization 
washes were performed using saline sodium citrate and 
Tween-20 solutions. The chromosomes were counterstained 
with DAPI and an Olympus AX-70 microscope with appro-
priate filter sets were used to visualize the probe hybridization 
on the chromosomes. 
For the studies with human prostate epithelial cells, the 
following procedures were used. Mounted frozen tissue 
removed from —80'C. for 30 min room temp prior to staining. 
Sections were rinsed in PBS, fixed in 100% methanol at —20° 
C. for 10 min, washed PBS, and placed in 4% PFA 3 min at 
room temp. Slides washed 2x. Total protein was extracted 
from frozen sample by standard extraction protocol. A 50 µg 
quantity of total protein from each tissue extract was sepa-
rated on 12% SDS gels (Bio-Rad) and transferred to nitrocel-
lulose membranes (AmershamBiosciences). The membranes 
were treated in PBS containing 0.05% Tween 20 and 5% 
nonfat dry milk for 1 h, then probed with monoclonal anti-
body to PSA (Scripps Laboratories) at 1:1000 4° C. over-
night. After wash, membranes were incubated with horserad-
ish peroxidase-conjugated secondary antibody (diluted 
1:2000, DAKO) 1 hours room temp. An ECL Plus detection 
kit (Amersham Biosciences) was used to visualize the reac-
tion by chemiluminescence with PBS for 5 min each at room 
temperature. To each tissue section hybridization buffer was 
added containing 20 mM Tris-HCl [pH 7.2], 0.01% SDS, 
0.9M NaCl, and 15% formamide. An oligonucleotide was 
labeled with Alexa 488 (Eurofins MWG Operon, Huntsville, 
Ala., USA) for the PSA probe (sequence obtained from NCBI 
Accession: BC005301 and probe sequence used: 3' GCA 
GGG CAG TCT GCG GCG GTG TTC TGG TGC ACC CCC 
AGT GGG TCC TCA CAG CTG CCC ACT GC 5'). Hybrid-
ization on the slide was at 46° C., 16 hr, in dark. After hybrid-
ization, slides were rinsed PBS, 46° C., and placed in wash 
buffer (20 mM Tris-HCl [pH 7.2], 0.01 % SDS, 0.318M NaCI) 
at 48° C., 15 min, in dark. Slides were quickly immersed in 
PBS. For nuclear staining, 1 mM To-Pro-3 (Molecular 
Probes) diluted to 2 µM in PBS and incubated on tissue 
sections for 15 min room temp in dark. Tissue was rinsed in 
PBS 5 min, and anti-fade mounting solution added. Slides 
were coverslipped, sealed and stored at —20° C. 
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Immunofiuorescence Antibodies. 
For immunofiuorescence Anti-CD44 (A020), Human 
(Rat) (Calbiochem, San Diego, Calif.) was used at a dilution 
of 1:400 for dual stain, goat polyclonal MMP-9 (C-20) (Santa 
5 Cruz Biotechnology, Inc, Santa Cruz, Calif.) was used at a 
dilution of 1:100 for dual stain, and monoclonal anti-rabbit 
monoclonal OPN antibody (this antibody was generously and 
kindly provided by Dr. Larry Fisher from NIH) at a dilution of 
1:400 for dual stain. 
10 	 Immunofiuorescence Staining. 
For the studies with mouse lung cells, the following pro- 
cedures were used. Cells were placed on 22x22 mm glass 
cover slips (Brain Research Laboratories, Cambridge, Mass.) 
in 6-well plates from Corning (Corning, N.Y.). The cover 
15 slips were prepared for cells by sterilizing under UV light for 
1 hour. 1 ml of ECL cell attachment matrix (entacin-collagen 
IV-laminin) from Upstate (Temecula, Calif.) was added to 
each well at a concentration of 20 µg/ml. The 6-well plates 
were placed at 37° C. for one hour. The ECL cell attachment 
20 matrix was removed from each well. The cover slips were 
rinsed with DMEM, low glucose with 10% FBS. Cells were 
added to the coverslips and incubated at 37° C. until the 
desired cell density was reached. Media from the cells on 
cover slips in 6 well-plates were removed and cells were 
25 washed once with 1 xPBS. 4% paraformaldehyde (PFA) was 
added for 15 minutes at 20° C. PFA was removed and cells 
were washed twice with IXPBS, and incubated with 1% 
bovine serum albumin (BSA) (Sigma, St. Louis, Mo.) for 1 
hour at room temperature. Another blocking step for 1.5 
3o hours incubation at room temperature was done using Mouse 
Detective from Biocare Medical (Concord, Calif.). For dual 
antibody stains, cells were incubated at room temperature for 
2 hours with a mix of the appropriate antibodies in 1% BSA. 
The cells were washed once with 10% goat serum (Gibco 
35 Invitrogen Cell Culture) after two hours. For CD44 stain, the 
cells were first stained with anti-rat Alexa 488 secondary 
antibody (Molecular Probes, Carlsbad, Calif.) at a dilution of 
1:300 in 10% goat serum for 1 hour in the dark. For MMP-9 
stain, the cells were first stained with anti-goat Alexa 488 
40 secondary antibody (Molecular Probes) at a dilution of 1:300 
in 10% donkey serum for 1 hour in the dark. 1 x wash in 
1xPBS followed for 5 minutes at room temperature, and 
another hour incubation in the dark occurred for OPN stain 
with anti-rabbit Alexa 555 secondary antibody (Molecular 
45 Probes) at a dilution of 1:300 in 10% goat serum. After last 
secondary antibody step, 2 washes with 1 xPBS was done for 
5 minutes each at room temperature. To stain the nucleus, 1 
mM of To-Pro®-3 (Molecular Probes) was diluted to 2 µM in 
1xPBS and incubated on the cells for 10 minutes at room 
50 temperature in the dark. The cells were rinsed once with 
1 xPBS and Vectashield® anti-fade mounting solution (Vec-
tor Laboratories, Burlingame, Calif.) was added. The cover 
slips were placed on slides and sealed with nail polish. The 
slides were stored at —20° C. until evaluation. 
55 	 For the studies with human prostate epithelial cells, the 
following procedures were used. Frozen tissue sections 
removed from —80° C. and placed 30 min room temp for prior 
to staining. Sections rinsed PBS, fixed: 10 min at —20° C. in 
80% methanol and 3 min room temperature in 4% PFA. 
60 Slides washed 3xPBS (5 min) at room temp. Nonspecific sites 
blocked by incubation with 1% BSA room temp. 1 hr. Addi-
tional blocking done using mouse detective (Biocare Medi-
cal, Concord, Calif.) 4 hours room temp. For PSA immunof-
luorescence, sections incubated with rabbit monoclonal 
65 Prostate Specific Antigen (PSA) antibody (Abcam Inc., Cam-
bridge, Mass., USA) at 1:100 dilution in 1% BSA at 4° C. 
overnight. Next day sections washed 10% goat serum 3x (5 
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min) at room temperature. Alexa Fluor® 555 goat anti-rabbit 
IgG secondary antibody (Molecular Probes, Carlsbad, Calif.) 
applied at 1:300 in 10% appropriate serum and placed 1 hour 
in the dark. Sections were washed 2x in PBS, 5 min room 
temp. For nuclear staining, 1 mM To-Pro-3 (Molecular 
Probes) diluted to 2 µM in PBS and incubated on sections for 
15 minutes in darkness at room temperature. Sections rinsed 
PBS (5 min) and anti-fade mounting solution added. Slides 
coverslipped, sealed, stored at —20° C. 
F-Actin Staining. 
Cells were washed twice with 1xPBS on cover slips. 4% 
paraformaldehyde (PEA) was added for 15 minutes at room 
temperature. PEA was removed and cells were washed twice 
with IXPBS. 0.1% Triton X-100 (Sigma-Aldrich) in 1xPBS 
was placed on cells to permeabalize membrane for 5 minutes. 
Cells were washed twice with 1 xPBS. Cells were incubated 
with 1 %bovine serum albumin (BSA) for 30 minutes at room 
temperature. Cells were washed again two more times with 
1 xPBS. Cells were stained with 10 ld Alexa Fluor 594 phal-
loidin (Molecular Probes) with 200 µl of 1 xPBS per cover slip 
for 20 minutes. Cells were washed two more times with 
1 xPBS and stained with the same nuclear dye as the previous 
section. 
Microscopy. 
Cells or tissue sections were viewed using a Zeiss® LSM 
510 Meta Confocal Scanning System (Carl Zeiss, Jena, Ger-
many) equipped with an Argon laser, HeNe laser 543 nun, 
HeNe laser 633 nun, and 3 separate detectors that allow 3 
sequential or simultaneous imaging using 3 different fluoro-
phores. The third detector, referred to as the Meta detector, 
can be configured to capture up to 8 separate color channels. 
Images were captured using 3 separate photomultiplier tubes 
for each detector at 1024x10 24 pixels. Z-stacks were obtained 
when necessary. Reconstruction of the z-stack was done 
using Zeiss software. 
Murine Skin Xenograft Model. 
For the studies with mouse lung cells, the following pro-
cedures were used. Mice were not less than 8 weeks of age at 
the time of injection. In preparation for injection, the caudal 
half of the back was shaved and swabbed with antiseptic 
solution. Mice were anesthetized with a 0.5 mg/g intra-peri-
toneal dose ofAvertin, marked with an ear tag, and marked at 
the tail for easy short-term identification. Tumor cells and 
sorted fused cells were suspended in a solution of PBS. Using 
a Icc syringe and a 27G needle, 1x10 6 tumor cells or fused 
cells were injected subcutaneously in 0.2 cc PBS. 
Following injection, mice were monitored regularly. 
Tumor size was measured every day with calipers. Once 
tumors reached about 1500-2000 mm 3 , mice were sacrificed 
and the tissues processed. 
For the studies with human prostate epithelial cells, the 
following procedures were used. Balb/c (CByJ.Cg-Foxnlnu/ 
J) and SCID (NOD.CB17-Prkdcscid/J) mice, at least 8 weeks 
of age, were used (Jackson Labs, Bar Harbor, Me.). Subcu-
taneous cell injections (0.2 ml in PBS) and serial passaging of 
1 mm3 tumor fragments was made into the caudal portion of 
the back. Mice were monitored and tumor size and animal 
weight measured daily. When subcutaneous tumors reached 
1000-1500 mm3, mice were in distress, or have lost 20% of 
total body weight (indicative of internal tumor burden), ani-
mals were sacrificed. Full autopsy and tissue collection per-
formed at sacrifice. Tissues were divided and aliquoted for 
assays. Samples were slow-frozenin OCT (TissueTek, Fisher 
Scientific) in the gas phase of liquid nitrogen. Tissue samples 
were placed in 10% formalin for not more than 24 hr, pro-
cessed and paraffin-embedded. 
56 
Tissue Processing. 
Mice were anesthetized with 0.5 mg/g intra-peritoneal 
dose of Avertin. Mice were sacrificed with an overdose of 
Avertin (1.2 mg/g). When the animal was unresponsive to tail 
5 pinch, and exhibited physiologic signs of deep anesthesia, the 
thoracic cavity was immediately opened by median sterno-
tomy. Ice cold PBS and Heparin (Sigma) at 1000 U/L were 
flushed through the left ventricle and out a vent in the right 
atrium. A portion of the tissue was quickly dissected and 
10 slow-frozen in OCT (Tissue Tek, Fisher Scientific) in the gas 
phase of liquid nitrogen. The rest of the tissue was placed in 
10% formalin and processed for paraffin embedding. The 
tissue was embedded in paraffin cassettes and stored until 
ready for staining. 
15 	 Immunohistochemistry. 
For the studies with mouse lung cells, the following pro-
cedures were used. Paraffin-embedded tissue was cut into 4 
µm slices using a microtome and placed on positively charged 
slides (Fisher Scientific). Standard procedure was used to 
20 stain the tissue for H&E. All slides were stained with different 
antibodies using the Benchmark® XT IHC/ISH Staining 
Module from Ventana Medical Systems, Inc (Tucson, Ariz., 
USA). All antibodies and reagents were furnished at the cor-
rect final dilutions and concentrations, for the Benchmark® 
25 XT staining module, from Ventana Medical Systems. Freshly 
cut tissue sections on slides were placed in the Benchmark XT 
module and slides were stained with the appropriate antibody 
using the automated system. Once the staining was complete 
coverslips were applied to each slide. 
30 	 For the studies with human prostate epithelial cells, the 
following procedures were used. Standard H&E staining was 
done on 4 µm sections from formalin-fixed paraffin-embed-
ded tumor samples. PSA antibody staining was done using 
the Benchmark XT IHC/ISH Staining Module from Ventana 
35 Medical Systems, Inc (Tucson, Ariz.). Antibodies and 
reagents (Ventana Medical Systems) were furnished at the 
final concentrations used in the Benchmark XT staining mod-
ule. Tissue sectioning and staining done by clinical histology 
unit (EXCELL, Caritas St. Elizabeth's Medical Center, Tufts 
40 Univ. School of Med., Boston, Mass.). Histopathological 
staging was done by clinical pathologist Dr. Douglas 
Schneider, CSEMC. 
Immunohistochemistry. 
Total protein was extracted from frozen tissue samples by 
45 standard extraction protocol. A 50 µg quantity of total protein 
from each tissue extract was separated on a 12% SDS gels 
(Bio-Rad) and transferred to nitrocellulose membranes (Am-
ersham Biosciences). The membranes were treated in PBS 
containing 0.05% Tween 20 and 5% nonfat dry milk for 1 h, 
50 then probed with monoclonal antibody to PSA (Scripps 
Laboratories) at 1:1000 overnight, 4° C. After washing, the 
membranes were incubated with horseradish peroxidase-
conjugated secondary antibody (diluted 1:2000, DAKO) for 1 
hr, room temp. An ECL Plus detection kit (Amersham Bio- 
55 sciences) was used to visualize the reaction by chemilumi-
nescence. 
OTHER EMBODIMENTS 
60 	 From the foregoing description, it will be apparent that 
variations and modifications may be made to the invention 
described herein to adopt it to various usages and conditions. 
Such embodiments are also within the scope of the following 
claims. 
65 	 The recitation of a listing of elements in any definition of a 
variable herein includes definitions of that variable as any 
single element or combination (or subcombination) of listed 
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elements. The recitation of an embodiment herein includes 	 15. Bugge, T. H., Kombrinck, K. W., Xiao Q., Holmback, K., 
that embodiment as any single embodiment or in combination 	 Daugherty, C. C., Witte, D. P. & Degen, J. L. Growth and 
with any other embodiments or portions thereof. 	 dissemination of Lewis lung carcinoma in plasminogen- 
All patents and publications mentioned in this specification 	 deficient mice. Blood 90(11), 4522-4531 (1997). 
are herein incorporated by reference to the same extent as if 5 16. Chen, E. H., Grote, E., Mohler, W. & Vignery, A. Cell-cell 
each independent patent and publication was specifically and 
	 fusion. FEBS Letters 581, 2181-2193 (2007) 
individually indicated to be incorporated by reference. 	 17. Ciardiello, F. & Tortora, G. Inhibition of bcl-2 as cancer 
therapy. Ann Oncol. 13(4), 501-502 (2002). 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 1 
<210> SEQ ID NO 1 
<211> LENGTH: 62 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
probe 
<400> SEQUENCE: 1 
cgtcacccgt cgacactcct gggtgacccc cacgtggtct tgtggcggcg tctgacggga 	 60 
cg 	 62 
What is claimed is: 
1. An isolated self-renewing cell selected as the product of 
a spontaneous cell-cell fusion or a descendant thereof, 
wherein the spontaneous fusion is between a non-neoplastic 
cell and a non-neoplastic cell of the same cell type, wherein 
said cell is aneuploid, has periodically increased expression 
of an oncogene selected from the group consisting of VEGF, 
MMP-9, k-ras, myc and l3cl-2 relative to a reference cell, and 
has periodically reduced expression of CDKn2A, p53, and 
CD44 relative to a reference cell. 
2. A tumor-initiating cell selected as the product of a spon-
taneous cell-cell fusion or a descendant thereof, wherein said 
cell gives rise to a neoplasia in vitro or in vivo under suitable 
growth conditions, wherein the spontaneous fusion is 
between a non-neoplastic cell and a non-neoplastic cell of the 
same cell type, wherein said cell is aneuploid, has periodi-
cally increased expression of an oncogene selected from the 
group consisting of VEGF, MMP-9, k-ras, myc and l3cl-2 
relative to a reference cell, and has periodically reduced 
expression of CDKn2A, p53, and CD44 relative to a refer-
ence cell. 
3. The cell of claim 1 or 2, wherein said cell exhibits a 
characteristic selected from the group consisting of: 
increased cellular proliferation rate relative to a corre- 
sponding reference cell, 
formation of a colony in soft agar in vitro, and 
formation of a tumor in vivo. 
4. The cell of claim 1 or 2, wherein the cell is selected using 
two distinct detectable labels. 
5. An isolated cell population comprising cells selected as 
the product of a spontaneous cell-cell fusion or descendants 
thereof, and cultured under conditions sufficient to promote 
further fusion, wherein at least one cell of said population is 
a self-renewing tumor-initiating cell, wherein the spontane-
ous fusion is between a non-neoplastic cell and a non-neo-
plastic cell of the same cell type, wherein said cell is aneup-
loid, has periodically increased expression of an oncogene 
selected from the group consisting of VEGF, MMP-9, k-ras, 
myc and l3cl-2 relative to a reference cell, and has periodi-
cally reduced expression of CDKn2A, p53, and CD44 rela-
tive to a reference cell. 
6. The isolated cell population of claim 5, wherein at least 
about 50-75% of said population are tumor-initiating cells or 
highly tumorogenic cells. 
7. The isolated cell population of claim 5, wherein said cell 
population exhibits a characteristic selected from the group 
consisting of:  
20 	 increased cellular proliferation rate relative to a corre- 
sponding reference cell, 
able to form a colony in soft agar in vitro, and 
able to form a tumor in vivo. 
8. The isolated cell population of claim 5, wherein at least 
about 50% of said cells are aneuploid and show increased 
25 expression of an oncogene selected from the group consisting 
of k-ras, myc and l3cl-2, and show decreased expression of 
CDKn2A and p53 relative to a corresponding reference cell. 
9. The isolated cell population of claim 5, wherein the 
population has a tumor producing efficiency that is at least 
30 about 10-fold greater than a reference cell. 
10. The isolated cell population of claim 5, wherein injec-
tion of at least about 10-500 cells of said population forms a 
tumor of about 1 cm diameter in at least about 50% of nude 
mice within about 2-6 weeks. 
35 	 11. The isolated cell population of claim 5, wherein at least 
about 50% of the cells in the population exhibit synchronous 
differential expression of at least two markers selected from 
the group consisting of Myc, K-ras, l3cl-2, p53, CDKn2a, 
CD44, SPP I , and VEGF relative to a corresponding reference 
40 population. 
12. The isolated cell population of claim 5, wherein one of 
the non-neoplastic cells is a fibroblast or epithelial cell. 
13. The isolated cell population of claim 5, wherein the 
cell-cell fusion does not give rise to a macrophage, muscle 
45 cell, hybridoma cell, or virus infected cell. 
14. The isolated cell population of claim 5, wherein the cell 
is derived from a subject identified as having or having a 
propensity to develop a neoplasia. 
15. The isolated cell population of claim 14, wherein the 
5o neoplasia is a solid tumor or blood tumor. 
16. The isolated cell population of claim 5, wherein con-
ditions sufficient to promote further fusion include culturing 
the cells at a density of about 80% confluence. 
17. A method of generating the tumor-initiating cell of 
55 claim 2, comprising selecting a cell that is the product of a 
spontaneous cell-cell fusion or a descendant thereof and cul-
turing said cells, thereby generating a tumor-initiating cell 
population, wherein the spontaneous fusion is between a 
non-neoplastic cell and a non-neoplastic cell, and wherein the 
60 selected cell is aneuploid, has periodically increased expres-
sion of an oncogene selected from the group consisting of 
VEGF, MMP-9, k-ras, myc and l3cl-2 relative to a reference 
cell, and has periodically reduced expression of CDKn2A, 
p53, and CD44 relative to a reference cell. 
65 	 18. The method of claim 17, further comprising culturing 
said cells under conditions sufficient to promote further 
fusion. 
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19. The method of claim 17, wherein said cells comprise at 
least two nuclei. 
20. The method of claim 17, wherein the method further 
comprises selecting a cell comprising at least 3 or 4 nuclei, 
and allowing said cell to proliferate. 
21. The method of claim 17, wherein the cell that is a 
product of the spontaneous cell-cell fusion is identified using 
detectable cellular markers. 
22. The method of claim 21, where said detectable cellular 
markers are cytoplasmic vital dyes. 
23. The method of claim 17, wherein at least one of the cells 
that undergoes spontaneous cell-cell fusion is derived from a 
subject identified as having or having a propensity to develop 
a neoplasia. 
24. An isolated tumor-initiating cell made by the process of 
claim 17. 
25. The isolated cell of claim 24, wherein the cell or cell 
population is self-renewing, capable of forming a tumor when 
injected into a SCID mouse, a nude mouse, an immune com-
petent mouse, or is resistant to exposure to radiation or che-
motherapy. 
26. The isolated cell of claim 24 or 25, wherein said cell 
exhibits a characteristic selected from the group consisting 
of: 
genomic instability, 
increased cellular proliferation rate relative to a corre-
sponding reference cell, 
able to form a colony in soft agar in vitro, and 
able to form a tumor in vivo. 
27. The isolated cell of claim 24 or 25, wherein said cell is 
aneuploid, has increased expression of k-ras, myc and Bcl-2, 
and has reduced expression of CDKn2A and p53 relative to a 
control cell. 
28. The isolated cell of claim 24 or 25, wherein the cell is 
tumorogenic. 
29. The isolated cell of claim 24 or 25, wherein said cell has 
a tumor producing efficiency that is at least 10-fold greater 
than a reference cell not the product of a cell-cell fusion event. 
30. A composition comprising a population of tumor-ini-
tiating cells made by the process of claim 17. 
31. The composition of claim 30, wherein injection of at 
least about 10-500 cells of said population forms a tumor of 
about I cm diameter in at least about 50% of nude mice within 
about 2-6 weeks. 
32. The composition of claim 30 or 31, wherein at least 
about 50% of the cells in the population exhibit periodic 
differential expression of at least two markers selected from 
the group consisting of Myc, K-ras, Bcl-2, p53, CDKn2a, 
CD44, SPPI, and VEGF relative to a corresponding reference 
population. 
33. A method for identifying an agent for the treatment or 
prevention of a neoplasia, hyperplasia or a hyperproliferative 
disorder comprising: 
contacting the tumor-initiating cell or cell population of 
claim 2 with an agent; and 
detecting a decrease in cell survival or proliferation relative 
to an untreated control cell or cell population. 
34. A method for identifying an agent that inhibits cell-cell 
fusion comprising: 
contacting the isolated cell of claim 5 with an agent; and 
detecting a reduction in cell-cell fusion relative to an 
untreated control population. 
68 
35. The method of claim 34, wherein a reduction in multi-
nucleate cell number in the treated population identifies an 
agent that inhibits cell-cell fusion. 
36. The method of claim 33 or 34, wherein the agent 
5 increases cell death. 
37. The method of claim 33 or 34, further comprising 
maintaining the cell in culture under conditions sufficient to 
generate mononucleate cells from a multinucleate cell, and 
identifying a reduction in the generation of said cells relative 
10 to a corresponding control culture. 
38. The method of claim 34, wherein the cell is a fibroblast 
or epithelial cell. 
39. A method of identifying an agent that prevents neopla- 
sia relapse following chemotherapy, the method comprising: 
15 	 contacting the isolated cell population of claim 14 with an 
agent; 
detecting a decrease in cell survival, proliferation, or fusion 
relative to an untreated control cell or cell population, 
wherein said decrease identifies that agent as preventing 
20 	 neoplasia relapse following chemotherapy. 
40. An immunogenic composition for the treatment or 
prevention of a neoplasia in a subject, the composition com-
prising an effective amount of a cell population of any one of 
claim 1, 2, or 5, and an excipient, wherein the cell population 
25 has been rendered non-viable. 
41. The immunogenic composition of claim 40, further 
comprising an adjuvant. 
42. The immunogenic composition of claim 40, wherein 
said cell population is derived from a subject identified as 
30 having or having a propensity to develop a neoplasia. 
43. A method for inducing an immune response against a 
tumor-initiating cell or neoplasia, the method comprising 
administering the immunogenic composition of claim 40 to a 
subject. 
35 44. The method of claim 43, wherein the immunogenic 
composition comprises a cell derived from the subject to be 
treated. 
45. The method of claim 43, wherein the method treats or 
prevents a neoplasia. 
40 46. The method of claim 43, wherein the method treats or 
prevents the relapse of a neoplasia. 
47. The method of claim 43, wherein the method is admin-
istered prior to, concurrent with, or following chemotherapy 
or radiation therapy. 
45 	 48. A method of immortalizing a primary cell in culture 
comprising: 
selecting the isolated self-renewing cell of claim 1 or the 
tumor-initiating cell of claim 2; and 
culturing the selected cell under conditions that promote 
50 	 further cell-cell fusions, thereby generating an immor- 
talized cell. 
49. The method of claim 48, wherein the selected cell is bi 
or multinucleate. 
50. The method of claim 48, further comprising the step of 
55 maintaining the bi or multinucleate cells in culture for a time 
sufficient to generate a population comprising at least 50% 
mononucleate aneuploid cells. 
51. A method for producing a differentiated cell from a 
tumor-initiating cell, the method comprising providing a cell 
60 according to claim 1 or 2, and contacting the cell with a 
differentiation agent, thereby producing a differentiated cell. 
